JPH08337566A - Glutamic acid derivative and its production - Google Patents
Glutamic acid derivative and its productionInfo
- Publication number
- JPH08337566A JPH08337566A JP8182579A JP18257996A JPH08337566A JP H08337566 A JPH08337566 A JP H08337566A JP 8182579 A JP8182579 A JP 8182579A JP 18257996 A JP18257996 A JP 18257996A JP H08337566 A JPH08337566 A JP H08337566A
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- compound
- added
- glutamic acid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002306 glutamic acid derivatives Chemical class 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- -1 9-fluorenylmethoxycarbonyl Chemical group 0.000 claims abstract description 94
- 125000006239 protecting group Chemical group 0.000 claims abstract description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 5
- 239000004220 glutamic acid Substances 0.000 claims abstract description 5
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical class C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 abstract description 158
- 229920002643 polyglutamic acid Polymers 0.000 abstract description 58
- 108010020346 Polyglutamic Acid Proteins 0.000 abstract description 27
- 125000003277 amino group Chemical group 0.000 abstract description 10
- 238000012377 drug delivery Methods 0.000 abstract description 8
- 239000013543 active substance Substances 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 229910052783 alkali metal Inorganic materials 0.000 abstract description 2
- 150000001340 alkali metals Chemical class 0.000 abstract description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 abstract 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 230000003372 organotropic effect Effects 0.000 abstract 1
- 229960002317 succinimide Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 106
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 95
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 239000000203 mixture Substances 0.000 description 59
- 125000003118 aryl group Chemical group 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 239000000126 substance Substances 0.000 description 45
- 239000011541 reaction mixture Substances 0.000 description 43
- 238000005160 1H NMR spectroscopy Methods 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 238000000034 method Methods 0.000 description 40
- 238000003756 stirring Methods 0.000 description 32
- 239000000706 filtrate Substances 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 238000010898 silica gel chromatography Methods 0.000 description 22
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 238000001816 cooling Methods 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 238000001914 filtration Methods 0.000 description 17
- RBDXDFOXVNNMNG-UHFFFAOYSA-N 2-(8-hydroxyoctyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCCCCCO)C(=O)C2=C1 RBDXDFOXVNNMNG-UHFFFAOYSA-N 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 239000002244 precipitate Substances 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 238000000502 dialysis Methods 0.000 description 15
- 239000008213 purified water Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 239000011148 porous material Substances 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 9
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- YFDGPXJJUSYWRX-UHFFFAOYSA-N 8-(oxan-2-yloxy)octan-1-ol Chemical compound OCCCCCCCCOC1CCCCO1 YFDGPXJJUSYWRX-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- VRVIRDKYTHYKJD-UHFFFAOYSA-N O1C(CCCC1)OCCCCCCCCN1C(C=2C(C1=O)=CC=CC2)=O Chemical compound O1C(CCCC1)OCCCCCCCCN1C(C=2C(C1=O)=CC=CC2)=O VRVIRDKYTHYKJD-UHFFFAOYSA-N 0.000 description 7
- 229920005654 Sephadex Polymers 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000002523 gelfiltration Methods 0.000 description 7
- 239000002198 insoluble material Substances 0.000 description 7
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- PCQHHGZMQLZGQM-ZOHVZMGWSA-N (2r,3s,4s,5r,6r)-2-chloro-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxane Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](OCC=2C=CC=CC=2)[C@@H]1OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)Cl)OCC1=CC=CC=C1 PCQHHGZMQLZGQM-ZOHVZMGWSA-N 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RNGLREVZONTJLS-AANPDWTMSA-N C(C)(=O)O[C@@H]1[C@@H](OCCCCCCCC)O[C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O Chemical compound C(C)(=O)O[C@@H]1[C@@H](OCCCCCCCC)O[C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O RNGLREVZONTJLS-AANPDWTMSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- 102000004856 Lectins Human genes 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 229960002989 glutamic acid Drugs 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000003456 ion exchange resin Substances 0.000 description 6
- 229920003303 ion-exchange polymer Polymers 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000002523 lectin Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- LMQFOQKXXCJYJJ-YIDVYQOGSA-N C(C)(=O)N[C@@H]1[C@H](OCCCCCCCCN)O[C@@H]([C@H]([C@@H]1O)O)CO Chemical compound C(C)(=O)N[C@@H]1[C@H](OCCCCCCCCN)O[C@@H]([C@H]([C@@H]1O)O)CO LMQFOQKXXCJYJJ-YIDVYQOGSA-N 0.000 description 5
- LQGTUGMIAIEHTM-GTFHEYDISA-N C(C1=CC=CC=C1)O[C@@H]1[C@@H](OCCCCCCCCNC(=O)OCC2=CC=CC=C2)O[C@@H]([C@H]([C@@H]1OCC1=CC=CC=C1)OCC1=CC=CC=C1)COCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@@H](OCCCCCCCCNC(=O)OCC2=CC=CC=C2)O[C@@H]([C@H]([C@@H]1OCC1=CC=CC=C1)OCC1=CC=CC=C1)COCC1=CC=CC=C1 LQGTUGMIAIEHTM-GTFHEYDISA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- FWOLMEHMWOLBOL-BFMQNEDBSA-N O=C(C1=CC=CC=C11)N(CCCCCCCCO[C@@H]([C@H]([C@H]2OCC3=CC=CC=C3)OCC3=CC=CC=C3)O[C@H](COCC3=CC=CC=C3)[C@H]2OCC2=CC=CC=C2)C1=O Chemical compound O=C(C1=CC=CC=C11)N(CCCCCCCCO[C@@H]([C@H]([C@H]2OCC3=CC=CC=C3)OCC3=CC=CC=C3)O[C@H](COCC3=CC=CC=C3)[C@H]2OCC2=CC=CC=C2)C1=O FWOLMEHMWOLBOL-BFMQNEDBSA-N 0.000 description 5
- BJAUCJWWQPIMMW-WMDMXHCLSA-N O[C@@H]([C@H]1OCC2=CC=CC=C2)[C@@H](OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)O[C@H](COCC2=CC=CC=C2)[C@H]1OCC1=CC=CC=C1 Chemical compound O[C@@H]([C@H]1OCC2=CC=CC=C2)[C@@H](OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)O[C@H](COCC2=CC=CC=C2)[C@H]1OCC1=CC=CC=C1 BJAUCJWWQPIMMW-WMDMXHCLSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- CEFTXUSFUMNCIW-VKHMYHEASA-N [(3s)-2,6-dioxooxan-3-yl]carbamic acid Chemical class OC(=O)N[C@H]1CCC(=O)OC1=O CEFTXUSFUMNCIW-VKHMYHEASA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 5
- 239000002808 molecular sieve Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 4
- FQVYUFFVLDCTSD-KKRIOZGLSA-N CC(N[C@@H]([C@H]1O)[C@H](OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)O[C@H](CO)[C@H]1O)=O Chemical compound CC(N[C@@H]([C@H]1O)[C@H](OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)O[C@H](CO)[C@H]1O)=O FQVYUFFVLDCTSD-KKRIOZGLSA-N 0.000 description 4
- 229930182847 D-glutamic acid Natural products 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HEGSGKPQLMEBJL-DGTMBMJNSA-N (2r,3s,4s,5s,6s)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HEGSGKPQLMEBJL-DGTMBMJNSA-N 0.000 description 3
- DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 3
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 3
- RTKMFQOHBDVEBC-UHFFFAOYSA-N 3-bromo-3-buten-1-ol Chemical compound OCCC(Br)=C RTKMFQOHBDVEBC-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- NPIQTQNNUMBGJD-APDHKMKFSA-N C(C)(=O)O[C@@H]1[C@H]([C@@H](OCCCCCCCCN2C(C=3C(C2=O)=CC=CC3)=O)OC[C@H]1OC(C)=O)O Chemical compound C(C)(=O)O[C@@H]1[C@H]([C@@H](OCCCCCCCCN2C(C=3C(C2=O)=CC=CC3)=O)OC[C@H]1OC(C)=O)O NPIQTQNNUMBGJD-APDHKMKFSA-N 0.000 description 3
- FWOLMEHMWOLBOL-FECILGGUSA-N C(C1=CC=CC=C1)O[C@@H]1[C@@H](OCCCCCCCCN2C(C=3C(C2=O)=CC=CC3)=O)O[C@@H]([C@H]([C@@H]1OCC1=CC=CC=C1)OCC1=CC=CC=C1)COCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@@H](OCCCCCCCCN2C(C=3C(C2=O)=CC=CC3)=O)O[C@@H]([C@H]([C@@H]1OCC1=CC=CC=C1)OCC1=CC=CC=C1)COCC1=CC=CC=C1 FWOLMEHMWOLBOL-FECILGGUSA-N 0.000 description 3
- UPDANDSOFVKHKG-RQHKYSNLSA-N CC(OC[C@H]([C@@H]([C@@H]([C@H]1OC(C)=O)OC(C)=O)OC(C)=O)O[C@H]1OCCCCCCCCN(C(C1=CC=CC=C11)=O)C1=O)=O Chemical compound CC(OC[C@H]([C@@H]([C@@H]([C@H]1OC(C)=O)OC(C)=O)OC(C)=O)O[C@H]1OCCCCCCCCN(C(C1=CC=CC=C11)=O)C1=O)=O UPDANDSOFVKHKG-RQHKYSNLSA-N 0.000 description 3
- XBUSMMNTYAUAQL-WFFVNDTGSA-N CC(O[C@@H]([C@H]1OCC2=CC=CC=C2)[C@@H](OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)O[C@H](COCC2=CC=CC=C2)[C@H]1OCC1=CC=CC=C1)=O Chemical compound CC(O[C@@H]([C@H]1OCC2=CC=CC=C2)[C@@H](OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)O[C@H](COCC2=CC=CC=C2)[C@H]1OCC1=CC=CC=C1)=O XBUSMMNTYAUAQL-WFFVNDTGSA-N 0.000 description 3
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- BDYLUCCCTCPTKM-PNHLWVRCSA-N [(2r,3s,4s,5r,6r)-2-chloro-4,5-bis(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-3-yl] acetate Chemical compound C([C@H]1O[C@H](Cl)[C@H]([C@H]([C@@H]1OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)OC(=O)C)OCC1=CC=CC=C1 BDYLUCCCTCPTKM-PNHLWVRCSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940075610 mercuric cyanide Drugs 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- ATCFYQUZTYQTJN-QVDQXJPCSA-N (2r)-2-amino-4-benzylpentanedioic acid Chemical compound OC(=O)[C@H](N)CC(C(O)=O)CC1=CC=CC=C1 ATCFYQUZTYQTJN-QVDQXJPCSA-N 0.000 description 2
- BGGHCRNCRWQABU-SNVBAGLBSA-N (2r)-2-azaniumyl-5-oxo-5-phenylmethoxypentanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-SNVBAGLBSA-N 0.000 description 2
- MJZXQAVNDOYDAP-RBGCBHJMSA-N (2s,3s,4r,5r,6s)-2-bromo-6-methyl-3,4,5-tris(phenylmethoxy)oxane Chemical compound O([C@@H]1[C@H](Br)O[C@H]([C@H]([C@H]1OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)C)CC1=CC=CC=C1 MJZXQAVNDOYDAP-RBGCBHJMSA-N 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 2
- AVNRQUICFRHQDY-YTWAJWBKSA-N [(3r,4s,5r,6r)-4,5-diacetyloxy-6-bromooxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@H](Br)[C@H](OC(C)=O)[C@H]1OC(C)=O AVNRQUICFRHQDY-YTWAJWBKSA-N 0.000 description 2
- IHQVSVVWDSBEMQ-ZPXGPAEQSA-N [N-]=[N+]=N[C@@H]([C@H]1O)[C@H](OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)O[C@H](CO)[C@H]1O Chemical compound [N-]=[N+]=N[C@@H]([C@H]1O)[C@H](OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)O[C@H](CO)[C@H]1O IHQVSVVWDSBEMQ-ZPXGPAEQSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 1
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JVLRBIADOALMLB-UHFFFAOYSA-N 2-ethoxy-1,2-dihydroquinoline Chemical compound C1=CC=C2C=CC(OCC)NC2=C1 JVLRBIADOALMLB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HWAVIYAFGOQVNJ-UHFFFAOYSA-N 4-n,4-n-bis(2-chloroethyl)benzene-1,4-diamine Chemical compound NC1=CC=C(N(CCCl)CCCl)C=C1 HWAVIYAFGOQVNJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VKUSFQIQAGKGKX-MZLPPYGWSA-N CC(O[C@H](CO[C@@H]([C@@H]1OC(C)=O)OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)[C@@H]1OC(C)=O)=O Chemical compound CC(O[C@H](CO[C@@H]([C@@H]1OC(C)=O)OCCCCCCCCN(C(C2=CC=CC=C22)=O)C2=O)[C@@H]1OC(C)=O)=O VKUSFQIQAGKGKX-MZLPPYGWSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 241001061257 Emmelichthyidae Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 240000007015 Melilotus indicus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CYAYKKUWALRRPA-HTOAHKCRSA-N [(2r,3s,4s,5r,6r)-3,4,5-triacetyloxy-6-bromooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O CYAYKKUWALRRPA-HTOAHKCRSA-N 0.000 description 1
- YFHNDHXQDJQEEE-UHFFFAOYSA-N acetic acid;hydrazine Chemical compound NN.CC(O)=O YFHNDHXQDJQEEE-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229940095564 anhydrous calcium sulfate Drugs 0.000 description 1
- 230000000690 anti-lymphoma Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 150000004651 carbonic acid esters Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- SVWLIIFHXFGESG-UHFFFAOYSA-N formic acid;methanol Chemical compound OC.OC=O SVWLIIFHXFGESG-UHFFFAOYSA-N 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OQTOQAYHQVKZET-UHFFFAOYSA-N oxalonitrile;silver Chemical compound [Ag].N#CC#N OQTOQAYHQVKZET-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LAYPMCGIWDGYKX-UHFFFAOYSA-N trichloromethyl hydrogen carbonate Chemical compound OC(=O)OC(Cl)(Cl)Cl LAYPMCGIWDGYKX-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、臓器指向性のある
薬物運搬担体として有用な糖修飾ポリグルタミン酸誘導
体の合成中間体であるグルタミン酸誘導体に関する。TECHNICAL FIELD The present invention relates to a glutamic acid derivative which is a synthetic intermediate of a sugar-modified polyglutamic acid derivative useful as an organ-directing drug delivery carrier.
【0002】[0002]
【従来の技術】ポリグルタミン酸を薬物運搬担体として
使用する試みは、例えば下記文献に示されるように、主
として抗癌剤の運搬担体として研究されてきた。 1)Goldberg, E.P.ら,Org. Coat Plast. chem. 44, 1
32-136(1981) 2)イスラエル特許第68449/3号 3)Hurwitz, E. ら, J. Appl. Biochem. 2, 25-35(198
0) 4)Morimoto, Y.ら,J. Pharm. Dyn. 7, 688-698(1984) 5)Kato, A.ら, Chem. Pharm. Bull. 30, 2951-2957(1
982) 6)Kato, Y.ら, Cancer Res. 44, 25-30(1984) 7)Rowland, G.F. ら, Nature 255, 487-488(1975) 8)Tsukada, Y. ら, J. Natl. Cancer Institute 73,
721-729(1984)2. Description of the Related Art Attempts to use polyglutamic acid as a drug delivery carrier have been mainly studied as a delivery carrier for anticancer agents, as shown in the following documents. 1) Goldberg, EP et al., Org. Coat Plast. Chem. 44 , 1
32-136 (1981) 2) Israel Patent No. 68449/3 3) Hurwitz, E. et al., J. Appl. Biochem. 2, 25-35 (198
0) 4) Morimoto, Y. et al., J. Pharm. Dyn. 7, 688-698 (1984) 5) Kato, A. et al., Chem. Pharm. Bull. 30, 2951-2957 (1
982) 6) Kato, Y. et al., Cancer Res. 44, 25-30 (1984) 7) Rowland, GF et al., Nature 255, 487-488 (1975) 8) Tsukada, Y. et al., J. Natl. Cancer Institute 73,
721-729 (1984)
【0003】上記文献1)〜3)にはドキソルビシンあ
るいはダウノルビシンをポリグルタミン酸に結合させた
例が示され、4)にはメルファランを結合させた例が示
され、5)にはマイトマイシンCを結合させた例が示さ
れ、6)にはアラビノフラノシルシトシンを結合させた
例が示され、7)にはフェニレンジアミンマスタードと
抗リンパ腫イムノグロブリンとを結合させた例が示さ
れ、8)にはダウノルビシンと抗α−フェトプロテイン
抗体とを結合させた例が示されている。References 1) to 3) above show examples of doxorubicin or daunorubicin bound to polyglutamic acid, 4) examples of melphalan binding, and 5) mitomycin C binding. 6) shows an example in which arabinofuranosyl cytosine is bound, 7) shows an example in which phenylenediamine mustard and an anti-lymphoma immunoglobulin are bound, and 8) Shows an example in which daunorubicin is bound to an anti-α-fetoprotein antibody.
【0004】これらの例におけるように、ポリグルタミ
ン酸に直接あるいは薬物結合のための修飾を加えたポリ
グルタミン酸に抗癌剤あるいは抗腫瘍剤を結合させ、癌
組織や腫瘍細胞への選択的な運搬を可能にする目的で、
これらの組織や細胞を認識する抗体を更に結合させるこ
とが提案されている。したがって、ポリグルタミン酸が
臓器指向性を付与された薬物運搬担体となり得ることは
予測されていた。しかしながら、この予測を実現する具
体的な試みはなく、薬物運搬技術上の解決すべき課題と
して残されている。As in these examples, an anticancer agent or an antitumor agent is bound to polyglutamic acid directly or to polyglutamic acid modified for drug binding to enable selective delivery to cancer tissues or tumor cells. For the purpose of
It has been proposed to further bind an antibody that recognizes these tissues and cells. Therefore, it was predicted that polyglutamic acid could serve as a drug delivery carrier with organ-directivity. However, there is no specific attempt to realize this prediction, and it remains as a problem to be solved in drug delivery technology.
【0005】[0005]
【発明が解決しようとする課題】従来技術における上記
の実状にかんがみ、本発明者らは種々の検討を行ったと
ころ、ポリグルタミン酸を糖で修飾することにより、臓
器指向性が付与されることを見い出し、本発明を完成す
るに至った。In light of the above situation in the prior art, the present inventors have made various studies and found that modification of polyglutamic acid with sugar imparts organ-directivity. They have found the present invention and completed the present invention.
【0006】[0006]
(物質)本発明における最終目的物質は、下記式(I)
で示される糖修飾ポリグルタミン酸誘導体である。(Substance) The final target substance in the present invention is the following formula (I)
It is a sugar-modified polyglutamic acid derivative represented by.
【0007】[0007]
【化3】 Embedded image
【0008】(式中、R1 はOR′またはNHR″を表
し、R′は水素原子、アルカリ金属原子または生理活性
物質をし、R″は水素原子または生理活性物質を表す。
R2は、グリコシル基であって、その水酸基又は2位の
アミノ基にアセチル基が置換していてもよい。nは7〜
10の整数を表す。kに対するmのモル比は1〜100
である)(In the formula, R 1 represents OR ′ or NHR ″, R ′ represents a hydrogen atom, an alkali metal atom or a physiologically active substance, and R ″ represents a hydrogen atom or a physiologically active substance.
R 2 is a glycosyl group, and its hydroxyl group or amino group at the 2-position may be substituted with an acetyl group. n is 7-
Represents an integer of 10. The molar ratio of m to k is 1 to 100
Is)
【0009】式(I)は、本発明の糖修飾ポリグルタミ
ン酸誘導体が2種類の異なるグルタミン酸単位から構成
されることを示す。第一の単位(A)は修飾されていな
いグルタミン酸単位であり、第二の単位(B)はスペー
サーとしてのアミノアルキル鎖を介して、糖によって修
飾されたグルタミン酸単位である。更に式(I)は、こ
れら2種類の単位(A)及び(B)が1分子中にそれぞ
れk個、m個含まれていることを意味する。しかし、式
(I)の記述は、各単位(A)及び(B)がランダムに
共重合していることを意味する。Formula (I) shows that the sugar-modified polyglutamic acid derivative of the present invention is composed of two different glutamic acid units. The first unit (A) is an unmodified glutamic acid unit, and the second unit (B) is a glutamic acid unit modified with a sugar via an aminoalkyl chain as a spacer. Further, the formula (I) means that these two kinds of units (A) and (B) are contained in one molecule in k and m units, respectively. However, the description of formula (I) means that each unit (A) and (B) is randomly copolymerized.
【0010】R2 のグリコシル基としては、マンノピラ
ノシル、ガラクトピラノシル、キシロピラノシル、フコ
ピラノシル、2−アミノ−2−デオキシ−マンノピラノ
シル、2−アミノ−2−デオキシ−フコピラノシル等が
挙げられ、;グリコシル基の水酸基又はアミノ基にアセ
チル基が置換したものとしては、2,3,4,6−テト
ラ−0−アセチル−マンノピラノシル、2−アセタミド
−2−デオキシ−フコピラノシル等が挙げられる。Examples of the glycosyl group for R 2 include mannopyranosyl, galactopyranosyl, xylopyranosyl, fucopyranosyl, 2-amino-2-deoxy-mannopyranosyl, 2-amino-2-deoxy-fucopyranosyl and the like; Examples of the hydroxyl group or amino group substituted with an acetyl group include 2,3,4,6-tetra-0-acetyl-mannopyranosyl and 2-acetamido-2-deoxy-fucopyranosyl.
【0011】生理活性物質は、標的臓器に運搬されて薬
理効果を示す薬物であって、例えばダウノルビシン、ト
リプロリジン、ドキソルビシン、末端にアミノ基を有す
るスペーサーを介したメトトレキサート等が挙げられ
る。The physiologically active substance is a drug which is delivered to a target organ and exhibits a pharmacological effect, and examples thereof include daunorubicin, triprolidine, doxorubicin, and methotrexate via a spacer having an amino group at the terminal.
【0012】本発明の糖修飾ポリグルタミン酸誘導体
(I)は、単位(A)及び単位(B)を必須の構成単位
とするものであるが、第三の単位、例えば糖修飾ポリグ
ルタミン酸誘導体(I)を動物実験に供すべくヨードラ
ベル化する場合の便益のために必要な構成単位(C)The sugar-modified polyglutamic acid derivative (I) of the present invention has a unit (A) and a unit (B) as essential constitutional units, and a third unit, for example, the sugar-modified polyglutamic acid derivative (I). ) Is a constituent unit (C) necessary for the benefit of iodine labeling for animal experiments.
【0013】[0013]
【化4】 [Chemical 4]
【0014】を含んでいてもよい。May be included.
【0015】式(I)の物質が薬物運搬担体として使用
される場合に、薬物は前記第一の単位(A)、すなわち
修飾されていないグルタミン酸単位の中のいくつかに結
合させる。結合は薬物のアミノ基を介して直接に、ある
いはアミノ基を有するスペーサーの該アミノ基を介して
間接に行えばよく、酸アミド結合を形成させる通常の方
法に従って実施すればよい。またエステル結合、酸無水
物結合を介した薬物の結合も可能である。When the substance of formula (I) is used as a drug delivery carrier, the drug is bound to some of the first units (A), ie the unmodified glutamic acid units. The coupling may be carried out directly via the amino group of the drug or indirectly via the amino group of the spacer having an amino group, and may be carried out according to a usual method for forming an acid amide bond. It is also possible to bond a drug through an ester bond or an acid anhydride bond.
【0016】式(II)の物質は、式(I)の物質を共重
合法によって合成する場合に有用であり、この目的のた
めの合成中間体である。The substance of formula (II) is useful when the substance of formula (I) is synthesized by a copolymerization method, and is a synthetic intermediate for this purpose.
【0017】[0017]
【化5】 Embedded image
【0018】(式中、R2 及びnは前記と同じ) 式(III) の物質は、式(II)の物質を合成するための有
用な出発物質であり、グルタミン酸のアミノ基の保護に
9−フルオレニルメトキシカルボニル基が特に選択され
ている。この選択により式(II)の物質に至る一連の反
応工程が実現可能となった点に特徴がある。(Wherein R 2 and n are the same as above) The substance of the formula (III) is a useful starting material for synthesizing the substance of the formula (II), and is used for protecting the amino group of glutamic acid. The -fluorenylmethoxycarbonyl group is particularly selected. This selection is characterized in that a series of reaction steps leading to the substance of formula (II) can be realized.
【0019】[0019]
【化6】 [Chemical 6]
【0020】(式中、R3 は9−フルオレニルメトキシ
カルボニル基を表し、R4 はカルボキシル基の保護基を
表す)。R4 の保護基としては、t−ブチル等があげら
れる。(In the formula, R 3 represents a 9-fluorenylmethoxycarbonyl group, and R 4 represents a protecting group for a carboxyl group). Examples of the protecting group for R 4 include t-butyl and the like.
【0021】式(IV)の物質は、式(II)の物質を合成
するために、あるいはポリグルタミン酸を原料にして式
(I)の物質を合成するために有用である。The substance of formula (IV) is useful for synthesizing the substance of formula (II) or for synthesizing the substance of formula (I) from polyglutamic acid as a raw material.
【0022】[0022]
【化7】 [Chemical 7]
【0023】(製造法)式(IV)の物質を製造するに
は、グリコシドの水酸基を保護した、あるいは更に2位
水酸基をアジド基に換えたグリコシルハライドに、下記
式(V)のN−(ヒドロキシアルキル)フタルイミドを
反応させ、更に必要に応じて脱保護し、あるいは更にア
ジド基を還元してアミノ基とし、更にアミノ基をアセチ
ル化し、次にこれをヒドラジンで処理してフタルイミド
を脱離することにより得られる。反応は−10℃以下の
低温で銀シリケート等の存在下で行われる。(Production Method) To produce the substance of the formula (IV), a glycosyl halide in which the hydroxyl group of glycoside is protected or the 2-position hydroxyl group is further replaced with an azide group is added to N- (of the following formula (V): (Hydroxyalkyl) phthalimide is reacted and further deprotected if necessary, or azido group is further reduced to an amino group, and the amino group is further acetylated, and then this is treated with hydrazine to eliminate phthalimide. It is obtained by The reaction is carried out at a low temperature of -10 ° C or lower in the presence of silver silicate or the like.
【0024】[0024]
【化8】 Embedded image
【0025】(式中、nは前記と同じ) なお、式(V)の物質は、例えば一方の末端OH基を
2,3−ジヒドロピラニル基で保護したアルカンジオー
ルにフタルイミドを反応させ、次に脱保護してOH基を
遊離させることにより得られる。(In the formula, n is the same as the above) In the substance of the formula (V), for example, an alkane diol in which one terminal OH group is protected with a 2,3-dihydropyranyl group is reacted with phthalimide, It can be obtained by deprotection to liberate the OH group.
【0026】式(III) の物質を製造するには、γ−カル
ボキシル基が保護されたグルタミン酸のα−アミノ基
に、9−フルオレニルメトキシカルボン酸の反応性誘導
体、例えば該酸にコハク酸イミドを反応させ、更にα−
カルボキシル基を保護し、次にγ−カルボキシル基の保
護基を脱離することにより得られる。To prepare the substance of formula (III), a reactive derivative of 9-fluorenylmethoxycarboxylic acid, such as succinic acid, can be added to the α-amino group of glutamic acid having a protected γ-carboxyl group. The imide is reacted, and α-
It is obtained by protecting the carboxyl group and then removing the protecting group for the γ-carboxyl group.
【0027】式(II)の物質を製造するには、式(III)
で示されるグルタミン酸誘導体に、式(IV)で示される
グリコシルオキシアルキルアミンまたはその塩を反応さ
せ、更にα−カルボキシル基の保護基及びα−アミノ基
の保護基を脱離し、次にビス(トリクロロメチル)カー
ボネートのような炭酸エステルを反応させて、N−カル
ボキシグルタミン酸無水物誘導体が得られる。To prepare the substance of formula (II), the formula (III)
The glutamic acid derivative represented by the formula (4) is reacted with the glycosyloxyalkylamine represented by the formula (IV) or a salt thereof to remove the protecting group for the α-carboxyl group and the protecting group for the α-amino group. The N-carboxyglutamic anhydride derivative is obtained by reacting a carbonic acid ester such as methyl) carbonate.
【0028】式(I)の糖修飾ポリグルタミン酸誘導体
を製造するには2つの方法がある。第一の方法は、式
(II)で示されるN−カルボキシグルタミン酸無水物誘
導体と、下記式(VI)で示されるN−カルボキシグルタ
ミン酸無水物とを共重合させる方法であり、第二の方法
は、式(VI)のN−カルボキシグルタミン酸無水物を共
重合させ、カルボキシル基の保護基を脱離して得られる
ポリグルタミン酸に、式(IV)で示されるグリコシルオ
キシアルキルアミン又はその塩を反応させる方法であ
る。There are two methods for preparing the sugar-modified polyglutamic acid derivative of formula (I). The first method is a method of copolymerizing an N-carboxyglutamic anhydride derivative represented by the formula (II) and an N-carboxyglutamic acid anhydride represented by the following formula (VI), and the second method is A method of reacting a polyglutamic acid obtained by copolymerizing N-carboxyglutamic acid anhydride of the formula (VI) and removing a protecting group of a carboxyl group with a glycosyloxyalkylamine represented by the formula (IV) or a salt thereof. Is.
【0029】[0029]
【化9】 [Chemical 9]
【0030】(式中、R5 はベンジル基のようなカルボ
キシル基の保護基を表す) 第一の共重合法は、共重合の常法に従って行えばよく、
異なる上記式(II)と(VI)の二種のN−カルボキシグ
ルタミン酸無水物を、例えばヘキシルアミンのような縮
合剤の存在下に、ジメチルホルムアミド中で反応させ、
次にカルボキシル基の保護基を脱離し、要すればカルボ
キシル基に生理活性物質を結合させることにより、式
(I)の物質が得られる。(In the formula, R 5 represents a protecting group for a carboxyl group such as benzyl group) The first copolymerization method may be carried out according to a conventional method of copolymerization,
Reacting two different N-carboxyglutamic anhydrides of the above formulas (II) and (VI) in dimethylformamide in the presence of a condensing agent such as hexylamine,
Next, the protective group of the carboxyl group is eliminated, and if necessary, a physiologically active substance is bound to the carboxyl group to obtain the substance of formula (I).
【0031】第二の方法は、ポリグルタミン酸に、グリ
コシルオキシアルキルアミン又はその塩(IV)を、縮合
剤として、例えば1,3−ジシクロヘキシルカルボジイ
ミド、1−エトキシカルボニル−2−エトキシ−1,2
−ジヒドロキノリンの存在下に、ジメチルホルムアミド
中で反応させ、要すればγ−カルボキシル基に生理活性
物質を結合させることにより、式(I)の物質が得られ
る。The second method is to use polyglutamic acid with glycosyloxyalkylamine or a salt thereof (IV) as a condensing agent such as 1,3-dicyclohexylcarbodiimide, 1-ethoxycarbonyl-2-ethoxy-1,2.
By reacting in dimethylformamide in the presence of dihydroquinoline and optionally attaching a physiologically active substance to the γ-carboxyl group, a substance of formula (I) is obtained.
【0032】また必要があれば、グリコシルオキシアル
キルアミンまたはその塩(IV)と共に、2−(4−ヒド
ロキシフェニル)エチルアミンを加えて同様に反応させ
れば、前記第三の単位(C)を含む式(I)の物質を得
ることができる。If necessary, 2- (4-hydroxyphenyl) ethylamine may be added together with glycosyloxyalkylamine or its salt (IV) and reacted in the same manner to contain the third unit (C). A substance of formula (I) can be obtained.
【0033】なお、ポリグルタミン酸を製造するにあた
って、N−カルボキシ−L−グルタミン酸無水物及びN
−カルボキシ−D−グルタミン酸無水物を共重合させれ
ば、L−グルタミン酸及びD−グルタミン酸が不規則に
配列したポリグルタミン酸が得られる。In producing polyglutamic acid, N-carboxy-L-glutamic acid anhydride and N
By copolymerizing -carboxy-D-glutamic acid anhydride, polyglutamic acid in which L-glutamic acid and D-glutamic acid are irregularly arranged can be obtained.
【0034】[0034]
【発明の効果】式(I)の物質の薬物運搬体としての効
力は、後記実験例に示すように、ガラクトースで修飾さ
れた式(I)の物質では、無修飾のポリグルタミン酸に
比較して、腎臓への蓄積が小さく、反対に肝臓への蓄積
が大きいことがわかった。従来から肝臓には特異的なガ
ラクトースを認識するレクチンの存在が知られているの
で、ガラクトースで修飾された式(I)の物質が、該レ
クチンによって認識されたものと推定される。したがっ
て、臓器あるいは癌細胞などが特異的な糖を認識するレ
クチンを有する場合には、式(I)の物質は臓器指向性
のある薬物運搬担体となり得る。The efficacy of the substance of the formula (I) as a drug carrier is shown in the following experimental examples in the substance of the formula (I) modified with galactose as compared with unmodified polyglutamic acid. It was found that the accumulation in the kidney was small and the accumulation in the liver was large. Since the existence of a lectin that specifically recognizes galactose has been known in the liver, it is presumed that the substance of formula (I) modified with galactose is recognized by the lectin. Therefore, when the organ, cancer cell, or the like has a lectin that recognizes a specific sugar, the substance of formula (I) can serve as a drug delivery carrier having organ-directivity.
【0035】[0035]
【実施例】実施例によって本発明を更に具体的に説明す
る。なお実施例に対応する反応工程を反応式1〜17に
示す。また反応式中の化合物番号は参考例及び実施例中
に記載した化合物番号に対応する。The present invention will be described more specifically with reference to examples. The reaction steps corresponding to the examples are shown in reaction formulas 1 to 17. The compound numbers in the reaction formulas correspond to the compound numbers described in Reference Examples and Examples.
【0036】[0036]
【化10】 [Chemical 10]
【0037】[0037]
【化11】 [Chemical 11]
【0038】[0038]
【化12】 [Chemical 12]
【0039】[0039]
【化13】 [Chemical 13]
【0040】[0040]
【化14】 Embedded image
【0041】[0041]
【化15】 [Chemical 15]
【0042】[0042]
【化16】 Embedded image
【0043】[0043]
【化17】 [Chemical 17]
【0044】[0044]
【化18】 Embedded image
【0045】[0045]
【化19】 [Chemical 19]
【0046】[0046]
【化20】 Embedded image
【0047】[0047]
【化21】 [Chemical 21]
【0048】[0048]
【化22】 [Chemical formula 22]
【0049】[0049]
【化23】 [Chemical formula 23]
【0050】[0050]
【化24】 [Chemical formula 24]
【0051】[0051]
【化25】 [Chemical 25]
【0052】[0052]
【化26】 [Chemical formula 26]
【0053】[0053]
【化27】 [Chemical 27]
【0054】参考例1 1,8−オクタンジオール モ
ノテトラヒドロピラニルエーテル(2) 2,3−ジヒドロピラン36ml(392ミリモル)を、
1,8−オクタンジオール(1)50g(342ミリモ
ル)及び濃塩酸0.5ml(6ミリモル)のエチレングリ
コールジメチルエーテル400ml溶液に撹拌しながら加
えた。更に室温で2時間撹拌した後、反応液にトリエチ
ルアミン1mlを加えて中和した。析出したトリエチルア
ミン塩酸塩を濾過して除いた後、濾液を減圧下濃縮乾固
した。得られた残渣を高度真空下で蒸留して精製して、
標記化合物(2)32.1g(41%)を得た。Reference Example 1 36 ml (392 mmol) of 1,8-octanediol monotetrahydropyranyl ether (2) 2,3-dihydropyran,
50 g (342 mmol) of 1,8-octanediol (1) and 0.5 ml (6 mmol) of concentrated hydrochloric acid were added to a solution of 400 ml of ethylene glycol dimethyl ether with stirring. After further stirring at room temperature for 2 hours, 1 ml of triethylamine was added to the reaction solution for neutralization. After removing the precipitated triethylamine hydrochloride by filtration, the filtrate was concentrated to dryness under reduced pressure. The residue obtained is purified by distillation under high vacuum,
32.1 g (41%) of the title compound (2) was obtained.
【0055】2:Bp1.5mmHg 140-150℃ IR(CHCl3)cm-1 : 3400(OH), 1460, 1355, 10151 H-NMR(CDCl3):δ 4.55(1H, m, -OCHO-)2: Bp 1.5 mmHg 140-150 ° C. IR (CHCl 3 ) cm −1 : 3400 (OH), 1460, 1355, 1015 1 H-NMR (CDCl 3 ): δ 4.55 (1H, m, -OCHO- )
【0056】参考例2 8−フタルイミドオクタノール
テトラヒドロピラニルエーテル(3) 化合物(2)14.9g(64.7ミリモル)、トリフ
ェニルホスフィン18.67g(71.2ミリモル)及
びフタルイミド10.47g(71.2ミリモル)の無
水テトラヒドロフラン300ml溶液に、窒素気流中で、
撹拌しながら室温でジエチルアゾジカルボン酸エステル
11.2ml(71.2ミリモル)をゆっくりと滴下し
た。更に室温で4時間撹拌した後、減圧下溶媒を留去し
た。得られた残渣をシリカゲルカラムクロマトグラフィ
ー(ヘキサン−酢酸エチル=3:1)で精製して、標記
化合物(3)23g(定量的)を得た。Reference Example 2 8-phthalimidooctanol tetrahydropyranyl ether (3) 14.9 g (64.7 mmol) of compound (2), 18.67 g (71.2 mmol) of triphenylphosphine and 10.47 g (71. 2 mmol) in 300 ml of anhydrous tetrahydrofuran in a nitrogen stream,
With stirring, 11.2 ml (71.2 mmol) of diethyl azodicarboxylic acid ester was slowly added dropwise at room temperature. After further stirring at room temperature for 4 hours, the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate = 3: 1) to obtain 23 g (quantitative) of the title compound (3).
【0057】3:1H-NMR(CDCl3):δ 7.9-7.7(4H, m, aromatic H) 4.58(1H, m, CH)3: 1 H-NMR (CDCl 3 ): δ 7.9-7.7 (4H, m, aromatic H) 4.58 (1H, m, CH)
【0058】参考例3 8−フタルイミドオクタノール
(4) 化合物(3)47g(137ミリモル)を80%酢酸5
00mlに溶解した後、80℃で3時間加熱撹拌した。反
応混合物を減圧下濃縮乾固した後、得られた残渣を水層
と酢酸エチル層とに分配した。有機層を分離し、水、炭
酸水素ナトリウム水溶液及び水で順次洗浄した。硫酸マ
グネシウムで乾燥した後、減圧下で溶媒を留去した。得
られた残渣をシリカゲルカラムクロマトグラフィー(ヘ
キサン−酢酸エチル=2:1)で精製して、標記化合物
(4)24.3g(65%)を得た。Reference Example 3 8-phthalimidooctanol (4) 47 g (137 mmol) of compound (3) was added to 80% acetic acid 5%.
After dissolving in 00 ml, the mixture was heated with stirring at 80 ° C. for 3 hours. The reaction mixture was concentrated to dryness under reduced pressure, and the obtained residue was partitioned into an aqueous layer and an ethyl acetate layer. The organic layer was separated and washed successively with water, aqueous sodium hydrogen carbonate solution and water. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate = 2: 1) to obtain 24.3 g (65%) of the title compound (4).
【0059】4: m.p. 64.5 - 65°℃ IR(CHCl3)cm-1 : 3630(OH), 1773, 1712, 13901 H-NMR(CDCl3):δ 7.9-7.65(4H, m, aromatic H) 3.8-3.6(4H, m, -CH2N, -CH2O) 1.8-1.2(12H, m, -(CH2)6-)4: mp 64.5-65 ° C IR (CHCl 3 ) cm -1 : 3630 (OH), 1773, 1712, 1390 1 H-NMR (CDCl 3 ): δ 7.9-7.65 (4H, m, aromatic H ) 3.8-3.6 (4H, m, -CH 2 N, -CH 2 O) 1.8-1.2 (12H, m,-(CH 2 ) 6- )
【0060】参考例4 8−フタルイミドオクチル 2
−O−アセチル−3,4,6−トリ−O−ベンジル−α
−D−マンノピラノシド(6) 文献記載の方法(T. OGAWA ら、Tetrahedron, 37, 2779
(1981))で合成した2−O−アセチル−3,4,6−ト
リ−O−ベンジル−α−D−マンノピラノシルクロリド
(5)1.6g(31.58ミリモル)、8−フタルイ
ミドオクタノール(4)8.7g(31.58ミリモ
ル)及び1,1,3,3−テトラメチル尿素17ml(1
26.3ミリモル)をジクロロエタン200mlに溶解し
た後、窒素気流下−40℃に冷却した。この混合物に銀
トリフレート8.93g(34.73ミリモル)を加え
同温度で30分間撹拌した。冷却浴を除いた後、更に室
温で16時間撹拌した。反応混合物をセライトを用いて
濾過した後、濾液を炭酸水素ナトリウム水溶液及び水で
順次洗浄した。硫酸マグネシウムで乾燥した後、減圧下
溶媒を留去した。得られた残渣をシリカゲルカラムクロ
マトグラフィー(ヘキサン−酢酸エチル=3:1)で精
製して、標記化合物(6)12.3g(52%)を得
た。Reference Example 4 8-phthalimidooctyl 2
-O-acetyl-3,4,6-tri-O-benzyl-α
-D-mannopyranoside (6) Method described in literature (T. OGAWA et al., Tetrahedron, 37, 2779).
(1981)) 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl chloride (5) 1.6 g (31.58 mmol), 8- 8.7 g (31.58 mmol) of phthalimidooctanol (4) and 17 ml of 1,1,3,3-tetramethylurea (1
(26.3 mmol) was dissolved in 200 ml of dichloroethane and then cooled to -40 ° C under a nitrogen stream. To this mixture was added 8.93 g (34.73 mmol) of silver triflate and the mixture was stirred at the same temperature for 30 minutes. After removing the cooling bath, the mixture was further stirred at room temperature for 16 hours. The reaction mixture was filtered through Celite, and the filtrate was washed successively with aqueous sodium hydrogen carbonate solution and water. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate = 3: 1) to obtain 12.3 g (52%) of the title compound (6).
【0061】6:シロップ状 〔α〕D 24 + 17.7°(c 0.61, CHCl3) IR(CHCl3)cm-1 : 1710, 1522, 1477, 14231 H-NMR(CDCl3):δ 7.81(2H, d, J=10Hz, aromatic H) 7.68(2H, d, J=10Hz, aromatic H) 7.4-7.2(15H, m, aromatic H) 5.33(1H, dd, J1,2=1.5Hz, J2,3=3.5Hz, H-2) 4.80(1H, d, J1,2=1.5Hz, H-1) 3.96(1H, dd, J2,3=3.5Hz, H-3) 3.86(1H, t, J3,4=10Hz, H-4) 2.13(3H, s, OAc) 1.75-1.20(12H, m, -(CH2)6-) 1.45(9H, s, C(CH3)3)6: Syrup-like [α] D 24 + 17.7 ° (c 0.61, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1710, 1522, 1477, 1423 1 H-NMR (CDCl 3 ): δ 7.81 ( 2H, d, J = 10Hz, aromatic H) 7.68 (2H, d, J = 10Hz, aromatic H) 7.4-7.2 (15H, m, aromatic H) 5.33 (1H, dd, J 1 , 2 = 1.5Hz, J 2 , 3 = 3.5Hz, H-2) 4.80 (1H, d, J 1 , 2 = 1.5Hz, H-1) 3.96 (1H, dd, J 2 , 3 = 3.5Hz, H-3) 3.86 (1H , t, J 3 , 4 = 10Hz, H-4) 2.13 (3H, s, OAc) 1.75-1.20 (12H, m,-(CH 2 ) 6- ) 1.45 (9H, s, C (CH 3 ) 3 )
【0062】参考例5 8−フタルイミドオクチル
3,4,6−トリ−O−ベンジル−α−D−マンノピラ
ノシド(7) 化合物(6)12.3g(16.4ミリモル)のメタノ
ール200ml及びテトラヒドロフラン50ml混液に、1
M ナトリウムメトキシド−メタノール溶液4.1mlを加
え室温に4時間放置した。反応液にイオン交換樹脂アン
バーライトIR120B(H+ 型)を加えて中和した
後、樹脂を濾去し、メタノールで洗浄した。濾液及び洗
液を合わせ減圧下で溶媒を留去して、シロップ状残渣1
1.4gを得た。残渣をシリカゲルカラムクロマトグラ
フィー(ヘキサン−酢酸エチル=2:1)で精製して、
標記化合物(7)8.5g(73.3%)を得た。Reference Example 5 8-phthalimidooctyl
3,4,6-Tri-O-benzyl-α-D-mannopyranoside (7) 12.3 g (16.4 mmol) of compound (6) in 200 ml of methanol and 50 ml of tetrahydrofuran were mixed with 1
M sodium methoxide-methanol solution (4.1 ml) was added and the mixture was allowed to stand at room temperature for 4 hours. Ion exchange resin Amberlite IR120B (H + type) was added to the reaction solution for neutralization, then the resin was filtered off and washed with methanol. The filtrate and washings are combined and the solvent is distilled off under reduced pressure to give a syrup-like residue 1
1.4 g were obtained. The residue was purified by silica gel column chromatography (hexane-ethyl acetate = 2: 1),
8.5 g (73.3%) of the title compound (7) was obtained.
【0063】7:シロップ状 〔α〕D 26.5 + 31.4°(c 1.12, CHCl3) IR(film)cm-1 : 3467, 1772, 1712, 1395, 13651 H-NMR(CDCl3):δ 7.83(2H, d, J=10Hz, aromatic H) 7.70(2H, d, J=10Hz, aromatic H) 7.4-7.2(15H, m, aromatic H) 5.33(1H, dd, J1,2=1.5Hz, J2,3=3.5Hz, H-2) 4.87(1H, d, J1,2=1.5Hz, H-1)7: Syrup [α] D 26.5 + 31.4 ° (c 1.12, CHCl 3 ) IR (film) cm −1 : 3467, 1772, 1712, 1395, 1365 1 H-NMR (CDCl 3 ): δ 7.83 (2H, d, J = 10Hz, aromatic H) 7.70 (2H, d, J = 10Hz, aromatic H) 7.4-7.2 (15H, m, aromatic H) 5.33 (1H, dd, J 1 , 2 = 1.5Hz, J 2 , 3 = 3.5Hz, H-2) 4.87 (1H, d, J 1 , 2 = 1.5Hz, H-1)
【0064】参考例6 8−アミノオクチル 3,4,
6−トリ−O−ベンジル−α−D−マンノピラノシド
(8) 化合物(7)8.5g(12ミリモル)のエタノール6
0ml溶液に、ヒドラジン・水和物3ml(60ミリモル)
を加えて油浴上で3時間加熱還流した。室温まで冷却し
た後、減圧下で溶媒を留去した。残渣にトルエンを加
え、減圧下で濃縮乾固して残存するヒドラジンを除去し
て、標記化合物(8)7.1g(定量的)を得た。Reference Example 6 8-Aminooctyl 3,4
6-Tri-O-benzyl-α-D-mannopyranoside (8) Compound (7) 8.5 g (12 mmol) of ethanol 6
3 ml (60 mmol) of hydrazine hydrate in 0 ml solution
Was added and the mixture was heated under reflux on an oil bath for 3 hours. After cooling to room temperature, the solvent was distilled off under reduced pressure. Toluene was added to the residue, and the residue was concentrated to dryness under reduced pressure to remove the remaining hydrazine to obtain 7.1 g (quantitative) of the title compound (8).
【0065】8:無定形粉末 〔α〕D 27 + 37.1°(c 0.21, MeOH) IR(film)cm-1 : 3300, 1496, 1454, 1363, 1103, 10581 H-NMR(CDCl3):δ 7.4-7.1(15H, m, aromatic H) 4.75(1H, d, J1,2=1.5Hz, H-1) 4.00(1H, dd J2,3=3.5Hz, H-2) 2.62(2H, t, J=8Hz, -CH2N) 1.6-1.25(12H, m, -(CH2)6-)8: Amorphous powder [α] D 27 + 37.1 ° (c 0.21, MeOH) IR (film) cm −1 : 3300, 1496, 1454, 1363, 1103, 1058 1 H-NMR (CDCl 3 ): δ 7.4-7.1 (15H, m, aromatic H) 4.75 (1H, d, J 1 , 2 = 1.5Hz, H-1) 4.00 (1H, dd J 2 , 3 = 3.5Hz, H-2) 2.62 (2H , t, J = 8Hz, -CH 2 N) 1.6-1.25 (12H, m,-(CH 2 ) 6- )
【0066】参考例7 8−アミノオクチル α−D−
マンノピラノシド(9) 化合物(8)6.9g(12ミリモル)のメタノール2
00ml溶液に、1M 塩酸12ml及び10%パラジウム−
炭素1gを加えて室温で16時間水素添加した。触媒を
濾去した後、濾液を減圧下に濃縮乾固して、標記化合物
(9)の塩酸塩3.99g(定量的)を得た。Reference Example 7 8-Aminooctyl α-D-
Mannopyranoside (9) Compound (8) 6.9 g (12 mmol) of methanol 2
To a 00 ml solution, 12 ml of 1M hydrochloric acid and 10% palladium-
1 g of carbon was added and hydrogenated at room temperature for 16 hours. After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure to give 3.99 g (quantitative) of the hydrochloride of the title compound (9).
【0067】9(塩酸塩):無定形粉末 〔α〕D 26 + 42.9°(c 1.13, MeOH) IR(Nujol)cm-1 : 3346, 1620, 1506, 1460, 13771 H-NMR(CD3OD):δ 4.72(1H, d, J1,2=2Hz, H-1) 3.81(1H, dd J5,6a=2.5Hz, J6a,6b=11.5Hz, H-6a) 3.76(1H, dd, J2,3=3.5Hz, H-2) 3.59(1H, t, J3,4=9.5Hz, H-4) 3.51(1H, m, H-5) 2.90(2H, t, J=8Hz, -CH2N) 1.7-1.35(12H, m, -(CH2)6-)9 (hydrochloride): amorphous powder [α] D 26 + 42.9 ° (c 1.13, MeOH) IR (Nujol) cm −1 : 3346, 1620, 1506, 1460, 1377 1 H-NMR (CD 3 OD): δ 4.72 (1H, d, J 1 , 2 = 2Hz, H-1) 3.81 (1H, dd J 5 , 6a = 2.5Hz, J 6a , 6b = 11.5Hz, H-6a) 3.76 (1H, dd, J 2 , 3 = 3.5Hz, H-2) 3.59 (1H, t, J 3 , 4 = 9.5Hz, H-4) 3.51 (1H, m, H-5) 2.90 (2H, t, J = 8Hz, -CH 2 N) 1.7-1.35 (12H, m,-(CH 2 ) 6- )
【0068】上記で得た化合物(9)の塩酸塩2.64
gを含水メタノールに溶解して、イオン交換樹脂アンバ
ーライトIRA−400(OH型)50mlのカラムを通
した。カラムを50%含水メタノール500mlで洗浄し
た。溶出液及び洗浄液を合わせて減圧下で濃縮乾固し
て、標記化合物(9)の遊離塩基2.31gを得た。Hydrochloride of compound (9) obtained above 2.64
g was dissolved in aqueous methanol and passed through a column of 50 ml of ion exchange resin Amberlite IRA-400 (OH type). The column was washed with 500 ml of 50% hydrous methanol. The eluate and the washing solution were combined and concentrated under reduced pressure to dryness to obtain 2.31 g of the free base of the title compound (9).
【0069】9(遊離塩基):無定形粉末 〔α〕D 22 + 51.5°(c 1.02, MeOH)1 H-NMR(CD3OD):δ 4.69(1H, d, J1,2=1.5Hz, H-1) 3.78(1H, dd J5,6a=2.5Hz, J6a,6b=12Hz, H-6a) 3.74(1H, dd, J2,3=3Hz, H-2) 3.57(1H, t, J3,4=9.5Hz, H-4) 3.49(1H, ddd, H-5) 2.59(2H, t, J=7.5Hz, -CH2N) 1.6-1.25(12H, m, -(CH2)6-)9 (free base): amorphous powder [α] D 22 + 51.5 ° (c 1.02, MeOH) 1 H-NMR (CD 3 OD): δ 4.69 (1H, d, J 1 , 2 = 1.5Hz , H-1) 3.78 (1H, dd J 5 , 6a = 2.5Hz, J 6a , 6b = 12Hz, H-6a) 3.74 (1H, dd, J 2 , 3 = 3Hz, H-2) 3.57 (1H, t, J 3 , 4 = 9.5Hz, H-4) 3.49 (1H, ddd, H-5) 2.59 (2H, t, J = 7.5Hz, -CH 2 N) 1.6-1.25 (12H, m,-( CH 2 ) 6- )
【0070】参考例8 8−フタルイミドオクチル
2,3,4,6−テトラ−O−ベンジル−β−D−マン
ノピラノシド(11)及び8−フタルイミドオクチル
2,3,4,6−テトラ−O−ベンジル−α−D−マン
ノピラノシド(12) (i)文献記載の方法(Bull. Soc. Chem. Jpn, 49, 26
39(1976))で合成した2,3,4,6−テトラ−O−ベ
ンジル−α−D−マンノピラノシルクロリド(10)
1.7g(2.89ミリモル)のトルエン10ml溶液を
窒素気流下、撹拌しながら−18℃で8−フタルイミド
オクタノール(4)795mg(2.89ミリモル)、粉
末状モレキュラーシーブ4Aを2g及び銀シリケート2
gのトルエン懸濁液に滴下した。冷却浴を除き更に室温
で18時間撹拌した。反応混合物をセライトを用いて濾
過した後、濾液を減圧下で濃縮乾固した。得られた残渣
をローバーカラム C(ヘキサン−酢酸エチル=4:
1)で精製して、標記化合物(11)1.51g(6
5.4%)及び標記化合物(12)180mg(7.8
%)を得た。Reference Example 8 8-phthalimidooctyl
2,3,4,6-Tetra-O-benzyl-β-D-mannopyranoside (11) and 8-phthalimidooctyl 2,3,4,6-tetra-O-benzyl-α-D-mannopyranoside (12) ( i) Method described in literature (Bull. Soc. Chem. Jpn, 49, 26
39 (1976)), 2,3,4,6-tetra-O-benzyl-α-D-mannopyranosyl chloride (10)
A solution of 1.7 g (2.89 mmol) of toluene in 10 ml of nitrogen was stirred at -18 ° C at -18 ° C to prepare 795 mg (2.89 mmol) of 8-phthalimidooctanol (4), 2 g of powdery molecular sieve 4A and silver silicate. Two
g to a toluene suspension. The cooling bath was removed, and the mixture was further stirred at room temperature for 18 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated to dryness under reduced pressure. The obtained residue was rovers column C (hexane-ethyl acetate = 4:
Purified in 1), 1.51 g (6) of the title compound (11).
5.4%) and 180 mg (7.8) of the title compound (12).
%) Was obtained.
【0071】11:シロップ状 〔α〕D 26 - 39.2°(c 0.13, CHCl3) IR(film)cm-1 : 1770, 1712, 1496, 1467, 1396, 1365,
1105, 10681 H-NMR(CDCl3):δ 7.82(2H, dd, aromatic H) 7.68(2H, dd, aromatic H) 7.5-7.2(20H, m, aromatic H) 3.96(1H, s, H-1) 1.7-1.2(12H, m, -(CH2)6-)11: Syrup-like [α] D 26 -39.2 ° (c 0.13, CHCl 3 ) IR (film) cm −1 : 1770, 1712, 1496, 1467, 1396, 1365,
1105, 1068 1 H-NMR (CDCl 3 ): δ 7.82 (2H, dd, aromatic H) 7.68 (2H, dd, aromatic H) 7.5-7.2 (20H, m, aromatic H) 3.96 (1H, s, H- 1) 1.7-1.2 (12H, m,-(CH 2 ) 6- )
【0072】12:シロップ状 〔α〕D 26 + 26.2℃ (c 0.13, CHCl3) IR(film)cm-1 : 1770, 1712, 1496, 1467, 1346, 1365,
1105, 10681 H-NMR(CDCl3):δ 7.82(2H, dd, aromatic H) 7.68(2H, dd, aromatic H) 7.4-7.2(20H, m, aromatic H) 4.62(1H, s, H-1) 3.97(1H, t, J3,4=9.5Hz, H-4) 3.80(1H, dd, J2,3=3Hz, J3,4=9.5Hz, H-3) 3.31(1H, m, -CH2N) 1.7-1.2(12H, m, -(CH2)6-)12: Syrup [α] D 26 + 26.2 ° C. (c 0.13, CHCl 3 ) IR (film) cm −1 : 1770, 1712, 1496, 1467, 1346, 1365,
1105, 1068 1 H-NMR (CDCl 3 ): δ 7.82 (2H, dd, aromatic H) 7.68 (2H, dd, aromatic H) 7.4-7.2 (20H, m, aromatic H) 4.62 (1H, s, H- 1) 3.97 (1H, t, J 3 , 4 = 9.5Hz, H-4) 3.80 (1H, dd, J 2 , 3 = 3Hz, J 3 , 4 = 9.5Hz, H-3) 3.31 (1H, m , -CH 2 N) 1.7-1.2 (12H, m,-(CH 2 ) 6- )
【0073】(ii)2,3,4,6−テトラ−O−ベン
ジル−α−D−マンノピラノシルクロリド(10)8.
9g(14.5ミリモル)の塩化メチレン20ml溶液
を、アルゴン気流下、室温で、8−フタルイミドオクタ
ノール(4)10.0g(36.25ミリモル)、炭酸
銀7.8g(26.1ミリモル)及び硫酸カルシウム
7.8gの塩化メチレン50ml懸濁液に滴下した。反応
混合物をアルミホイルで遮光して、更に室温で19時間
撹拌した。反応混合物をセライトを用いて濾過した後、
濾液を減圧下で濃縮乾固した。得られた残渣をシリカゲ
ルカラムクロマトグラフィー(ヘキサン−酢酸エチル=
4:1)で精製して上記と同一の標記化合物(11)
7.49g(65.7%)を得た。(Ii) 2,3,4,6-tetra-O-benzyl-α-D-mannopyranosyl chloride (10) 8.
A solution of 9 g (14.5 mmol) in 20 ml of methylene chloride was added to a solution of 10.0 g (36.25 mmol) of 8-phthalimidooctanol (4), 7.8 g (26.1 mmol) of silver carbonate at room temperature under a stream of argon. It was added dropwise to a suspension of 7.8 g of calcium sulfate in 50 ml of methylene chloride. The reaction mixture was protected from light with an aluminum foil and further stirred at room temperature for 19 hours. After filtering the reaction mixture through Celite,
The filtrate was concentrated to dryness under reduced pressure. The obtained residue is subjected to silica gel column chromatography (hexane-ethyl acetate =
4: 1) and the same title compound (11) as above
7.49 g (65.7%) were obtained.
【0074】参考例9 8−アミノオクチル 2,3,
4,6−テトラ−O−ベンジル−β−D−マンノピラノ
シド(13) 化合物(11)1.39g(1.74ミリモル)及びヒ
ドラジン酢酸塩8.0g(87ミリモル)をメタノール
90mlに溶解した後、油浴上で4時間加熱還流した。室
温まで冷却した後、反応混合物を大量の水に注ぎ、析出
した生成物を酢酸エチルで抽出した。有機層を分離して
水で洗浄した後、硫酸マグネシウムで乾燥し減圧下で溶
媒を留去した。得られた結晶性残渣にエーテルを加えて
濾取して化合物(13)1.1g(95%)を得た。Reference Example 9 8-aminooctyl 2,3
4,6-Tetra-O-benzyl-β-D-mannopyranoside (13) 1.39 g (1.74 mmol) of compound (11) and 8.0 g (87 mmol) of hydrazine acetate were dissolved in 90 ml of methanol. The mixture was heated under reflux on an oil bath for 4 hours. After cooling to room temperature, the reaction mixture was poured into a large amount of water, and the precipitated product was extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. Ether was added to the obtained crystalline residue and filtered to obtain 1.1 g (95%) of compound (13).
【0075】13: m.p. 89-90℃ 〔α〕D 23 - 42.2°(c 0.49, MeOH) IR(film)cm-1 : 1661, 1603, 1497, 1454, 1302, 1113,
10591 H-NMR(CDCl3):δ 7.5-7.1(20H, m, aromatic H) 4.37(1H, s, H-1) 3.90(1H, dd, J2,3=2.5Hz, H-2) 3.85(1H, t, J3,4=9.5Hz, H-4) 3.50(1H, dd, J2,3=2.5Hz, J3,4=9.5Hz, H-3) 2.66(2H, t, -CH2N) 1.7-1.2(12H, m, -(CH2)6-)13: mp 89-90 ° C. [α] D 23 -42.2 ° (c 0.49, MeOH) IR (film) cm −1 : 1661, 1603, 1497, 1454, 1302, 1113,
1059 1 H-NMR (CDCl 3 ): δ 7.5-7.1 (20H, m, aromatic H) 4.37 (1H, s, H-1) 3.90 (1H, dd, J 2 , 3 = 2.5Hz, H-2) 3.85 (1H, t, J 3 , 4 = 9.5Hz, H-4) 3.50 (1H, dd, J 2 , 3 = 2.5Hz, J 3 , 4 = 9.5Hz, H-3) 2.66 (2H, t, -CH 2 N) 1.7-1.2 (12H, m,-(CH 2 ) 6- )
【0076】参考例10 8−ベンジルオキシカルボニ
ルアミノオクチル 2,3,4,6−テトラ−O−ベン
ジル−α−D−マンノピラノシド(14) 化合物(13)0.29g及びトリエチルアミン0.0
7gのクロロホルム20ml溶液に、室温で撹拌しながら
ベンジルオキシカルボニルクロリド0.044gを加え
た。室温で3時間撹拌した後、反応混合物を水で洗浄し
た。有機層を分離して硫酸ナトリウムで乾燥した後、減
圧下で濃縮乾固した。得られた残渣をシリカゲルカラム
クロマトグラフィー(ヘキサン−酢酸エチル=4:1)
で精製して標記化合物(14)0.29g(83%)を
得た。Reference Example 10 8-Benzyloxycarbonylaminooctyl 2,3,4,6-tetra-O-benzyl-α-D-mannopyranoside (14) 0.29 g of the compound (13) and 0.03 of triethylamine.
To a solution of 7 g of chloroform in 20 ml, 0.044 g of benzyloxycarbonyl chloride was added with stirring at room temperature. After stirring at room temperature for 3 hours, the reaction mixture was washed with water. The organic layer was separated, dried over sodium sulfate, and then concentrated to dryness under reduced pressure. The obtained residue is subjected to silica gel column chromatography (hexane-ethyl acetate = 4: 1).
The title compound (14) (0.29 g, 83%) was obtained after purification.
【0077】14:無定形粉末 〔α〕D 22 - 38.7°(c 1.27, CHCl3)1 H-NMR(CDCl3):δ 7.16-7.48(25H, m, aromatic H) 4.38(1H, s, H-1) 3.17(2H, m) 1.67-1.25(12H, m, -(CH2)6-)14: Amorphous powder [α] D 22 -38.7 ° (c 1.27, CHCl 3 ) 1 H-NMR (CDCl 3 ): δ 7.16-7.48 (25H, m, aromatic H) 4.38 (1H, s, H-1) 3.17 (2H, m) 1.67-1.25 (12H, m,-(CH 2 ) 6- )
【0078】参考例11 8−アミノオクチル β−D
−マンノピラノシド(15) 塩酸塩 化合物(13)200mg(0.299ミリモル)のメタ
ノール15ml溶液に、1M 塩酸0.3ml及び10%パラ
ジウム−炭素50mgを加え、室温で8時間水素添加し
た。触媒を濾去後、濾液を減圧下で濃縮乾固して、標記
化合物(15)の塩酸塩153mgを得た。Reference Example 11 8-Aminooctyl β-D
-Mannopyranoside (15) hydrochloride To a solution of 200 mg (0.299 mmol) of compound (13) in 15 ml of methanol was added 0.3 ml of 1M hydrochloric acid and 50 mg of 10% palladium-carbon and hydrogenated at room temperature for 8 hours. After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure to obtain 153 mg of the hydrochloride of the title compound (15).
【0079】15(塩酸塩):無定形粉末 〔α〕D 24 - 10.3°(c 0.62, MeOH) IR(KBr)cm-1 : 3358, 1614, 10741 H-NMR(CD3OD):δ 4.49(1H, s, H-1) 3.44(1H, dd, J5,6b=3.5Hz, H-6b) 3.19(1H, ddd, H-5) 2.90(2H, t, J=7.5Hz, -CH2N) 1.7-1.3(12H, m, -(CH2)6-)[0079] 15 (hydrochloride): amorphous powder [α] D 24 - 10.3 ° (c 0.62 , MeOH) IR (KBr) cm -1: 3358, 1614, 1074 1 H-NMR (CD 3 OD): δ 4.49 (1H, s, H-1) 3.44 (1H, dd, J 5 , 6b = 3.5Hz, H-6b) 3.19 (1H, ddd, H-5) 2.90 (2H, t, J = 7.5Hz,- CH 2 N) 1.7-1.3 (12H, m,-(CH 2 ) 6- )
【0080】参考例12 8−アミノオクチル β−D
−マンノピラノシド(15)のp−トルエンスルホン酸
塩 化合物(14)2.64g(3.3ミリモル)及びp−
トルエンスルホン酸0.63g(3.3ミリモル)をメ
タノール20mlに溶解した後、10%パラジウム−炭素
50mgを加え、室温で3時間水素添加した。触媒を濾過
した後、濾液を減圧下で濃縮乾固して、標記化合物(1
5)のp−トルエンスルホン酸塩1.57g(定量的)
を得た。Reference Example 12 8-Aminooctyl β-D
P-toluenesulfonate of mannopyranoside (15) 2.64 g (3.3 mmol) of compound (14) and p-
After dissolving 0.63 g (3.3 mmol) of toluenesulfonic acid in 20 ml of methanol, 50 mg of 10% palladium-carbon was added and hydrogenated at room temperature for 3 hours. After filtering the catalyst, the filtrate was concentrated to dryness under reduced pressure to give the title compound (1
1.57 g of p-toluenesulfonate of 5) (quantitative)
I got
【0081】15(p−トルエンスルホン酸塩):無定
形粉末 〔α〕D 24 - 10.3°(c 0.62, MeOH) IR(KBr)cm-1 : 3358, 1614, 10741 H-NMR(CD3OD):δ 7.71(2H, d, J=7.8Hz, aromatic H) 7.23(2H, d, J=7.8Hz, aromatic H) 4.49(1H, d, J1,2=0.7Hz, H-1) 3.24(2H, m) 2.90(2H, t, J=7.5Hz, -CH2N) 1.65-1.4(12H, m, -(CH2)6-)[0081] 15 (p-toluenesulfonate): amorphous powder [α] D 24 - 10.3 ° (c 0.62 , MeOH) IR (KBr) cm -1: 3358, 1614, 1074 1 H-NMR (CD 3 OD): δ 7.71 (2H, d, J = 7.8Hz, aromatic H) 7.23 (2H, d, J = 7.8Hz, aromatic H) 4.49 (1H, d, J 1 , 2 = 0.7Hz, H-1) 3.24 (2H, m) 2.90 (2H, t, J = 7.5Hz, -CH 2 N) 1.65-1.4 (12H, m,-(CH 2 ) 6- )
【0082】参考例13 8−アミノオクチル−β−D
−マンノピラノシド(15) 参考例11の方法で合成した8−アミノオクチル β−
D−マンノピラノシド(15)の塩酸塩を含水メタノー
ルに溶解した後、イオン交換樹脂IRC−50(NH4
型)のカラム(4.5cm×40cm)を通した。水800
mlで溶出した後、6%アンモニア水1,700mlで溶出
した。1,000mlの溶出液を流した後の分画を集め
て、減圧下で濃縮乾固して、標記化合物(15)の遊離
塩基1.305g(58%)を得た。Reference Example 13 8-Aminooctyl-β-D
-Mannopyranoside (15) 8-aminooctyl β- synthesized by the method of Reference Example 11
After dissolving the hydrochloride of D-mannopyranoside (15) in water-containing methanol, the ion-exchange resin IRC-50 (NH 4
Type) column (4.5 cm × 40 cm). Water 800
After elution with 1 ml of 6% aqueous ammonia, the elution was performed with 1700 ml of 6% aqueous ammonia. Fractions were collected after flowing 1,000 ml of eluate and concentrated to dryness under reduced pressure to give 1.305 g (58%) of the free base of the title compound (15).
【0083】15(遊離塩基):無定形粉末 〔α〕D 21 - 38.9°(c 1.01, MeOH)1 H-NMR(D2O):δ 4.66(1H, d, J1,2=1.0Hz, H-1) 3.97(1H, d, J2,3=3.0Hz, H-2) 3.92(1H, dd, J5,6a=2.2Hz, J6a,6b=12Hz, H-6a) 3.87(1H, dd, J=3.2Hz, 10Hz, -CH2O) 3.72(1H, dd, J5,6b=6.6Hz, H-6b) 3.65(1H, m, -CH2O) 3.63(1H, dd, J2,3=3.2, J3,4=9.8Hz, H-3) 3.56(1H, t, J3,4=9.8Hz, H-4) 3.35(1H, ddd, H-5) 2.68(2H, t, J=7.0Hz, -CH2N) 1.60-1.30(12H, m, -(CH2)6-)15 (free base): amorphous powder [α] D 21 -38.9 ° (c 1.01, MeOH) 1 H-NMR (D 2 O): δ 4.66 ( 1 H, d, J 1 , 2 = 1.0 Hz) , H-1) 3.97 (1H, d, J 2 , 3 = 3.0Hz, H-2) 3.92 (1H, dd, J 5 , 6a = 2.2Hz, J 6a , 6b = 12Hz, H-6a) 3.87 ( 1H, dd, J = 3.2Hz, 10Hz, -CH 2 O) 3.72 (1H, dd, J 5 , 6b = 6.6Hz, H-6b) 3.65 (1H, m, -CH 2 O) 3.63 (1H, dd , J 2 , 3 = 3.2, J 3 , 4 = 9.8Hz, H-3) 3.56 (1H, t, J 3 , 4 = 9.8Hz, H-4) 3.35 (1H, ddd, H-5) 2.68 ( 2H, t, J = 7.0Hz, -CH 2 N) 1.60-1.30 (12H, m,-(CH 2 ) 6- )
【0084】参考例14 8−フタルイミドオクチル
3,4,6−トリ−O−アセチル−2−アジド−2−デ
オキシ−β−D−マンノピラノシド(17)及び8−フ
タルイミドオクチル 3,4,6−トリ−O−アセチル
−2−アジド−2−デオキシ−α−D−マンノピラノシ
ド(18)Reference Example 14 8-phthalimidooctyl
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-β-D-mannopyranoside (17) and 8-phthalimidooctyl 3,4,6-tri-O-acetyl-2-azide-2 -Deoxy-α-D-mannopyranoside (18)
【0085】文献記載の方法(Carbohydr. Res., 136,
153(1985))で合成した3,4,6−トリ−O−アセチル
−2−アジド−2−デオキシ−α−D−マンノピラノシ
ルブロミド(16)9.5g(24.1ミリモル)のト
ルエン80ml溶液を、窒素気流下撹拌しながら−15℃
で、8−フタルイミドオクタノール(4)6.63g
(24.09ミリモル)、粉末状モレキュラーシーブ4
Aを10g、銀シリケート10gのトルエン80ml懸濁
液に滴下した。反応混合物を同温度で3時間撹拌した。
冷却浴を除き更に室温で15時間撹拌した。反応混合物
をセライトを用いて濾過した後、濾液を減圧下で濃縮乾
固した。得られた残渣をローバーカラムC(ヘキサン−
酢酸エチル=2:1)で精製して、標記化合物(17)
5.01g(35.6%)及び標記化合物(18)1.
84g(12.4%)を得た。Methods described in literature (Carbohydr. Res., 136,
153 (1985)), 9.5 g (24.1 mmol) of 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-mannopyranosyl bromide (16) Is stirred at -15 ° C under a nitrogen stream.
Then, 6.63 g of 8-phthalimidooctanol (4)
(24.09 mmol), powdered molecular sieve 4
10 g of A and 10 g of silver silicate were added dropwise to a suspension of 80 ml of toluene. The reaction mixture was stirred at the same temperature for 3 hours.
The cooling bath was removed, and the mixture was further stirred at room temperature for 15 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated to dryness under reduced pressure. The obtained residue is applied to a row bar column C (hexane-
Purify with ethyl acetate = 2: 1) to give the title compound (17)
5.01 g (35.6%) and the title compound (18) 1.
84 g (12.4%) was obtained.
【0086】17:シロップ状 〔α〕D 23 - 49°(c 0.5, CHCl3) IR(CHCl3)cm-1 : 2250, 1750, 1715, 1398, 13701 H-NMR(CDCl3):δ 7.82(2H, dd, aromatic H) 7.69(2H, dd, aromatic H) 5.23(1H, t, J3,4=9.5Hz, H-4) 4.96(1H, dd, J2,3=3.5Hz, H-3) 4.64(1H, d, J1,2=1.5Hz, H-1) 4.25(1H, dd, J5,6a=5Hz, J6a,6b=12.5Hz, H-6a) 4.11(1H, dd, J5,6b=2.5Hz, H-6b) 4.07(1H, dd, J2,3=3.5Hz, H-2) 3.89(1H, m, CH2N) 3.65(1H, t, J=7.5Hz, -CH2O) 3.58(1H, ddd, H-5) 3.48(1H, m, -CH2N) 2.09(3H, s, OAc) 2.07(3H, s, OAc) 2.02(3H, s, OAc) 1.7-1.2(12H, m, -(CH2)6-)17: Syrup-like [α] D 23 -49 ° (c 0.5, CHCl 3 ) IR (CHCl 3 ) cm -1 : 2250, 1750, 1715, 1398, 1370 1 H-NMR (CDCl 3 ): δ 7.82 (2H, dd, aromatic H) 7.69 (2H, dd, aromatic H) 5.23 (1H, t, J 3 , 4 = 9.5Hz, H-4) 4.96 (1H, dd, J 2 , 3 = 3.5Hz, H-3) 4.64 (1H, d, J 1 , 2 = 1.5Hz, H-1) 4.25 (1H, dd, J 5 , 6a = 5Hz, J 6a , 6b = 12.5Hz, H-6a) 4.11 (1H , dd, J 5 , 6b = 2.5Hz, H-6b) 4.07 (1H, dd, J 2 , 3 = 3.5Hz, H-2) 3.89 (1H, m, CH 2 N) 3.65 (1H, t, J = 7.5Hz, -CH 2 O) 3.58 (1H, ddd, H-5) 3.48 (1H, m, -CH 2 N) 2.09 (3H, s, OAc) 2.07 (3H, s, OAc) 2.02 (3H, s, OAc) 1.7-1.2 (12H, m,-(CH 2 ) 6- )
【0087】18:シロップ状 〔α〕D 23 + 47.7°(c 0.56, CHCl3) IR(CHCl3)cm-1 : 2250, 1750, 1715, 1398, 13701 H-NMR(CDCl3):δ 7.83(2H, dd, aromatic H) 7.70(2H, dd, aromatic H) 5.38(1H, dd, J2,3=4Hz, J3,4=9.5Hz, H-3) 5.30(1H, t, J3,4=9.5Hz, H-4) 4.81(1H, d, J1,2=1.5Hz, H-1) 4.24(1H, dd, J5,6a=5Hz, J6a,6b=12.5Hz, H-6a) 4.07(1H, dd, J5,6b=2.5Hz, H-6b) 4.00(1H, dd, J2,3=3.5Hz, H-2) 3.72-3.62(3H, m, -CH2O, -CH2N) 3.41(1H, m, -CH2N) 3.58 (1H, ddd, H-5) 2.09 (3H, s, OAc) 2.08 (3H, s, OAc) 2.04 (3H, s, OAc) 1.7-1.2 (12H, m, -(CH2)6-)18: syrupy [α] D 23 + 47.7 ° (c 0.56, CHCl 3 ) IR (CHCl 3 ) cm -1 : 2250, 1750, 1715, 1398, 1370 1 H-NMR (CDCl 3 ): δ 7.83 (2H, dd, aromatic H) 7.70 (2H, dd, aromatic H) 5.38 (1H, dd, J 2 , 3 = 4Hz, J 3 , 4 = 9.5Hz, H-3) 5.30 (1H, t, J 3 , 4 = 9.5Hz, H-4) 4.81 (1H, d, J 1 , 2 = 1.5Hz, H-1) 4.24 (1H, dd, J 5 , 6a = 5Hz, J 6a , 6b = 12.5Hz, H-6a) 4.07 (1H, dd, J 5 , 6b = 2.5Hz, H-6b) 4.00 (1H, dd, J 2 , 3 = 3.5Hz, H-2) 3.72-3.62 (3H, m, -CH 2 O, -CH 2 N) 3.41 (1H, m, -CH 2 N) 3.58 (1H, ddd, H-5) 2.09 (3H, s, OAc) 2.08 (3H, s, OAc) 2.04 (3H, s , OAc) 1.7-1.2 (12H, m,-(CH 2 ) 6- )
【0088】参考例15 8−フタルイミドオクチル
2−アジド−2−デオキシ−β−D−マンノピラノシド
(19) 化合物(17)4.0g(6.795ミリモル)のメタ
ノール55ml溶液に1M ナトリウムメトキシド−メタノ
ール溶液1.7mlを加え室温に16時間放置した。反応
液にイオン交換樹脂アンバーライトIR−120B(H
+ 型)を加えて中和した後、樹脂を濾去しメタノールで
洗浄した。濾液及び洗液を合わせ減圧下で濃縮乾固し
た。得られた残渣をシリカゲルカラムクロマトグラフィ
ー(クロロホルム−メタノール=10:1)で精製し
て、標記化合物(19)1.82g(58%)を得た。Reference Example 15 8-phthalimidooctyl
2-Azido-2-deoxy-β-D-mannopyranoside (19) To a solution of 4.0 g (6.795 mmol) of compound (17) in 55 ml of methanol was added 1.7 ml of a 1M sodium methoxide-methanol solution and the mixture was allowed to stand at room temperature for 16 hours. I left it. Ion exchange resin Amberlite IR-120B (H
(+ Type) was added to neutralize, the resin was filtered off, and washed with methanol. The filtrate and washings were combined and concentrated to dryness under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol = 10: 1) to obtain 1.82 g (58%) of the title compound (19).
【0089】19:シロップ状 〔α〕D 28 - 72.5°(c 1.03, CHCl3) IR(CHCl3)cm-1 : 3500, 2114, 1772, 1711, 1398, 10721 H-NMR(CD3OD):δ 7.77(2H, dd, aromatic H) 7.83(2H, dd, aromatic H) 4.64(1H, d, J1,2=1.5Hz, H-1) 3.89(1H, m, -CH2N) 3.56(1H, dd, J2,3=3.5Hz, J3,4=9.5Hz, H-3) 3.50(1H, m, -CH2N) 3.39(1H, t, J=9.5Hz, H-4) 3.16(1H, ddd, J5,6a=2.5Hz, J5,6b=6.3Hz, H-5) 1.7-1.25(12H, m, -(CH2)6-)19: Syrup [α] D 28 -72.5 ° (c 1.03, CHCl 3 ) IR (CHCl 3 ) cm -1 : 3500, 2114, 1772, 1711, 1398, 1072 1 H-NMR (CD 3 OD ): δ 7.77 (2H, dd, aromatic H) 7.83 (2H, dd, aromatic H) 4.64 (1H, d, J 1 , 2 = 1.5Hz, H-1) 3.89 (1H, m, -CH 2 N) 3.56 (1H, dd, J 2 , 3 = 3.5Hz, J 3 , 4 = 9.5Hz, H-3) 3.50 (1H, m, -CH 2 N) 3.39 (1H, t, J = 9.5Hz, H- 4) 3.16 (1H, ddd, J 5 , 6a = 2.5Hz, J 5 , 6b = 6.3Hz, H-5) 1.7-1.25 (12H, m,-(CH 2 ) 6- )
【0090】参考例16 8−フタルイミドオクチル
2−アセトアミド−2−デオキシ−β−D−マンノピラ
ノシド(20) 化合物(19)1.68g(3.63ミリモル)のエタ
ノール43ml溶液に、塩化ニッケル六水和物380mg
(1.6ミリモル)をエタノール10mlに溶解した液
0.68mlを加えた後、水素化ホウ素ナトリウム412
mg(10.89ミリモル)をエタノール40mlに溶解し
た液を撹拌しながらゆっくりと滴下した。室温で30分
間撹拌した後、反応液に酢酸を加えて中和した。反応混
合物に無水酢酸2mlを加え室温に18時間放置した。反
応混合物を減圧下で濃縮乾固した後、得られた残渣をシ
リカゲルカラムクロマトグラフィー(クロロホルム−メ
タノール=7:1)で精製して、標記化合物(20)5
87mg(34%)を得た。Reference Example 16 8-phthalimidooctyl
2-Acetamido-2-deoxy-β-D-mannopyranoside (20) To a solution of 1.68 g (3.63 mmol) of compound (19) in 43 ml of ethanol, 380 mg of nickel chloride hexahydrate was added.
After adding 0.68 ml of a solution prepared by dissolving (1.6 mmol) in 10 ml of ethanol, sodium borohydride 412 was added.
A solution of mg (10.89 mmol) dissolved in 40 ml of ethanol was slowly added dropwise while stirring. After stirring at room temperature for 30 minutes, acetic acid was added to the reaction solution to neutralize it. 2 ml of acetic anhydride was added to the reaction mixture and the mixture was allowed to stand at room temperature for 18 hours. After the reaction mixture was concentrated to dryness under reduced pressure, the obtained residue was purified by silica gel column chromatography (chloroform-methanol = 7: 1) to give the title compound (20) 5.
87 mg (34%) were obtained.
【0091】20:無定形粉末 〔α〕D 26.5 - 28.2°(c 1.42, MeOH) IR(KBr)cm-1 : 3425, 1672, 10601 H-NMR(CD3OD):δ 7.7-7.5(4H, m, aromatic H) 4.58(1H, d, J1,2=1.5Hz, H-1) 4.36(1H, dd, J2,3=3.5Hz, H-2) 3.48(1H, t, J3,4=9.5Hz, H-4) 2.00(3H, s, NAc) 1.8-1.2(12H, m, -(CH2)6-)[0091] 20: amorphous powder [α] D 26.5 - 28.2 ° (c 1.42 , MeOH) IR (KBr) cm -1: 3425, 1672, 1060 1 H-NMR (CD 3 OD): δ 7.7-7.5 ( 4H, m, aromatic H) 4.58 (1H, d, J 1 , 2 = 1.5Hz, H-1) 4.36 (1H, dd, J 2 , 3 = 3.5Hz, H-2) 3.48 (1H, t, J 3 , 4 = 9.5Hz, H-4) 2.00 (3H, s, NAc) 1.8-1.2 (12H, m,-(CH 2 ) 6- )
【0092】参考例17 8−アミノオクチル 2−ア
セトアミド−2−デオキシ−β−D−マンノピラノシド
(21) 化合物(20)580g(1.212ミリモル)のエタ
ノール10ml溶液に、ヒドラジン・水和物2mlを加えて
70℃で5時間加熱還流した。室温まで冷却した後、反
応液にトルエンを加えて希釈し、減圧化で溶媒を留去し
た。得られた残渣をシリカゲルカラムクロマトグラフィ
ー(クロロホルム−メタノール=7:1)で精製して、
標記化合物(21)140mg(34%)を得た。同時に
化合物(20)121mgを回収した。Reference Example 17 8-aminooctyl 2-acetamido-2-deoxy-β-D-mannopyranoside (21) A solution of 580 g (1.212 mmol) of compound (20) in 10 ml of ethanol was mixed with 2 ml of hydrazine hydrate. In addition, the mixture was heated under reflux at 70 ° C for 5 hours. After cooling to room temperature, the reaction solution was diluted by adding toluene, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol = 7: 1),
140 mg (34%) of the title compound (21) was obtained. At the same time, 121 mg of compound (20) was recovered.
【0093】21:無定形粉末 〔α〕D 21 - 35.8°(c 0.45, MeOH) IR(KBr)cm-1 : 3350, 1715, 1660, 1545, 1370, 10701 H-NMR(CD3OD):δ 4.47(1H, s, H-1) 4.56(1H, dd, J1,2=1.5Hz, J2,3=3.5Hz, H-2) 1.98(3H, s, NAc) 1.6-1.2(12H, m, -(CH2)6-)21: Amorphous powder [α] D 21 -35.8 ° (c 0.45, MeOH) IR (KBr) cm -1 : 3350, 1715, 1660, 1545, 1370, 1070 1 H-NMR (CD 3 OD) : δ 4.47 (1H, s, H-1) 4.56 (1H, dd, J 1 , 2 = 1.5Hz, J 2 , 3 = 3.5Hz, H-2) 1.98 (3H, s, NAc) 1.6-1.2 ( 12H, m,-(CH 2 ) 6- )
【0094】参考例18 8−フタルイミドオクチル
2,3,4,6−テトラ−O−アセチル−β−D−ガラ
クトピラノシド(23) 8−フタルイミドオクタノール(4)2.75g(10
ミリモル)、シアン化第2銀2.53g(10ミリモ
ル)及び無水硫酸カルシウム5gの乾燥ベンゼン50ml
−乾燥ニトロメタン50mlの懸濁液を、アルゴン気流下
室温で30分間撹拌した。この懸濁液に2,3,4,6
−テトラ−O−アセチル−α−D−ガラクトピラノシル
ブロミド(22)6g(14.6ミリモル)を乾燥ベン
ゼン20mlに溶解した液を室温で撹拌しながら滴下し
た。反応混合物を室温で12時間撹拌した。反応混合物
をセライトを用いて濾過した後、濾液を減圧下で濃縮乾
固した。得られた残渣をフラッシュカラムクロマトグラ
フィー(酢酸エチル−ヘキサン=1:1)で精製して、
標記化合物(23)5.48g(90.5%)を無色油
状物として得た。Reference Example 18 8-phthalimidooctyl
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranoside (23) 8-phthalimidooctanol (4) 2.75 g (10)
50 ml of dry benzene, 2.53 g (10 mmol) of silver cyano cyanide and 5 g of anhydrous calcium sulfate.
A suspension of 50 ml of dry nitromethane was stirred for 30 minutes at room temperature under a stream of argon. 2, 3, 4, 6 in this suspension
A solution of 6 g (14.6 mmol) of tetra-O-acetyl-α-D-galactopyranosyl bromide (22) in 20 ml of dry benzene was added dropwise at room temperature with stirring. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated to dryness under reduced pressure. The obtained residue was purified by flash column chromatography (ethyl acetate-hexane = 1: 1),
5.48 g (90.5%) of the title compound (23) was obtained as a colorless oil.
【0095】23:シロップ状 〔α〕D 27 - 1.02°(c 2.25, CHCl3) IR(CHCl3)cm-1 : 1750, 17101 H-NMR(CDCl3):δ 7.80-7.85(2H, m, aromatic H) 7.65-7.70(2H, m, aromatic H) 5.36(1H, d, J3,4=3.4Hz, H-4) 5.18(1H, dd, J2,3=10.5Hz, J1,2=7.8Hz, H-2) 4.99(1H, dd, J2,3=10.5Hz, J3,4=3.4Hz, H-3) 4.43(1H, d, J1,2=7.8Hz, H-1) 4.05-4.20(2H, m, -CH2O) 3.82-3.90(2H, m, -CH2O) 3.65(2H, t, J=7.6Hz, -CH2N) 3.40-3.50(1H, m, H-5) 2.12(3H, s, OAc) 2.03(6H, s, OAc ×2) 1.96(3H, s, OAc) 1.50-1.70(4H, m, CH2×2) 1.20-1.40(8H, m, CH2×4)[0095] 23: syrup [α] D 27 - 1.02 ° (c 2.25 , CHCl 3) IR (CHCl 3) cm -1: 1750, 1710 1 H-NMR (CDCl 3): δ 7.80-7.85 (2H, m, aromatic H) 7.65-7.70 (2H, m, aromatic H) 5.36 (1H, d, J 3 , 4 = 3.4Hz, H-4) 5.18 (1H, dd, J 2 , 3 = 10.5Hz, J 1 , 2 = 7.8Hz, H-2) 4.99 (1H, dd, J 2 , 3 = 10.5Hz, J 3 , 4 = 3.4Hz, H-3) 4.43 (1H, d, J 1 , 2 = 7.8Hz, H-1) 4.05-4.20 (2H, m, -CH 2 O) 3.82-3.90 (2H, m, -CH 2 O) 3.65 (2H, t, J = 7.6Hz, -CH 2 N) 3.40-3.50 ( 1H, m, H-5) 2.12 (3H, s, OAc) 2.03 (6H, s, OAc x 2) 1.96 (3H, s, OAc) 1.50-1.70 (4H, m, CH 2 x 2) 1.20-1.40 (8H, m, CH 2 × 4)
【0096】参考例19 8−フタルイミドオクチル
β−D−ガラクトピラノシド(24) 化合物(23)5.4g(8.9ミリモル)のメタノー
ル100ml溶液に28%ナトリウムメトキシド−メタノ
ール溶液0.5mlを加え、室温で16時間撹拌した。反
応混合物を減圧下で濃縮乾固した。得られた残渣を水5
0mlに溶解した後、イオン交換樹脂アンバーライトIR
−120B(H+ 型)を加えて中和した。樹脂を濾去し
た後、濾液を減圧下で濃縮乾固して、標記化合物(2
4)1.61g(41.3%)を得た。Reference Example 19 8-phthalimidooctyl
β-D-galactopyranoside (24) 0.5 ml of 28% sodium methoxide-methanol solution was added to a solution of 5.4 g (8.9 mmol) of compound (23) in 100 ml of methanol, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated to dryness under reduced pressure. The residue obtained is treated with water 5
After dissolving in 0 ml, ion exchange resin Amberlite IR
Neutralization was carried out by adding -120B (H + type). After the resin was filtered off, the filtrate was concentrated to dryness under reduced pressure to give the title compound (2
4) 1.61 g (41.3%) was obtained.
【0097】24: m.p. 123-125℃ 〔α〕D 27 - 11.4°(c 1.09, CHCl3)1 H-NMR(CD3OD):δ 7.80-7.90(2H, m, aromatic H) 7.75-7.80(2H, m, aromatic H) 4.16(1H, d, J1,2=7.6Hz, H-1) 3.82-3.88(1H, m) 3.79(1H, d, J=2.7Hz) 3.65-3.75(2H, m) 3.62(2H, t, J=7.3Hz, -CH2O) 3.40-3.52(4H, m) 1.50-1.70(4H, m, CH2×2) FAB−Mass : m/z 460(M+N
a)+, 438(M+H)+, 276, 258,
160[0097] 24: mp 123-125 ° C. [α] D 27 - 11.4 ° (c 1.09 , CHCl 3) 1 H-NMR (CD 3 OD): δ 7.80-7.90 (2H, m, aromatic H) 7.75-7.80 (2H, m, aromatic H) 4.16 (1H, d, J 1 , 2 = 7.6Hz, H-1) 3.82-3.88 (1H, m) 3.79 (1H, d, J = 2.7Hz) 3.65-3.75 (2H , m) 3.62 (2H, t, J = 7.3Hz, -CH 2 O) 3.40-3.52 (4H, m) 1.50-1.70 (4H, m, CH 2 × 2) FAB-Mass: m / z 460 (M + N)
a) + , 438 (M + H) + , 276, 258,
160
【0098】参考例20 8−アミノオクチル β−D
−ガラクトピラノシド(25) 化合物(24)970mg(2.22ミリモル)のエタ
ノール30ml溶液に、ヒドラジン・水和物500mgを加
えて油浴上66時間加熱還流した。室温まで冷却した
後、生じた不溶物を濾去した。濾液を減圧下に濃縮乾固
した。得られた粗生成物を精製水30mlに溶解した後、
濃塩酸を加えて中和した。反応混合物をイオン交換樹脂
IRC−50(NH4 +型)300mlのカラムに通した。
目的物を2Mアンモニア水800mlで溶出した。得られ
た溶出液を減圧下に濃縮乾固して、標記化合物(25)
の440mg(64.6%)を得た。Reference Example 20 8-aminooctyl β-D
-Galactopyranoside (25) To a solution of 970 mg (2.22 mmol) of compound (24) in 30 ml of ethanol was added 500 mg of hydrazine hydrate, and the mixture was heated under reflux on an oil bath for 66 hours. After cooling to room temperature, the resulting insoluble material was filtered off. The filtrate was concentrated to dryness under reduced pressure. After dissolving the obtained crude product in 30 ml of purified water,
It was neutralized by adding concentrated hydrochloric acid. The reaction mixture was passed through a column of 300 ml of ion exchange resin IRC-50 (NH 4 + type).
The target substance was eluted with 800 ml of 2M aqueous ammonia. The obtained eluate was concentrated to dryness under reduced pressure to give the title compound (25)
440 mg (64.6%) of
【0099】25: m.p. 135-142℃(EtOH-イソプロピ
ルエーテル) 〔α〕D 22 - 13.5°(c 0.55, MeOH)1 H-NMR(CD3OD):δ 4.19(1H, d, J1,2=7.6Hz, H-1) 3.85-3.92(1H, m) 3.81(2H, d, J=3.2Hz) 3.42-3.55(4H, m) 3.70-3.76(2H, q) 2.63(2H, t, J=7.1Hz, -CH2N) 1.58-1.65(2H, m, -CH2) 1.42-1.50(2H, m, -CH2) 1.35-1.42(2H, m, -CH2) 1.33(6H, m, -CH2×3) FAB-Mass : m/z 308(M+H)+, 146[0099] 25: mp 135-142 ℃ (EtOH- isopropyl ether) [α] D 22 - 13.5 ° (c 0.55 , MeOH) 1 H-NMR (CD 3 OD): δ 4.19 (1H, d, J 1, 2 = 7.6Hz, H-1) 3.85-3.92 (1H, m) 3.81 (2H, d, J = 3.2Hz) 3.42-3.55 (4H, m) 3.70-3.76 (2H, q) 2.63 (2H, t, J = 7.1Hz, -CH 2 N) 1.58-1.65 (2H, m, -CH 2 ) 1.42-1.50 (2H, m, -CH 2 ) 1.35-1.42 (2H, m, -CH 2 ) 1.33 (6H, m, -CH 2 × 3) FAB-Mass: m / z 308 (M + H) + , 146
【0100】参考例21 8−フタルイミドオクチル
2,3,4−トリ−O−アセチル−α−D−キシロピラ
ノシド(27)、8−フタルイミドオクチル 2,3,
4−トリ−O−アセチル−β−D−キシロピラノシド
(28)、及び8−フタルイミドオクチル 3,4−ジ
−O−アセチル−α−D−キシロピラノシド(29) 2,3,4−トリ−O−アセチル−α−D−キシロピラ
ノシルブロミド(26)1.85g(5.45ミリモ
ル)のベンゼン30ml溶液に、シアン化第二水銀1.3
8g(5.45ミリモル)、粉末状モレキュラーシーブ
4A(3.5g)及び8−フタルイミドオクタノール
(4)1.50g(5.45ミリモル)を加え、アルゴ
ン気流中室温で18時間撹拌した。反応混合物を濾過し
て不溶物を除いた後、濾液に酢酸エチル40mlを加え
た。反応液を水40mlで洗浄した後、硫酸マグネシウム
で乾燥し、減圧下で溶媒を留去した。得られたシロップ
状残渣をシリカゲルカラムクロマトグラフィー(トルエ
ン−酢酸エチル=10:1)で精製して、標記化合物
(27)694mg(23.9%)、化合物(28)31
7mg(10.9%)及び化合物(29)313mg(1
1.7%)を得た。Reference Example 21 8-phthalimidooctyl
2,3,4-tri-O-acetyl-α-D-xylopyranoside (27), 8-phthalimidooctyl 2,3
4-Tri-O-acetyl-β-D-xylopyranoside (28) and 8-phthalimidooctyl 3,4-di-O-acetyl-α-D-xylopyranoside (29) 2,3,4-tri-O- Acetyl-α-D-xylopyranosyl bromide (26) (1.85 g, 5.45 mmol) in benzene (30 ml) was added with mercuric cyanide (1.3).
8 g (5.45 mmol), powdered molecular sieve 4A (3.5 g) and 1.50 g (5.45 mmol) of 8-phthalimidooctanol (4) were added, and the mixture was stirred at room temperature in an argon stream for 18 hours. After the reaction mixture was filtered to remove insoluble matter, 40 ml of ethyl acetate was added to the filtrate. The reaction solution was washed with 40 ml of water, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained syrupy residue was purified by silica gel column chromatography (toluene-ethyl acetate = 10: 1) to give 694 mg (23.9%) of the title compound (27) and the compound (28) 31.
7 mg (10.9%) and compound (29) 313 mg (1
1.7%) was obtained.
【0101】27:〔α〕D + 81.5°(CHCl3) IR(KBr)cm-1 : 2940, 1760, 1710, 1230, 10501 H-NMR(CDCl3):δ 7.70-7.72(2H, m, aromatic H) 7.83-7.85(2H, m, aromatic H) 5.47(1H, t, J2,3=10.2Hz, H-3) 4.97(1H, d, J1,2=3.7Hz, H-1) 4.9-5.0(1H, m, H-4) 4.78(1H, dd, J2,3=10.2Hz, J1,2=3.7Hz, H-2) 3.76(1H, dd, J=11.0Hz, J=6.1Hz, H-5b) 3.6-3.8(4H, m, H-5a, -CH2O and -CH2N) 3.5-3.6(1H, m, -CH2O) 2.02(3H, s, OAc) 2.03(3H, s, OAc) 2.05(3H, s, OAc) 1.5-1.7(4H, m, -CH2 ×2) 1.3-1.4(8H, m, -CH2 ×4)27: [α] D + 81.5 ° (CHCl 3 ) IR (KBr) cm −1 : 2940, 1760, 1710, 1230, 1050 1 H-NMR (CDCl 3 ): δ 7.70-7.72 (2H, m , aromatic H) 7.83-7.85 (2H, m, aromatic H) 5.47 (1H, t, J 2 , 3 = 10.2Hz, H-3) 4.97 (1H, d, J 1 , 2 = 3.7Hz, H-1 ) 4.9-5.0 (1H, m, H-4) 4.78 (1H, dd, J 2 , 3 = 10.2Hz, J 1 , 2 = 3.7Hz, H-2) 3.76 (1H, dd, J = 11.0Hz, J = 6.1Hz, H-5b) 3.6-3.8 (4H, m, H-5a, -CH 2 O and -CH 2 N) 3.5-3.6 (1H, m, -CH 2 O) 2.02 (3H, s, OAc) 2.03 (3H, s, OAc) 2.05 (3H, s, OAc) 1.5-1.7 (4H, m, -CH 2 × 2) 1.3-1.4 (8H, m, -CH 2 × 4)
【0102】28:〔α〕D − 22.4°(CHCl3) IR(KBr)cm-1 : 2940, 1760, 1710, 1230, 10501 H-NMR(CDCl3):δ 7.83-7.85(2H, m, aromatic H) 7.70-7.72(2H, m, aromatic H) 5.12(1H, t, J=8.6Hz, H-3) 4.9-5.0(1H, m, H-4) 4.90(1H, dd, J2,3=8.6Hz, J1,2=6.8Hz, H-2) 4.45(1H, d, J=6.8Hz, H-1) 4.11(1H, dd, J=11.8Hz, J=5.1Hz, H-5b) 3.7-3.8(1H, m, -CH2O) 3.67(2H, t, J=7.1Hz, -CH2N) 3.4-3.5(1H, m, -CH2O) 3.35(1H, dd, J=11.8Hz, J=8.8Hz, H-5a) 2.03(3H, s, OAc) 2.04(3H, s, OAc) 2.05(3H, s, OAc) 1.5-1.7(4H, m, -CH2 ×2) 1.3-1.4(8H, m, -CH2 ×4)28: [α] D −22.4 ° (CHCl 3 ) IR (KBr) cm −1 : 2940, 1760, 1710, 1230, 1050 1 H-NMR (CDCl 3 ): δ 7.83-7.85 (2H , m, aromatic H) 7.70-7.72 (2H, m, aromatic H) 5.12 (1H, t, J = 8.6Hz, H-3) 4.9-5.0 (1H, m, H-4) 4.90 (1H, dd, J 2 , 3 = 8.6Hz, J 1 , 2 = 6.8Hz, H-2) 4.45 (1H, d, J = 6.8Hz, H-1) 4.11 (1H, dd, J = 11.8Hz, J = 5.1Hz , H-5b) 3.7-3.8 (1H, m, -CH 2 O) 3.67 (2H, t, J = 7.1Hz, -CH 2 N) 3.4-3.5 (1H, m, -CH 2 O) 3.35 (1H , dd, J = 11.8Hz, J = 8.8Hz, H-5a) 2.03 (3H, s, OAc) 2.04 (3H, s, OAc) 2.05 (3H, s, OAc) 1.5-1.7 (4H, m,- CH 2 × 2) 1.3-1.4 (8H, m, -CH 2 × 4)
【0103】29:〔α〕D + 79.8°(CHCl3) IR(KBr)cm-1 : 2940, 1760, 1710, 1230, 10501 H-NMR(CDCl3):δ 7.83-7.85(2H, m, aromatic H) 7.70-7.72(2H, m, aromatic H) 5.22(1H, t, J=9.5Hz, H-3) 4.7-4.8(1H, m, H-4) 3.6-3.8(4H, m, H-5b, -CH2O, -CH2N) 3.5-3.6(2H, m, H-2, H-5a) 4.82(1H, d, J=3.7Hz, H-1) 3.4-3.5(1H, m, -CH2O) 2.03(3H, s, OAc) 2.09(3H, s, OAc) 1.5-1.7(4H, m, -CH2 ×2) 1.3-1.4(8H, m, -CH2 ×4)29: [α] D + 79.8 ° (CHCl 3 ) IR (KBr) cm −1 : 2940, 1760, 1710, 1230, 1050 1 H-NMR (CDCl 3 ): δ 7.83-7.85 (2H, m , aromatic H) 7.70-7.72 (2H, m, aromatic H) 5.22 (1H, t, J = 9.5Hz, H-3) 4.7-4.8 (1H, m, H-4) 3.6-3.8 (4H, m, H-5b, -CH 2 O, -CH 2 N) 3.5-3.6 (2H, m, H-2, H-5a) 4.82 (1H, d, J = 3.7Hz, H-1) 3.4-3.5 (1H , m, -CH 2 O) 2.03 (3H, s, OAc) 2.09 (3H, s, OAc) 1.5-1.7 (4H, m, -CH 2 × 2) 1.3-1.4 (8H, m, -CH 2 × Four)
【0104】参考例22 8−アミノオクチル β−D
−キシロピラノシド(30) 化合物(27)680mg(1.27ミリモル)のメタノ
ール10ml溶液に、28%ナトリウムメトキシド−メタ
ノール溶液0.16mlを加え室温で2時間撹拌した。反
応溶液をアンバーライトIR−120B(H+)で中和し
た。樹脂を濾去した後、濾液を減圧下で濃縮乾固した。
得られたシロップ状残渣をエタノール1mlに溶解させた
後、ヒドラジン・水和物318mg(6.35ミリモル)
を加え、100℃で2時間加熱還流した。更にヒドラジ
ン・水和物318mg(6.35ミリモル)を加え、2時
間加熱還流した。析出した不溶物を濾去した後、濾液を
減圧下で濃縮乾固した。得られたシロップ状残渣をシリ
カゲルカラムクロマトグラフィー(クロロホルム−メタ
ノール−濃アンモニア水=10:10:1)で精製し
た。ニンヒドリン試薬に陽性の分画を集め減圧下で溶媒
を留去した。得られた粉末状物質を水30mlに溶解し、
3M 塩酸を加えて中和した。この溶液をアンバーライト
IRC−50(NH4 +型)100mlのカラムに通過させ
200mlの水で洗浄した。次いで2M アンモニア水で溶
出した。溶出液を集め減圧下で溶媒を留去して、標記化
合物(30)274mg(77.8%)を得た。Reference Example 22 8-Aminooctyl β-D
-Xylopyranoside (30) 0.16 ml of 28% sodium methoxide-methanol solution was added to a solution of 680 mg (1.27 mmol) of compound (27) in 10 ml of methanol, and the mixture was stirred at room temperature for 2 hours. The reaction solution was neutralized with Amberlite IR-120B (H + ). After removing the resin by filtration, the filtrate was concentrated to dryness under reduced pressure.
The syrup-like residue obtained was dissolved in 1 ml of ethanol and then 318 mg (6.35 mmol) of hydrazine hydrate.
Was added and the mixture was heated under reflux at 100 ° C. for 2 hours. Further, 318 mg (6.35 mmol) of hydrazine hydrate was added, and the mixture was heated under reflux for 2 hours. The precipitated insoluble material was filtered off, and the filtrate was concentrated to dryness under reduced pressure. The obtained syrupy residue was purified by silica gel column chromatography (chloroform-methanol-concentrated aqueous ammonia = 10: 10: 1). Fractions positive to the ninhydrin reagent were collected and the solvent was distilled off under reduced pressure. Dissolve the obtained powdery substance in 30 ml of water,
The mixture was neutralized by adding 3M hydrochloric acid. This solution was passed through a column of 100 ml of Amberlite IRC-50 (NH 4 + type) and washed with 200 ml of water. It was then eluted with 2M aqueous ammonia. The eluates were collected and the solvent was evaporated under reduced pressure to obtain 274 mg (77.8%) of the title compound (30).
【0105】30:〔α〕D + 72.5°(H2O) IR(KBr)cm-1 : 3300, 2940, 1580, 10301 H-NMR(D2O):δ 4.88(1H, d, J1,2=3.4Hz, H-1) 3.5-3.7(7H, m, H-2, H-3, H-4, H-5, -CH2O) 2.98(2H, t, J=7.8Hz, -CH2N) 1.6-1.7(4H, m, -CH2 ×2) 1.3-1.5(8H, m, -CH2 ×4)30: [α] D + 72.5 ° (H 2 O) IR (KBr) cm −1 : 3300, 2940, 1580, 1030 1 H-NMR (D 2 O): δ 4.88 (1H, d, J 1 , 2 = 3.4Hz, H-1) 3.5-3.7 (7H, m, H-2, H-3, H-4, H-5, -CH 2 O) 2.98 (2H, t, J = 7.8Hz , -CH 2 N) 1.6-1.7 (4H, m, -CH 2 × 2) 1.3-1.5 (8H, m, -CH 2 × 4)
【0106】参考例23 8−フタルイミドオクチル
2,3,4−トリ−O−ベンジル−β−L−フコピラノ
シド(32)及び8−フタルイミドオクチル2,3,4
−トリ−O−ベンジル−α−L−フコピラノシド(3
3) 2,3,4−トリ−O−ベンジル−α−L−フコピラノ
シルブロミド(31)4.26g(8.57ミリモル)
のベンゼン40ml溶液に、シアン化第二水銀2.17g
(8.57ミリモル)、粉末状モレキュラーシーブ4A
を4.0g及び8−フタルイミドオクタノール(4)
2.36g(8.57ミリモル)を加え、アルゴン気流
中室温で22時間撹拌した。反応混合物を濾過して不溶
物を除いた後、濾液に酢酸エチル30mlを加えた。反応
液を水80mlで洗浄した後、硫酸マグネシウムで乾燥
し、減圧下で溶媒を留去した。得られたシロップ状残渣
をシリカゲルカラムクロマトグラフィー(ヘキサン−酢
酸エチル=6:1)で精製して、標記化合物(32)
1.83g(30.9%)及び標記化合物(33)84
2mg(14.2%)を得た。Reference Example 23 8-phthalimidooctyl
2,3,4-Tri-O-benzyl-β-L-fucopyranoside (32) and 8-phthalimidooctyl 2,3,4
-Tri-O-benzyl-α-L-fucopyranoside (3
3) 4.26 g (8.57 mmol) of 2,3,4-tri-O-benzyl-α-L-fucopyranosyl bromide (31)
2.17 g of mercuric cyanide in 40 ml of benzene solution
(8.57 mmol), powdery molecular sieve 4A
And 4.0 g of 8-phthalimidooctanol (4)
2.36 g (8.57 mmol) was added, and the mixture was stirred at room temperature in an argon stream for 22 hours. After the reaction mixture was filtered to remove insoluble matter, 30 ml of ethyl acetate was added to the filtrate. The reaction solution was washed with 80 ml of water, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure. The resulting syrupy residue was purified by silica gel column chromatography (hexane-ethyl acetate = 6: 1) to give the title compound (32).
1.83 g (30.9%) and title compound (33) 84
2 mg (14.2%) were obtained.
【0107】32:〔α〕D + 4.0 °(CHCl3) IR(KBr)cm-1 : 2980, 1770, 1710, 1400, 10691 H-NMR(CDCl3):δ 7.6-7.7(2H, m, aromatic H) 7.8-7.9(2H, m, aromatic H) 7.2-7.4(15H, m, aromatic H) 4.9-5.0(2H, m, -CH2ph) 4.6-4.8(4H, m, -CH2ph) 4.29(1H, d, J1,2=7.6Hz, H-1) 3.78(1H, dd, J2,3=9.8Hz, J1,2=7.6Hz, H-2) 3.65(1H, t, J=7.3Hz, -CH2N) 3.54(1H, d, J3,4=2.9Hz, H-4) 3.50(1H, dd, J2,3=9.8Hz, J3,4=2.9Hz, H-3) 3.4-3.5(2H, m, H-5 and -CH2O) 3.9-4.0(1H, m, -CH2O) 1.5-1.7(4H, m, -CH2 ×2) 1.2-1.4(8H, m, -CH2 ×4) 1.16(3H, d, J=6.4Hz, H-6)32: [α] D + 4.0 ° (CHCl 3 ) IR (KBr) cm −1 : 2980, 1770, 1710, 1400, 1069 1 H-NMR (CDCl 3 ): δ 7.6-7.7 (2H, m , aromatic H) 7.8-7.9 (2H, m, aromatic H) 7.2-7.4 (15H, m, aromatic H) 4.9-5.0 (2H, m, -CH 2 ph) 4.6-4.8 (4H, m, -CH 2 ph) 4.29 (1H, d, J 1 , 2 = 7.6Hz, H-1) 3.78 (1H, dd, J 2 , 3 = 9.8Hz, J 1 , 2 = 7.6Hz, H-2) 3.65 (1H, t, J = 7.3Hz, -CH 2 N) 3.54 (1H, d, J 3 , 4 = 2.9Hz, H-4) 3.50 (1H, dd, J 2 , 3 = 9.8Hz, J 3 , 4 = 2.9 Hz, H-3) 3.4-3.5 (2H, m, H-5 and -CH 2 O) 3.9-4.0 (1H, m, -CH 2 O) 1.5-1.7 (4H, m, -CH 2 × 2) 1.2-1.4 (8H, m, -CH 2 × 4) 1.16 (3H, d, J = 6.4Hz, H-6)
【0108】33:〔α〕D - 35.2°(CHCl3) IR(KBr)cm-1 : 2970, 1770, 1400, 11001 H-NMR(CDCl3):δ 7.8-7.9(2H, m, aromatic H) 7.6-7.7(2H, m, aromatic H) 7.2-7.4(15H, m, aromatic H) 4.77(1H, d, J1,2=3.4Hz, H-1) 4.6-5.0(6H, m, -CH2ph ×3) 4.01(1H, dd, J2,3=10.3Hz, J1,2=3.4Hz, H-2) 3.93(1H, dd, J2,3=10.3Hz, J3,4=2.7Hz, H-3) 3.86(1H, q, J=6.4Hz, H-5) 3.6-3.7(3H, m, H-4 and -CH2N) 3.5-3.6(1H, m, -CH2O) 3.4-3.5(1H, m, -CH2O) 1.5-1.7(4H, m, -CH2 ×2) 1.3-1.4(8H, m, -CH2 ×4) 1.09(3H, d, J5,6=6.4Hz, H-6)33: [α] D -35.2 ° (CHCl 3 ) IR (KBr) cm -1 : 2970, 1770, 1400, 1100 1 H-NMR (CDCl 3 ): δ 7.8-7.9 (2H, m, aromatic H) 7.6-7.7 (2H, m, aromatic H) 7.2-7.4 (15H, m, aromatic H) 4.77 (1H, d, J 1 , 2 = 3.4Hz, H-1) 4.6-5.0 (6H, m, -CH 2 ph × 3) 4.01 (1H, dd, J 2 , 3 = 10.3Hz, J 1 , 2 = 3.4Hz, H-2) 3.93 (1H, dd, J 2 , 3 = 10.3Hz, J 3 , 4 = 2.7Hz, H-3) 3.86 (1H, q, J = 6.4Hz, H-5) 3.6-3.7 (3H, m, H-4 and -CH 2 N) 3.5-3.6 (1H, m,- CH 2 O) 3.4-3.5 (1H, m, -CH 2 O) 1.5-1.7 (4H, m, -CH 2 × 2) 1.3-1.4 (8H, m, -CH 2 × 4) 1.09 (3H, d , J 5 , 6 = 6.4Hz, H-6)
【0109】参考例24 8−フタルイミドオクチル
β−L−フコピラノシド(34) 化合物(32)1.70g(2.46ミリモル)のエタ
ノール10ml溶液に、酢酸1ml及び10%パラジウム−
炭素1g加え、パールの装置(50psi)で接触還元し
た。触媒を濾去した後、濾液を減圧下で濃縮乾固した。
得られたシロップ状残渣をシリカゲルカラムクロマトグ
ラフィー(クロロホルム−メタノール=40:1)で精
製して、標記化合物(34)894mg(86.2%)を
得た。Reference Example 24 8-phthalimidooctyl
β-L-fucopyranoside (34) To a solution of 1.70 g (2.46 mmol) of compound (32) in 10 ml of ethanol, 1 ml of acetic acid and 10% palladium-
1 g of carbon was added, and catalytic reduction was carried out using a Parr apparatus (50 psi). After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure.
The obtained syrupy residue was purified by silica gel column chromatography (chloroform-methanol = 40: 1) to obtain 894 mg (86.2%) of the title compound (34).
【0110】34:〔α〕D + 12.5°(MeOH) IR(KBr)cm-1 : 3510, 2940, 1690, 1400, 10801 H-NMR(CD3OD):δ 7.8-7.9(4H, m, aromatic H) 4.16(1H, d, J1,2=7.6Hz, H-1) 3.8-3.9(1H, m, -CH2O) 3.66(2H, t, J=7.1Hz, -CH2N) 3.5-3.6(2H, m, H-4 and H-5) 3.4-3.5(3H, m, H-2 H-3 and -CH2O) 1.6-1.7(4H, m, -CH2 ×2) 1.3-1.4(8H, m, -CH2 ×4) 1.25(3H, d, J5,6=6.4Hz, H-6)34: [α] D + 12.5 ° (MeOH) IR (KBr) cm −1 : 3510, 2940, 1690, 1400, 1080 1 H-NMR (CD 3 OD): δ 7.8-7.9 (4 H, m , aromatic H) 4.16 (1H, d, J 1 , 2 = 7.6Hz, H-1) 3.8-3.9 (1H, m, -CH 2 O) 3.66 (2H, t, J = 7.1Hz, -CH 2 N ) 3.5-3.6 (2H, m, H-4 and H-5) 3.4-3.5 (3H, m, H-2 H-3 and -CH 2 O) 1.6-1.7 (4H, m, -CH 2 × 2 ) 1.3-1.4 (8H, m, -CH 2 × 4) 1.25 (3H, d, J 5 , 6 = 6.4Hz, H-6)
【0111】参考例25 8−アミノオクチル β−L
−フコピラノシド(35) 化合物(34)800mg(1.90ミリモル)のエタノ
ール10ml溶液に、ヒドラジン・水和物476mg(9.
50ミリモル)を加え、100℃で2時間加熱還流し
た。更にヒドラジン・水和物476mg(9.50ミリモ
ル)を加え、同温で22時間加熱還流した。析出した不
溶物を濾去した後、濾液を減圧下で濃縮乾固した。得ら
れたシロップ状残渣をシリカゲルカラムクロマトグラフ
ィー(クロロホルム−メタノール−濃アンモニア水=2
0:10:1)で精製した。ニンヒドリン試薬陽性分画
を集めて減圧下で溶媒を留去した。得られた残渣を水1
0mlに溶解した後、3M 塩酸を加えて中和した。この溶
液をアンバーライトIRC−50(NH4 +型)50mlの
カラムを通過させた。カラムを水100mlで洗浄した
後、2M アンモニア水で目的物を溶出した。溶出液を減
圧下で濃縮乾固して、標記化合物(35)505mg(9
1.3%)を得た。Reference Example 25 8-Aminooctyl β-L
Fucopyranoside (35) To a solution of 800 mg (1.90 mmol) of compound (34) in 10 ml of ethanol, 476 mg of hydrazine hydrate (9.
(50 mmol) was added and the mixture was heated under reflux at 100 ° C. for 2 hours. Further, 476 mg (9.50 mmol) of hydrazine hydrate was added, and the mixture was heated under reflux at the same temperature for 22 hours. The precipitated insoluble material was filtered off, and the filtrate was concentrated to dryness under reduced pressure. The syrupy residue thus obtained was subjected to silica gel column chromatography (chloroform-methanol-concentrated aqueous ammonia = 2.
Purified at 0: 10: 1). The ninhydrin reagent positive fractions were collected and the solvent was distilled off under reduced pressure. The residue obtained is treated with water 1
After dissolving in 0 ml, 3M hydrochloric acid was added to neutralize. This solution was passed through a column of 50 ml Amberlite IRC-50 (NH 4 + type). After washing the column with 100 ml of water, the desired product was eluted with 2M aqueous ammonia. The eluate was concentrated to dryness under reduced pressure to give 505 mg (9) of the title compound (35).
(1.3%).
【0112】35:〔α〕D + 10.6°(H2O) IR(KBr)cm-1 : 3480, 2980, 1610, 1380, 10801 H-NMR(D2O):δ 4.36(1H, d, J1,2=8.1Hz, H-1) 3.88(1H, dt, J=10.0Hz, J=6.8Hz, -CH2O) 3.78(1H, q, J=6.8Hz, H-5) 3.74(1H, d, J3,4=3.2Hz, H-4) 3.65(1H, dt, J=10.0Hz, J=6.8Hz, -CH2O) 3.63(1H, dd, J2,3=10.0Hz, J3,4=3.2Hz, H-3) 3.45(1H, dd, J1,2=8.1Hz, J2,3=3.2Hz, H-2) 2.98(2H, t, J=7.8Hz, -CH2N) 1.6-1.7(4H, m, -CH2 ×2) 1.3-1.4(8H, m, -CH2 ×4) 1.25(3H, d, J5,6=6.4Hz, H-6)35: [α] D + 10.6 ° (H 2 O) IR (KBr) cm −1 : 3480, 2980, 1610, 1380, 1080 1 H-NMR (D 2 O): δ 4.36 (1H, d , J 1 , 2 = 8.1Hz, H-1) 3.88 (1H, dt, J = 10.0Hz, J = 6.8Hz, -CH 2 O) 3.78 (1H, q, J = 6.8Hz, H-5) 3.74 (1H, d, J 3 , 4 = 3.2Hz, H-4) 3.65 (1H, dt, J = 10.0Hz, J = 6.8Hz, -CH 2 O) 3.63 (1H, dd, J 2 , 3 = 10.0 Hz, J 3 , 4 = 3.2Hz, H-3) 3.45 (1H, dd, J 1 , 2 = 8.1Hz, J 2 , 3 = 3.2Hz, H-2) 2.98 (2H, t, J = 7.8Hz , -CH 2 N) 1.6-1.7 (4H, m, -CH 2 × 2) 1.3-1.4 (8H, m, -CH 2 × 4) 1.25 (3H, d, J 5 , 6 = 6.4Hz, H- 6)
【0113】参考例26 8−フタルイミドオクチル
3,4−ジ−O−アセチル−2−アジド−2−デオキシ
−α−L−フコピラノシド(37)及び8−フタルイミ
ドオクチル 3,4−ジ−O−アセチル−2−アジド−
2−デオキシ−β−L−フコピラノシド(38) 文献記載の方法(R.U. Lemieuxら、Canadian. J. Che
m., 57, 1244(1979))で合成した3,4−ジ−O−アセ
チル−2−アジド−2−デオキシ−β−L−フコピラノ
シルブロミド(36)911mg(2.71ミリモル)の
ベンゼン10ml溶液に、シアン化第二水銀685mg
(2.71ミリモル)、粉末状モレキュラーシーブ4A
を1g及び8−フタルイミドオクタノール(4)746
mg(2.71ミリモル)を加え、アルゴン気流中室温で
15時間撹拌した。反応混合物を濾過して不溶物を除い
た後、濾液に酢酸エチル20mlを加えた。反応液を水3
0mlで洗浄した後、硫酸マグネシウムで乾燥し、減圧下
で濃縮乾固した。得られたシロップ状残渣をシリカゲル
カラムクロマトグラフィー(ヘキサン−酢酸エチル=
4:1)で精製して、標記化合物(37)308mg(2
1.4%)及び標記化合物(38)610mg(42.4
%)を得た。Reference Example 26 8-phthalimidooctyl
3,4-di-O-acetyl-2-azido-2-deoxy-α-L-fucopyranoside (37) and 8-phthalimidooctyl 3,4-di-O-acetyl-2-azido-
2-Deoxy-β-L-fucopyranoside (38) Reference method (RU Lemieux et al., Canadian. J. Che.
m., 57, 1244 (1979)) 3,4-di-O-acetyl-2-azido-2-deoxy-β-L-fucopyranosyl bromide (36) 911 mg (2.71 mmol) 265 mg of mercuric cyanide in 10 ml of benzene solution
(2.71 mmol), powdery molecular sieve 4A
1 g and 8-phthalimidooctanol (4) 746
mg (2.71 mmol) was added, and the mixture was stirred at room temperature in an argon stream for 15 hours. After the reaction mixture was filtered to remove insoluble matter, 20 ml of ethyl acetate was added to the filtrate. The reaction solution is water 3
After washing with 0 ml, it was dried over magnesium sulfate and concentrated to dryness under reduced pressure. The resulting syrupy residue was subjected to silica gel column chromatography (hexane-ethyl acetate =
4: 1) and 308 mg (2) of the title compound (37).
1.4%) and 610 mg (42.4) of the title compound (38).
%) Was obtained.
【0114】37:〔α〕D - 110.4 °(CHCl3) IR(KBr)cm-1 : 2980, 2110, 1750, 12341 H-NMR(CDCl3):δ 7.70(2H, dd, J=5.4Hz, J=2.9Hz, aromatic H) 7.84(2H, dd, J=5.4Hz, J=2.9Hz, aromatic H) 5.36(1H, dd, J2,3=11.2Hz, J3,4=3.2Hz, H-3) 5.30(1H, d, J3,4=3.2Hz, H-4) 4.93(1H, d, J1,2=3.4Hz, H-1) 4.14(1H, q, J=6.6Hz, H-5) 3.6-3.7(3H, m, -CH2N and -CH2O) 3.57(1H, dd, J2,3=11.2Hz, J1,2=3.4Hz, H-2) 3.4-3.5(1H, m, -CH2O) 2.05(3H, s, OAc) 2.16(3H, s, OAc) 1.6-1.7(4H, m, -CH2 ×2) 1.13(3H, d, J5,6=6.5Hz, H-6) 1.2-1.4(8H, m, -CH2 ×4)37: [α] D -110.4 ° (CHCl 3 ) IR (KBr) cm -1 : 2980, 2110, 1750, 1234 1 H-NMR (CDCl 3 ): δ 7.70 (2H, dd, J = 5.4) Hz, J = 2.9Hz, aromatic H) 7.84 (2H, dd, J = 5.4Hz, J = 2.9Hz, aromatic H) 5.36 (1H, dd, J 2 , 3 = 11.2Hz, J 3 , 4 = 3.2Hz , H-3) 5.30 (1H, d, J 3 , 4 = 3.2Hz, H-4) 4.93 (1H, d, J 1 , 2 = 3.4Hz, H-1) 4.14 (1H, q, J = 6.6 Hz, H-5) 3.6-3.7 (3H, m, -CH 2 N and -CH 2 O) 3.57 (1H, dd, J 2 , 3 = 11.2Hz, J 1 , 2 = 3.4Hz, H-2) 3.4-3.5 (1H, m, -CH 2 O) 2.05 (3H, s, OAc) 2.16 (3H, s, OAc) 1.6-1.7 (4H, m, -CH 2 × 2) 1.13 (3H, d, J 5 , 6 = 6.5Hz, H-6) 1.2-1.4 (8H, m, -CH 2 × 4)
【0115】38:〔α〕D + 9.1 °(CHCl3) IR(KBr)cm-1 : 3020, 2110, 1750, 12421 H-NMR(CDCl3):δ 7.70(2H, dd, J=5.4Hz, J=2.9Hz, aromatic H) 7.84(2H, dd, J=5.4Hz, J=2.9Hz, aromatic H) 5.17(1H, d, J3,4=3.2Hz, H-4) 4.75(1H, dd, J2,3=10.7Hz, J3,4=3.2Hz, H-3) 4.31(1H, d, J1,2=7.8Hz, H-1) 3.9-4.0(1H, m, -CH2O) 3.73(1H, q, J5,6=6.6Hz, =6.6, H-5) 3.6-3.7(3H, m, H-2 and -CH2N) 3.5-3.6(1H, m, -CH2O) 2.05(3H, s, OAc) 2.16(3H, s, OAc) 1.6-1.7(4H, m, -CH2 ×2) 1.20(3H, d, J=6.4Hz, H-6) 1.2-1.4(8H, m, -CH2 ×4)38: [α] D + 9.1 ° (CHCl 3 ) IR (KBr) cm −1 : 3020, 2110, 1750, 1242 1 H-NMR (CDCl 3 ): δ 7.70 (2H, dd, J = 5.4 Hz, J = 2.9Hz, aromatic H) 7.84 (2H, dd, J = 5.4Hz, J = 2.9Hz, aromatic H) 5.17 (1H, d, J 3 , 4 = 3.2Hz, H-4) 4.75 (1H , dd, J 2 , 3 = 10.7Hz, J 3 , 4 = 3.2Hz, H-3) 4.31 (1H, d, J 1 , 2 = 7.8Hz, H-1) 3.9-4.0 (1H, m,- CH 2 O) 3.73 (1H, q, J 5 , 6 = 6.6Hz, = 6.6, H-5) 3.6-3.7 (3H, m, H-2 and -CH 2 N) 3.5-3.6 (1H, m, -CH 2 O) 2.05 (3H, s, OAc) 2.16 (3H, s, OAc) 1.6-1.7 (4H, m, -CH 2 × 2) 1.20 (3H, d, J = 6.4Hz, H-6) 1.2-1.4 (8H, m, -CH 2 x 4)
【0116】参考例27 8−アミノオクチル 2−ア
セトアミド−2−デオキシ−α−L−フコピラノシド
(40) 化合物(37)300mg(0.565ミリモル)のメタ
ノール5ml溶液に、28%ナトリウムメトキシド−メタ
ノール溶液0.08mlを加え、室温で24時間撹拌し
た。反応溶液をアンバーライトIR−120B(H+
型)で中和した。樹脂を濾去した後、濾液を減圧下で濃
縮乾固した。得られたシロップ状残渣をエタノール15
mlに溶解した後、水素化ホウ素ナトリウム64.1mg
(1.70ミリモル)及び塩化ニッケル・六水和物40
mgのエタノール溶液0.5mlを加え、室温で2時間撹拌
した。反応溶液を6M 塩酸で中和した後、沈殿物を濾去
した。濾液を減圧下で濃縮乾固し、得られたシロップ状
残渣をメタノール5mlに溶解した。この溶液に無水酢酸
1mlを加え室温で3時間撹拌した。反応溶液を減圧下で
濃縮乾固して得られたシロップ状残渣をシリカゲルカラ
ムクロマトグラフィー(クロロホルム−メタノール=3
0:1)で精製して、8−フタルイミドオクチル2−ア
セトアミド−2−デオキシ−α−L−フコピラノシド
(39)257mgを得た。化合物(39)257mgをエ
タノール5mlに溶解し、ヒドラジン・水和物141mg
(2.83ミリモル)を加えて100℃で2時間加熱還
流した。更にヒドラジン・水和物141mg(2.83ミ
リモル)を加え、同温で2時間加熱還流した。反応混合
物を濾過して不溶物を除いた後、濾液を減圧下で濃縮乾
固した。得られたシロップ状残渣をシリカゲルカラムク
ロマトグラフィー(クロロホルム−メタノール−濃アン
モニア水=30:10:1)で精製し、ニンヒドリン陽
性分画を集めて減圧下で濃縮乾固した。得られた残渣を
水10mlに溶解し、3M 塩酸で中和した。この溶液をア
ンバーライトIRC−50(NH4 +型)50mlのカラム
を通した。水100mlで洗浄した後、2M アンモニア水
で目的物を溶出した。溶出液を減圧下で濃縮乾固して、
標記化合物(40)41.1mg(23%)を得た。Reference Example 27 8-aminooctyl 2-acetamido-2-deoxy-α-L-fucopyranoside (40) Compound (37) 300 mg (0.565 mmol) in 5 ml of methanol was added with 28% sodium methoxide-methanol. A solution (0.08 ml) was added, and the mixture was stirred at room temperature for 24 hours. Amberlite IR-120B (H +
(Type). After removing the resin by filtration, the filtrate was concentrated to dryness under reduced pressure. The obtained syrupy residue is diluted with ethanol 15
After dissolving in ml, sodium borohydride 64.1mg
(1.70 mmol) and nickel chloride hexahydrate 40
0.5 mg of ethanol solution was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was neutralized with 6M hydrochloric acid, and the precipitate was filtered off. The filtrate was concentrated to dryness under reduced pressure, and the resulting syrupy residue was dissolved in 5 ml of methanol. 1 ml of acetic anhydride was added to this solution and stirred at room temperature for 3 hours. The syrupy residue obtained by concentrating the reaction solution to dryness under reduced pressure was subjected to silica gel column chromatography (chloroform-methanol = 3).
Purification by 0: 1) gave 257 mg of 8-phthalimidooctyl 2-acetamido-2-deoxy-α-L-fucopyranoside (39). 257 mg of compound (39) was dissolved in 5 ml of ethanol, and 141 mg of hydrazine hydrate
(2.83 mmol) was added and the mixture was heated under reflux at 100 ° C. for 2 hours. Further, 141 mg (2.83 mmol) of hydrazine hydrate was added, and the mixture was heated under reflux at the same temperature for 2 hours. After the reaction mixture was filtered to remove insoluble matter, the filtrate was concentrated to dryness under reduced pressure. The resulting syrupy residue was purified by silica gel column chromatography (chloroform-methanol-concentrated aqueous ammonia = 30: 10: 1), and ninhydrin-positive fractions were collected and concentrated to dryness under reduced pressure. The obtained residue was dissolved in 10 ml of water and neutralized with 3M hydrochloric acid. This solution was passed through a column of 50 ml Amberlite IRC-50 (NH 4 + type). After washing with 100 ml of water, the desired product was eluted with 2M aqueous ammonia. The eluate was concentrated to dryness under reduced pressure,
41.1 mg (23%) of the title compound (40) was obtained.
【0117】40:〔α〕D - 74.8°(H2O) IR(KBr)cm-1 : 3400, 1640, 10301 H-NMR(D2O) : δ 4.1-4.2(2H, m, H-2 and H-5) 3.92(1H, dd, J2,3=11.2Hz, J3,4=3.2Hz, H-3) 3.82(1H, d, J3,4=3.2Hz, H-4) 3.6-3.7(1H, m, -CH2O) 3.4-3.5(1H, m, -CH2O) 3.00(2H, t, J=7.6Hz, -CH2N) 2.05(3H, s, NAc) 1.5-1.7(4H, m, -CH2 ×2) 1.24(3H, d, J5,6=6.6Hz, H-6) 1.2-1.4(8H, m, -CH2 ×4)40: [α] D -74.8 ° (H 2 O) IR (KBr) cm -1 : 3400, 1640, 1030 1 H-NMR (D 2 O): δ 4.1-4.2 (2H, m, H -2 and H-5) 3.92 (1H, dd, J 2 , 3 = 11.2Hz, J 3 , 4 = 3.2Hz, H-3) 3.82 (1H, d, J 3 , 4 = 3.2Hz, H-4 ) 3.6-3.7 (1H, m, -CH 2 O) 3.4-3.5 (1H, m, -CH 2 O) 3.00 (2H, t, J = 7.6Hz, -CH 2 N) 2.05 (3H, s, NAc ) 1.5-1.7 (4H, m, -CH 2 × 2) 1.24 (3H, d, J 5 , 6 = 6.6Hz, H-6) 1.2-1.4 (8H, m, -CH 2 × 4)
【0118】参考例28 ポリ−L−グルタミン酸(4
5) 市販ポリ−L−グルタミン酸 ナトリウム塩(平均分子
量分布(粘度法)=13,300)(41)10g
(0.751ミリモル)の水溶液200mlに、氷冷下、
撹拌しながら1M 塩酸51mlを滴下して溶液のpH値を
約2に調整した。析出した沈殿物を遠心分離により集め
た。沈殿物を十分量の冷水で洗浄した後、精製水に懸濁
させて凍結乾燥してポリ−L−グルタミン酸(45)
6.5gを得た。化合物(45)の物理恒数を表1に示
した。Reference Example 28 Poly-L-glutamic acid (4
5) Commercially available poly-L-glutamic acid sodium salt (average molecular weight distribution (viscosity method) = 13,300) (41) 10 g
To 200 ml of an aqueous solution of (0.751 mmol) under ice cooling,
While stirring, 51 ml of 1M hydrochloric acid was added dropwise to adjust the pH of the solution to about 2. The deposited precipitate was collected by centrifugation. The precipitate was washed with a sufficient amount of cold water, suspended in purified water and lyophilized to give poly-L-glutamic acid (45).
6.5 g was obtained. The physical constants of compound (45) are shown in Table 1.
【0119】[0119]
【表1】 [Table 1]
【0120】参考例29 ポリ−L−グルタミン酸(4
6)、(47)及び(48) 参考例28の場合と同様にして、市販ポリ−L−グルタ
ミン酸ナトリウム塩(平均分子量分布(粘度法)=3
6,240)(42)、ポリ−L−グルタミン酸ナトリ
ウム塩(平均分子量分布(粘度法)=61,000)
(43)、ポリ−L−グルタミン酸ナトリウム塩(平均
分子量分布(粘度法)=77,800)(44)を水溶
液中、それぞれ1M 塩酸と処理して遊離酸にして標記化
合物(46)、(47)及び(48)を得た。得られた
化合物の物理恒数を表1に示した。Reference Example 29 Poly-L-glutamic acid (4
6), (47) and (48) In the same manner as in Reference Example 28, commercially available poly-L-glutamic acid sodium salt (average molecular weight distribution (viscosity method) = 3)
6,240) (42), poly-L-glutamic acid sodium salt (average molecular weight distribution (viscosity method) = 61,000)
(43), poly-L-glutamic acid sodium salt (average molecular weight distribution (viscosity method) = 77,800) (44) was treated with 1 M hydrochloric acid in an aqueous solution to give the free acid to give the title compounds (46), (47). ) And (48) were obtained. The physical constants of the obtained compound are shown in Table 1.
【0121】参考例30 ポリ−γ−〔2−(4−ヒド
ロキシフェニル)エチルアミノ〕−L−グルタミン酸ナ
トリウム塩(49) ポリ−L−グルタミン酸(45)100mg(0.007
51ミリモル)、2−(4−ヒドロキシフェニル)エチ
ルアミン10mg(0.072ミリモル)及び2−エトキ
シ−1−エトキシカルボニル−1,2−ジヒドロキノリ
ン19mg(0.0768ミリモル)を、N,N−ジメチ
ルホルムアミド3.5mlに溶解し、室温で18時間撹拌
した。反応液0.01M 等張燐酸緩衝液(pH7.4)1
0mlで希釈した後、ゲル濾過カラムクロマトグラフィー
(セファデックスG−100、50cm×2.5cm)にか
け、各分画5mlずつ溶出した。分画No. 15〜27を集
めてスペクトラ/ポア3(分子量カットオフ=約3,5
00)透析膜を用いて、精製水に対して4℃で16時間
透析した。透析内液を取り出し、凍結乾燥して標記化合
物(49)75mgを得た。導入された2−(4−ヒドロ
キシフェニル)エチルアミノ残基量を吸光度275nmを
用いて定量すると、ポリ−L−グルタミン酸1モル当り
5モルの2−(4−ヒドロキシフェニル)エチルアミノ
基が導入されていることが判明した。化合物(49)の
物理恒数を表2に示した。Reference Example 30 Poly-γ- [2- (4-hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (49) Poly-L-glutamic acid (45) 100 mg (0.007)
51 mmol), 2- (4-hydroxyphenyl) ethylamine 10 mg (0.072 mmol) and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 19 mg (0.0768 mmol), N, N-dimethyl. It was dissolved in 3.5 ml of formamide and stirred at room temperature for 18 hours. Reaction solution 0.01M Isotonic phosphate buffer (pH 7.4) 1
After diluting with 0 ml, it was subjected to gel filtration column chromatography (Sephadex G-100, 50 cm × 2.5 cm), and 5 ml of each fraction was eluted. Fraction Nos. 15 to 27 are collected to collect Spectra / Pore 3 (molecular weight cutoff = about 3.5
(00) Using a dialysis membrane, it was dialyzed against purified water at 4 ° C. for 16 hours. The dialysate was removed and lyophilized to give 75 mg of the title compound (49). When the amount of the introduced 2- (4-hydroxyphenyl) ethylamino residue was quantified using the absorbance of 275 nm, 5 mol of 2- (4-hydroxyphenyl) ethylamino group was introduced per mol of poly-L-glutamic acid. It turned out. The physical constants of compound (49) are shown in Table 2.
【0122】[0122]
【表2】 [Table 2]
【0123】参考例31 ポリ−γ−〔2−(4−ヒド
ロキシフェニル)エチルアミノ〕−L−グルタミン酸ナ
トリウム塩(50) ポリ−L−グルタミン酸(46)100mg(0.007
51ミリモル)、O−スルホベンズイミド145mg
(0.791ミリモル)及びN,N′−カルボニルジイ
ミダゾール141mg(0.869ミリモル)を、N,N
−ジメチルホルムアミド3mlに溶解し、室温で1時間3
0分撹拌した。この溶液に2−(4−ヒドロキシフェニ
ル)エチルアミン200mg(1.458ミリモル)及び
1,1,3,3−テトラメチルグアニジン0.19ml
(1.514ミリモル)を、N,N−ジメチルホルムア
ミド4mlに溶解した液0.07ml(0.025ミリモ
ル)を加え、室温で2日間撹拌した。反応混合物を0.
01M 等張燐酸緩衝液(pH7.4)で希釈した後、スペ
クトラ/ポア1(分子量カットオフ=6,000−8,
000)透析膜を用いて、精製水に対して4℃で48時
間透析した。透析内液を取り出し、凍結乾燥して標記化
合物(50)78mgを得た。導入された2−(4−ヒド
ロキシフェニル)エチルアミノ残基量を吸光度275nm
を用いて定量すると、ポリ−L−グルタミン酸1モル当
り5モルの2−(4−ヒドロキシフェニル)エチルアミ
ノ基が導入されたことが判明した。化合物(50)の物
理恒数を表2に示した。Reference Example 31 Poly-γ- [2- (4-hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (50) Poly-L-glutamic acid (46) 100 mg (0.007)
51 mmol), 145 mg of O-sulfobenzimide
(0.791 mmol) and 141 mg (0.869 mmol) of N, N'-carbonyldiimidazole were added to N, N
-Dissolve in 3 ml of dimethylformamide and stir for 3 hours at room temperature.
Stir for 0 minutes. 200 mg (1.458 mmol) of 2- (4-hydroxyphenyl) ethylamine and 0.19 ml of 1,1,3,3-tetramethylguanidine were added to this solution.
(1.514 mmol) was added to 0.07 ml (0.025 mmol) of a solution of 4 ml of N, N-dimethylformamide, and the mixture was stirred at room temperature for 2 days. The reaction mixture was charged to 0.
After dilution with 01M isotonic phosphate buffer (pH 7.4), Spectra / Pore 1 (molecular weight cutoff = 6,000-8,
000) It was dialyzed against purified water at 4 ° C. for 48 hours using a dialysis membrane. The dialyzed solution was taken out and freeze-dried to obtain 78 mg of the title compound (50). The amount of introduced 2- (4-hydroxyphenyl) ethylamino residue is measured by absorbance at 275 nm.
It was found that 5 mol of 2- (4-hydroxyphenyl) ethylamino group was introduced per mol of poly-L-glutamic acid. The physical constants of compound (50) are shown in Table 2.
【0124】参考例32 ポリ−γ−〔2−(4−ヒド
ロキシフェニル)エチルアミノ〕−L−グルタミン酸ナ
トリウム塩(51)及び(52) 参考例31の場合と同様にして、ポリ−L−グルタミン
酸(47)及び(48)に、それぞれ10モル当量の2
−(4−ヒドロキシフェニル)エチルアミンを用いて2
−(4−ヒドロキシフェニル)エチルアミノ基の導入を
行い、標記化合物(51)及び(52)を得た。導入さ
れた2−(4−ヒドロキシフェニル)エチルアミノ基量
(モル比)及び得られた化合物の物理恒数を表2に示し
た。Reference Example 32 Poly-γ- [2- (4-hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (51) and (52) In the same manner as in Reference Example 31, poly-L-glutamic acid. In (47) and (48), 10 molar equivalents of 2 respectively
2 with-(4-hydroxyphenyl) ethylamine
A-(4-hydroxyphenyl) ethylamino group was introduced to obtain the title compounds (51) and (52). The amount of introduced 2- (4-hydroxyphenyl) ethylamino group (molar ratio) and the physical constants of the obtained compound are shown in Table 2.
【0125】参考例33 ポリ−D−グルタミン酸(5
6)、(57)及び(58) 参考例28の場合と同様にして、市販ポリ−D−グルタ
ミン酸ナトリウム塩(平均分子量分布(粘度法)=1
0,600)(53)、ポリ−D−グルタミン酸ナトリ
ウム塩(平均分子量分布(粘度法)=41,000)
(54)、ポリ−L−グルタミン酸ナトリウム塩(平均
分子量分布(粘度法)=95,100)(55)を水溶
液中、それぞれ1M 塩酸で処理して遊離酸とし、標記化
合物(56)、(57)及び(58)を得た。得られた
化合物の物理恒数を表3に示した。Reference Example 33 Poly-D-glutamic acid (5
6), (57) and (58) In the same manner as in Reference Example 28, commercially available sodium salt of poly-D-glutamic acid (average molecular weight distribution (viscosity method) = 1)
0,600) (53), poly-D-glutamic acid sodium salt (average molecular weight distribution (viscosity method) = 41,000)
(54), poly-L-glutamic acid sodium salt (average molecular weight distribution (viscosity method) = 95, 100) (55) was treated with 1 M hydrochloric acid in an aqueous solution to give the free acid, and the title compounds (56), (57) were obtained. ) And (58) were obtained. The physical constants of the obtained compound are shown in Table 3.
【0126】[0126]
【表3】 [Table 3]
【0127】参考例34 ポリ−γ−〔2−(4−ヒド
ロキシフェニル)エチルアミノ〕−D−グルタミン酸ナ
トリウム塩(59)、(60)及び(61) 参考例30の場合と同様にして、化合物(56)、(5
7)及び(58)に、それぞれ2−(4−ヒドロキシフ
ェニル)エチルアミノ基の導入を行い、標記化合物(5
9)、(60)及び(61)を得た。導入された2−
(4−ヒドロキシフェニル)エチルアミノ基量(モル
比)及び得られた化合物の物理恒数を表4に示した。Reference Example 34 Poly-γ- [2- (4-hydroxyphenyl) ethylamino] -D-glutamic acid sodium salt (59), (60) and (61) In the same manner as in Reference Example 30, the compound was obtained. (56), (5
A 2- (4-hydroxyphenyl) ethylamino group was introduced into each of 7) and (58) to give the title compound (5
9), (60) and (61) were obtained. Introduced 2-
Table 4 shows the amount (molar ratio) of (4-hydroxyphenyl) ethylamino group and the physical constants of the obtained compound.
【0128】[0128]
【表4】 [Table 4]
【0129】参考例35 ポリ−γ−〔8−(β−D−
ガラクトピラノシルオキシ)オクチルアミノ〕−γ−
〔2−(4−ヒドロキシフェニル)エチルアミノ〕−L
−グルタミン酸ナトリウム塩(62) ポリ−L−グルタミン酸(45)75mg(0.0066
ミリモル)の乾燥N,N−ジメチルホルムアミド1.5
ml溶液に、8−アミノオクチル β−D−ガラクトピラ
ノシド(25)180mg(0.586ミリモル)、2−
(4−ヒドロキシフェニル)エチルアミン7.2mg
(0.0547ミリモル)及びN−ヒドロキシコハク酸
イミド80.5mg(0.7ミリモル)を乾燥N,N−ジ
メチルホルムアミド1.5mlに溶解した液を加えて氷冷
した。この反応混合物に撹拌しながら1−エチル−3−
(3−ジメチルアミノプロピル)−カルボジイミド塩酸
塩135mg(0.7ミリモル)、乾燥N,N−ジメチル
ホルムアミド10ml溶液を加えた。冷却浴を除いた後、
室温で一夜撹拌した。反応混合物に精製水30mlを加
え、析出した不溶物を遠心分離して除去した。上澄液を
スペクトラ/ポア3(分子量カットオフ=約3,50
0)透析膜を用いて、精製水に対して4℃で24時間透
析した。透析内液を取り出し、凍結乾燥した。得られた
残渣を0.01M 等張燐酸緩衝液(pH7.4)に溶解し
てゲル濾過カラムクロマトグラフィー(セファデックス
G−100、5cm×30cm)で精製した。溶出された各
分画を高速液体クロマトグラフィー(カラム:TSK−
GEL G3000PWXL、溶出液:0.2M 食塩
水、溶出速度:0.5ml/分、検出:紫外部吸収(28
0nm))でモニターした。ポリ−L−グルタミン酸誘導
体含有分画を集めて再びスペクトラ/ポア3(分子量カ
ットオフ=約3,500)透析膜を用いて、精製水に対
して4℃で48時間透析した。透析内液を取り出し、凍
結乾燥して標記化合物(62)89.2mgを得た。導入
された8−(β−D−ガラクピラノシルオキシ)オクチ
ルアミノ残基含量をフェノール−硫酸法で比色定量する
と、導入量はポリグルタミン酸1モル当り36モルであ
った。また、2−(4−ヒドロキシフェニル)エチルア
ミノ基量を吸光度275nmを用いて定量すると、その導
入量(モル比)は3であった。化合物の糖含量及び2−
(4−ヒドロキシフェニル)エチルアミノ基含量を表5
に示した。また、化合物の物理恒数を表6に示した。Reference Example 35 Poly-γ- [8- (β-D-
Galactopyranosyloxy) octylamino] -γ-
[2- (4-hydroxyphenyl) ethylamino] -L
-Glutamic acid sodium salt (62) Poly-L-glutamic acid (45) 75 mg (0.0066
1.5 mmol of dry N, N-dimethylformamide 1.5
180 ml (0.586 mmol) of 8-aminooctyl β-D-galactopyranoside (25), 2-
7.2 mg of (4-hydroxyphenyl) ethylamine
(0.0547 mmol) and 80.5 mg (0.7 mmol) of N-hydroxysuccinimide were dissolved in 1.5 ml of dry N, N-dimethylformamide, and the mixture was ice-cooled. The reaction mixture was stirred with 1-ethyl-3-
135 mg (0.7 mmol) of (3-dimethylaminopropyl) -carbodiimide hydrochloride and a 10 ml solution of dry N, N-dimethylformamide were added. After removing the cooling bath,
Stir overnight at room temperature. 30 ml of purified water was added to the reaction mixture, and the precipitated insoluble matter was removed by centrifugation. Spectra / Pore 3 (Molecular weight cutoff = approx. 3,50)
0) Dialysis was performed at 4 ° C. for 24 hours against purified water using a dialysis membrane. The dialyzed solution was taken out and freeze-dried. The obtained residue was dissolved in 0.01 M isotonic phosphate buffer (pH 7.4) and purified by gel filtration column chromatography (Sephadex G-100, 5 cm × 30 cm). Each eluted fraction was subjected to high performance liquid chromatography (column: TSK-
GEL G3000PWXL, eluent: 0.2M saline, elution rate: 0.5 ml / min, detection: ultraviolet absorption (28
0 nm)). Fractions containing the poly-L-glutamic acid derivative were collected and again dialyzed against purified water at 4 ° C. for 48 hours using a Spectra / Pore 3 (molecular weight cutoff = about 3,500) dialysis membrane. The dialyzed solution was taken out and freeze-dried to obtain 89.2 mg of the title compound (62). When the content of the introduced 8- (β-D-galactyranosyloxy) octylamino residue was colorimetrically determined by the phenol-sulfuric acid method, the introduced amount was 36 mol per mol of polyglutamic acid. Moreover, when the amount of 2- (4-hydroxyphenyl) ethylamino groups was quantified using the absorbance of 275 nm, the amount introduced (molar ratio) was 3. The sugar content of the compound and 2-
The content of (4-hydroxyphenyl) ethylamino group is shown in Table 5.
It was shown to. In addition, Table 6 shows the physical constants of the compounds.
【0130】[0130]
【表5】 [Table 5]
【0131】[0131]
【表6】 [Table 6]
【0132】参考例36 ポリ−γ−〔8−(β−D−
マンノピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−L−グ
ルタミン酸ナトリウム塩(63) ポリ−L−グルタミン酸(45)50mg(0.0037
ミリモル)の乾燥N,N−ジメチルホルムアミド2ml溶
液に、2−エトキシ−1−エトキシカルボニル−1,2
−ジヒドロキノリン152mg(0.615ミリモル)を
加え、室温で1時間撹拌した。この溶液に8−アミノオ
クチル β−D−マンノピラノシド(15)の塩酸塩1
90mg(0.56ミリモル)及びトリエチルアミン0.
48ml(0.56ミリモル)のN,N−ジメチルホルム
アミド2ml溶液を加え、室温で1.5時間撹拌した。次
いで、2−(4−ヒドロキシフェニル)エチルアミン5
mgを加え、更に15.5時間撹拌した。反応液にN,N
−ジメチルホルムアミド0.5mlを加えて希釈した後、
更に25時間撹拌を続けた。反応混合物に0.1M水酸
化ナトリウム水溶液0.5ml及び0.01M 等張燐酸緩
衝液15mlを加えた。析出した不溶物を遠心分離して除
いた後、上澄液をミリポア濾紙を用いて濾過した。濾液
をゲル濾過カラムクロマトグラフィー(セファデックス
G−100、2.5cm×40cm)で精製した。ポリ−L
−グルタミン酸誘導体含有分画を集め、スペクトラ/ポ
ア3(分子量カットオフ=約3,500)透析膜を用い
て、精製水に対して48時間透析した。透析内液を取り
出し、凍結乾燥すると無色アモルファス状の化合物(6
3)35mgを得た。糖含量をフェノール−硫酸法で比色
定量すると、ポリ−L−グルタミン酸1モル当り7モル
の8−(β−D−マンノピラノシルオキシ)オクチルア
ミノ基が導入されたことが判明した。また、2−(4−
ヒドロキシフェニル)エチルアミノ基量を吸光度275
nmを用いて定量すると、3モルの2−(4−ヒドロキシ
フェニル)エチルアミノ基が導入されていることが判明
した。得られた化合物の物理恒数を表6に示した。Reference Example 36 Poly-γ- [8- (β-D-
Mannopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (63) Poly-L-glutamic acid (45) 50 mg (0.0037
2-ethoxy-1-ethoxycarbonyl-1,2 in 2 ml of dry N, N-dimethylformamide.
-152 mg (0.615 mmol) of dihydroquinoline was added, and the mixture was stirred at room temperature for 1 hour. To this solution was added 8-aminooctyl β-D-mannopyranoside (15) hydrochloride 1
90 mg (0.56 mmol) and triethylamine 0.
48 ml (0.56 mmol) of a 2 ml solution of N, N-dimethylformamide were added and stirred at room temperature for 1.5 hours. Then 2- (4-hydroxyphenyl) ethylamine 5
mg was added and the mixture was further stirred for 15.5 hours. N, N in the reaction solution
-After adding 0.5 ml of dimethylformamide for dilution,
Stirring was continued for another 25 hours. To the reaction mixture was added 0.5 ml of 0.1 M aqueous sodium hydroxide solution and 15 ml of 0.01 M isotonic phosphate buffer. The precipitated insoluble matter was removed by centrifugation, and the supernatant was filtered using Millipore filter paper. The filtrate was purified by gel filtration column chromatography (Sephadex G-100, 2.5 cm × 40 cm). Poly-L
-Glutamic acid derivative-containing fractions were collected and dialyzed against purified water for 48 hours using a Spectra / Pore 3 (molecular weight cutoff = about 3,500) dialysis membrane. When the dialyzed solution is taken out and freeze-dried, a colorless amorphous compound (6
3) 35 mg was obtained. Colorimetric determination of the sugar content by the phenol-sulfuric acid method revealed that 7 moles of 8- (β-D-mannopyranosyloxy) octylamino group were introduced per mole of poly-L-glutamic acid. Also, 2- (4-
Hydroxyphenyl) ethylamino group amount of absorbance 275
When quantified using nm, it was found that 3 mol of 2- (4-hydroxyphenyl) ethylamino groups had been introduced. The physical constants of the obtained compound are shown in Table 6.
【0133】参考例37 ポリ−γ−〔8−(β−D−
マンノピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−L−グ
ルタミン酸ナトリウム塩(64) ポリ−L−グルタミン酸(45)50mg(0.0037
ミリモル)のN,N−ジメチルホルムアミド100ml溶
液に、1−エトキシカルボニル−2−エトキシ−1,2
−ジヒドロキノリン152mg(0.615ミリモル)を
加え、1時間40分撹拌した。次いで8−アミノオクチ
ル β−D−マンノピラノシド(15)の塩酸塩190
mg(0.56ミリモル)及びトリエチルアミン0.78
ml(0.56ミリモル)のN,N−ジメチルホルムアミ
ド50ml溶液ならびに2−(4−ヒドロキシフェニル)
エチルアミン5mgのN,N−ジメチルホルムアミド10
ml溶液を加え、室温で45時間撹拌した。反応混合物を
参考例36に記載した方法と同様の方法で精製して、標
記化合物(64)を得た。化合物の2−(4−ヒドロキ
シフェニル)エチルアミノ基含量ならびに糖含量を表5
に示した。また、化合物の物理恒数を表6に示した。Reference Example 37 Poly-γ- [8- (β-D-
Mannopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (64) Poly-L-glutamic acid (45) 50 mg (0.0037
Mmol) of N, N-dimethylformamide in 100 ml of 1-ethoxycarbonyl-2-ethoxy-1,2.
-152 mg (0.615 mmol) of dihydroquinoline was added and stirred for 1 hour and 40 minutes. Then, the hydrochloride salt of 8-aminooctyl β-D-mannopyranoside (15) 190
mg (0.56 mmol) and triethylamine 0.78
ml (0.56 mmol) N, N-dimethylformamide 50 ml solution and 2- (4-hydroxyphenyl)
Ethylamine 5 mg N, N-dimethylformamide 10
ml solution was added, and the mixture was stirred at room temperature for 45 hours. The reaction mixture was purified by a method similar to the method described in Reference Example 36 to obtain the title compound (64). Table 2 shows the 2- (4-hydroxyphenyl) ethylamino group content and the sugar content of the compound.
It was shown to. In addition, Table 6 shows the physical constants of the compounds.
【0134】参考例38 ポリ−γ−〔8−(β−D−
マンノピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−L−グ
ルタミン酸ナトリウム塩(65) ポリ−L−グルタミン酸(45)100mg(0.075
1ミリモル)の無水N,N−ジメチルホルムアミド3.
5ml溶液に、O−スルホベンズイミド96mg(0.52
4ミリモル)、N,N´−カルボニルジイミダゾール9
3mg(0.573ミリモル)を加え、室温で1.5時間
撹拌した。この混合物に2−(4−ヒドロキシフェニ
ル)エチルアミン20mg(0.146ミリモル)及び
1,1,3,3−テトラメチルグアニジン0.19ml
(1.514ミリモル)をN,N−ジメチルホルムアミ
ド4mlに溶解した液2.0ml及び8−アミノオクチル
β−D−マンノピラノシド(15)の塩酸塩153mg
(0.461ミリモル)のN,N−ジメチルホルムアミ
ド1ml溶液を加えて、室温で24時間撹拌した。反応混
合物を参考例36に記載した方法と同様にして精製し
て、標記化合物(65)を得た。化合物の糖含量ならび
に2−(4−ヒドロキシフェニル)エチルアミノ基含量
を表5に示した。また、化合物の物理恒数を表6に示し
た。Reference Example 38 Poly-γ- [8- (β-D-
Mannopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (65) Poly-L-glutamic acid (45) 100 mg (0.075
1 mmol) anhydrous N, N-dimethylformamide 3.
96 ml (0.52) of O-sulfobenzimide was added to a 5 ml solution.
4 mmol), N, N'-carbonyldiimidazole 9
3 mg (0.573 mmol) was added, and the mixture was stirred at room temperature for 1.5 hours. To this mixture was added 20 mg (0.146 mmol) of 2- (4-hydroxyphenyl) ethylamine and 0.19 ml of 1,1,3,3-tetramethylguanidine.
2.0 ml of a solution of (1.514 mmol) in 4 ml of N, N-dimethylformamide and 8-aminooctyl
β-D-mannopyranoside (15) hydrochloride 153 mg
A solution of (0.461 mmol) in N, N-dimethylformamide (1 ml) was added, and the mixture was stirred at room temperature for 24 hours. The reaction mixture was purified by the same method as in Reference Example 36 to obtain the title compound (65). Table 5 shows the sugar content and the 2- (4-hydroxyphenyl) ethylamino group content of the compound. In addition, Table 6 shows the physical constants of the compounds.
【0135】参考例39 ポリ−γ−〔8−(β−D−
マンノピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−L−グ
ルタミン酸ナトリウム塩(66) 参考例35に記載した方法と同様にして、ポリ−L−グ
ルタミン酸(45)に、8−アミノオクチル α−D−
マンノピラノシド(9)及び2−(4−ヒドロキシフェ
ニル)エチルアミンを用いて、8−(β−D−マンノピ
ラノシルオキシ)オクチルアミノ基及び2−(4−ヒド
ロキシフェニル)エチルアミノ基の導入を行い、標記化
合物(66)を得た。得られた化合物の糖含量及び2−
(4−ヒドロキシフェニル)エチルアミノ基含量を表5
に示した。また、化合物の物理恒数を表6に示した。Reference Example 39 Poly-γ- [8- (β-D-
Mannopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (66) In the same manner as in the method described in Reference Example 35, poly-L-glutamic acid (45) was added to 8-aminooctyl α-D-.
Using mannopyranoside (9) and 2- (4-hydroxyphenyl) ethylamine, introduction of 8- (β-D-mannopyranosyloxy) octylamino group and 2- (4-hydroxyphenyl) ethylamino group was performed. The title compound (66) was obtained. The sugar content of the obtained compound and 2-
The content of (4-hydroxyphenyl) ethylamino group is shown in Table 5.
It was shown to. In addition, Table 6 shows the physical constants of the compounds.
【0136】参考例40 ポリ−γ−〔8−(α−D−
マンノピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−L−グ
ルタミン酸ナトリウム塩(67) ポリ−L−グルタミン酸(45)75mg(0.0056
ミリモル)の乾燥N,N−ジメチルホルムアミド10ml
溶液に、撹拌しながら8−アミノオクチル α−D−マ
ンノピラノシド(9)180mg(0.611ミリモ
ル)、2−(4−ヒドロキシフェニル)エチルアミン
7.5mg(0.00546ミリモル)及び1−エトキシ
カルボニル−2−エトキシ−1,2−ジヒドロキノリン
98mg(0.0396ミリモル)の乾燥N,N−ジメチ
ルホルムアミド3ml溶液を加え、室温で16時間撹拌し
た。反応混合物を0.01M 等張燐酸緩衝液30mlで希
釈した後、スペクトラ/ポア3(分子量カットオフ=約
3,500)透析膜を用いて、精製水に対して4℃で2
4時間透析した。透析内液を取り出し、凍結乾燥した。
得られた残渣を0.01M 等張燐酸緩衝液(pH7.4)
に溶解してゲル濾過カラムクロマトグラフィー(セファ
デックスG100、5cm×30cm)で精製した。溶出さ
れた各分画を高速液体クロマトグラフィー(カラム:T
SK−GEL G3000PWXL、溶出液:0.2M
食塩水、溶出速度:0.5ml/min.、検出:紫外部吸収
(280nm))でモニターした。ポリ−L−グルタミン
酸誘導体含有分画を集めて、再びスペクトラ/ポア3
(分子量カットオフ=約3,500)透析膜を用いて、
精製水に対して4℃で48時間透析した。透析内液を取
り出し、凍結乾燥して標記化合物(67)80mgを得
た。得られた化合物の糖含量及び2−(4−ヒドロキシ
フェニル)エチルアミノ基含量を表5に示した。また、
化合物の物理恒数を表6に示した。Reference Example 40 Poly-γ- [8- (α-D-
Mannopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (67) Poly-L-glutamic acid (45) 75 mg (0.0056
10 ml of dry N, N-dimethylformamide
To the solution, with stirring, 180 mg (0.611 mmol) of 8-aminooctyl α-D-mannopyranoside (9), 7.5 mg (0.00546 mmol) of 2- (4-hydroxyphenyl) ethylamine and 1-ethoxycarbonyl- A solution of 98 mg (0.0396 mmol) of 2-ethoxy-1,2-dihydroquinoline in 3 ml of dry N, N-dimethylformamide was added, and the mixture was stirred at room temperature for 16 hours. After diluting the reaction mixture with 30 ml of 0.01 M isotonic phosphate buffer, it was diluted with purified water using Spectra / Pore 3 (molecular weight cut-off = about 3,500) dialysis membrane at 4 ° C. at 2 ° C.
It was dialyzed for 4 hours. The dialyzed solution was taken out and freeze-dried.
The obtained residue is used as a 0.01 M isotonic phosphate buffer solution (pH 7.4).
It was dissolved in and purified by gel filtration column chromatography (Sephadex G100, 5 cm × 30 cm). Each eluted fraction was subjected to high performance liquid chromatography (column: T
SK-GEL G3000PWXL, eluent: 0.2M
Saline solution, dissolution rate: 0.5 ml / min. , Detection: ultraviolet absorption (280 nm)). Fractions containing the poly-L-glutamic acid derivative were collected and recollected in Spectra / Pore 3
(Molecular weight cutoff = about 3,500) Using a dialysis membrane,
Dialysis was performed at 4 ° C. for 48 hours against purified water. The dialyzed solution was taken out and freeze-dried to obtain 80 mg of the title compound (67). Table 5 shows the sugar content and the 2- (4-hydroxyphenyl) ethylamino group content of the obtained compound. Also,
The physical constants of the compound are shown in Table 6.
【0137】参考例41 ポリ−γ−〔8−(α−D−
キシロピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−L−グ
ルタミン酸ナトリウム塩(68) 参考例37に記載した方法と同様にして、ポリ−L−グ
ルタミン酸(45)に、8−アミノオクチル α−D−
キシロピラノシド(30)及び2−(4−ヒドロキシフ
ェニル)エチルアミンを用いて、8−(α−D−キシロ
ピラノシルオキシ)オクチルアミノ基及び2−(4−ヒ
ドロキシフェニル)エチルアミノ基の導入を行い、標記
化合物(68)を得た。化合物の2−(4−ヒドロキシ
フェニル)エチルアミノ基含量ならびに糖含量を表5に
示した。また、化合物の物理恒数を表6に示した。Reference Example 41 Poly-γ- [8- (α-D-
Xylopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (68) In the same manner as in the method described in Reference Example 37, poly-L-glutamic acid (45) was added to 8-aminooctyl α-D-.
Using xylopyranoside (30) and 2- (4-hydroxyphenyl) ethylamine, 8- (α-D-xylopyranosyloxy) octylamino group and 2- (4-hydroxyphenyl) ethylamino group were introduced. , The title compound (68) was obtained. Table 5 shows the 2- (4-hydroxyphenyl) ethylamino group content and the sugar content of the compound. In addition, Table 6 shows the physical constants of the compounds.
【0138】参考例42 ポリ−γ−〔8−(β−L−
フコピラノシルオキシ)オクチルアミノ〕−γ−〔2−
(4−ヒドロキシフェニル)エチルアミノ〕−L−グル
タミン酸ナトリウム塩(69) 参考例37に記載した方法と同様にして、ポリ−L−グ
ルタミン酸(45)に、化合物(34)及び2−(4−
ヒドロキシフェニル)エチルアミンを用いて、8−(β
−L−フコピラノシルオキシ)オクチルアミノ基及び2
−(4−ヒドロキシフェニル)エチルアミノ基の導入を
行い、標記化合物(69)を得た。化合物の2−(4−
ヒドロキシフェニル)エチルアミノ基含量ならびに糖含
量を表5に示した。また、化合物の物理恒数を表6に示
した。Reference Example 42 Poly-γ- [8- (β-L-
Fucopyranosyloxy) octylamino] -γ- [2-
(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (69) In the same manner as in the method described in Reference Example 37, poly-L-glutamic acid (45) was added to compound (34) and 2- (4-).
Using hydroxyphenyl) ethylamine, 8- (β
-L-fucopyranosyloxy) octylamino group and 2
A-(4-hydroxyphenyl) ethylamino group was introduced to obtain the title compound (69). Compound 2- (4-
The hydroxyphenyl) ethylamino group content and sugar content are shown in Table 5. In addition, Table 6 shows the physical constants of the compounds.
【0139】参考例43 ポリ−γ−〔8−(2−アセ
タミド−2−デオキシ−α−L−フコピラノシルオキ
シ)オクチルアミノ〕−γ−〔2−(4−ヒドロキシフ
ェニル)エチルアミノ〕−L−グルタミン酸ナトリウム
塩(70) 参考例37に記載した方法と同様にして、ポリ−L−グ
ルタミン酸(45)に、化合物(40)及び2−(4−
ヒドロキシフェニル)エチルアミンを用いて、8−(2
−アセタミド−2−デオキシ−α−L−フコピラノシル
オキシ)オクチルアミノ基及び2−(4−ヒドロキシフ
ェニル)エチルアミノ基の導入を行い、標記化合物(7
0)を得た。化合物(70)の糖含量を求めるために、
4M 塩酸と100℃で4時間加熱撹拌して加水分解し
た。得られた加水分解生成物をElson-Morgan法で比色定
量すると、8−(2−アセタミド−2−デオキシ−α−
L−フコピラノシルオキシ)オクチルアミノ基含量は、
ポリ−L−グルタミン酸1モル当り3モルであった。化
合物の2−(4−ヒドロキシフェニル)エチルアミノ基
含量ならびに糖含量を表5に示した。また、化合物の物
理恒数を表6に示した。Reference Example 43 Poly-γ- [8- (2-acetamido-2-deoxy-α-L-fucopyranosyloxy) octylamino] -γ- [2- (4-hydroxyphenyl) ethylamino] -L-Glutamic acid sodium salt (70) In the same manner as in the method described in Reference Example 37, poly-L-glutamic acid (45) was added to compound (40) and 2- (4-).
Using hydroxyphenyl) ethylamine, 8- (2
-Acetamide-2-deoxy-α-L-fucopyranosyloxy) octylamino group and 2- (4-hydroxyphenyl) ethylamino group were introduced to give the title compound (7
0) was obtained. To determine the sugar content of compound (70),
It was hydrolyzed by heating and stirring with 4M hydrochloric acid at 100 ° C. for 4 hours. Colorimetric determination of the obtained hydrolysis product by the Elson-Morgan method gave 8- (2-acetamido-2-deoxy-α-
L-fucopyranosyloxy) octylamino group content is
It was 3 mol per mol of poly-L-glutamic acid. Table 5 shows the 2- (4-hydroxyphenyl) ethylamino group content and the sugar content of the compound. In addition, Table 6 shows the physical constants of the compounds.
【0140】参考例44 ポリ−γ−〔8−(2−アセ
タミド−2−デオキシ−β−D−マンノピラノシルオキ
シ)オクチルアミノ〕−γ−〔2−(4−ヒドロキシフ
ェニル)エチルアミノ〕−L−グルタミン酸ナトリウム
塩(71) 参考例35に記載した方法と同様にして、ポリ−L−グ
ルタミン酸(45)に、化合物(21)及び2−(4−
ヒドロキシフェニル)エチルアミンを用いて、8−(2
−アセタミド−2−デオキシ−β−D−マンノピラノシ
ルオキシ)オクチルアミノ基及び2−(4−ヒドロキシ
フェニル)エチルアミノ基の導入を行い、標記化合物
(71)を得た。化合物(71)の糖含量を参考例43
に記載した方法と同様の方法により、4M 塩酸で加水分
解後、Elson-Morgan法で比色定量した。化合物の糖含量
及び2−(4−ヒドロキシフェニル)エチルアミノ基含
量を表5に示した。また、化合物の物理恒数を表6に示
した。Reference Example 44 Poly-γ- [8- (2-acetamido-2-deoxy-β-D-mannopyranosyloxy) octylamino] -γ- [2- (4-hydroxyphenyl) ethylamino ] -L-Glutamic acid sodium salt (71) In the same manner as in the method described in Reference Example 35, poly-L-glutamic acid (45) was added to compound (21) and 2- (4-).
Using hydroxyphenyl) ethylamine, 8- (2
-Acetamide-2-deoxy-β-D-mannopyranosyloxy) octylamino group and 2- (4-hydroxyphenyl) ethylamino group were introduced to obtain the title compound (71). The sugar content of the compound (71) was used as in Reference Example 43.
After hydrolysis with 4M hydrochloric acid by the same method as described in 1., colorimetric determination was carried out by Elson-Morgan method. Table 5 shows the sugar content and the 2- (4-hydroxyphenyl) ethylamino group content of the compound. In addition, Table 6 shows the physical constants of the compounds.
【0141】参考例45 ポリ−L−グルタミン酸ナト
リウム塩(73) 文献記載の方法(J. Am. Chem. Soc., 78, 941(1956))
で合成したγ−ベンジル−N,O−カルボニル−L−グ
ルタメ−ト(72)2.63g(10.0ミリモル)を
乾燥N,N−ジメチルホルムアミド10mlに窒素気流下
で撹拌しながら溶解した。この溶解にヘキシルアミン
6.6μl を乾燥N,N−ジメチルホルムアミド100
μl に溶解した溶液を加え、窒素気流下室温で24時間
撹拌した。反応混合物をイソプロピルエーテル500ml
に撹拌しながら注ぎ、析出した沈殿物を濾取した。沈殿
物をエタノールでよく洗浄した後、減圧下で乾燥した。
得られた沈殿物を、トリフルオロ酢酸17mlとアニソー
ル3mlの混合液に溶解した後、窒素気流下でメタンスル
ホン酸17mlを加えた。反応混合物を氷冷下で20分撹
拌した。冷却浴を除き、更に室温で30分撹拌した。反
応液をイソプロピルエーテル300mlに撹拌しながら注
ぎ、析出した沈殿物を濾取した。沈殿物をイソプロピル
エーテルで洗浄した後、5%炭酸水素ナトリウム水溶液
20mlに添加して、室温で30分間撹拌した。得られた
溶液をスペクトラ/ポア透析膜を用いて、精製水に対し
て4℃で2日間透析した。透析内液を取り出し、凍結乾
燥して、標記化合物(73)1.1gを得た。標準物質
としてポリエチレングリコールを用いたゲルパーミエイ
ションクロマトグラフィー法(カラム:TSK−GEL
G4000PWXL+G3000PWXL、溶出液:
0.2M 食塩水、溶出速度:0.5ml/分)で求めた重
量平均分子量(Mw)は22,000であった。得られ
た化合物の物理恒数を表7に示した。Reference Example 45 Poly-L-glutamic acid sodium salt (73) The method described in the literature (J. Am. Chem. Soc., 78, 941 (1956)).
2.63 g (10.0 mmol) of .gamma.-benzyl-N, O-carbonyl-L-glutamate (72) synthesized in 1. was dissolved in 10 ml of dry N, N-dimethylformamide with stirring under a nitrogen stream. To this solution was added 6.6 μl of hexylamine to dry N, N-dimethylformamide 100.
A solution dissolved in μl was added, and the mixture was stirred at room temperature under a nitrogen stream for 24 hours. 500 ml of isopropyl ether to the reaction mixture
While stirring, and the deposited precipitate was collected by filtration. The precipitate was washed well with ethanol and then dried under reduced pressure.
The obtained precipitate was dissolved in a mixed solution of 17 ml of trifluoroacetic acid and 3 ml of anisole, and then 17 ml of methanesulfonic acid was added under a nitrogen stream. The reaction mixture was stirred under ice cooling for 20 minutes. The cooling bath was removed, and the mixture was further stirred at room temperature for 30 minutes. The reaction solution was poured into 300 ml of isopropyl ether while stirring, and the deposited precipitate was collected by filtration. The precipitate was washed with isopropyl ether, added to 20 ml of a 5% aqueous sodium hydrogen carbonate solution, and stirred at room temperature for 30 minutes. The obtained solution was dialyzed against purified water at 4 ° C. for 2 days using a Spectra / Pore dialysis membrane. The dialyzed solution was taken out and freeze-dried to obtain 1.1 g of the title compound (73). Gel permeation chromatography using polyethylene glycol as a standard substance (column: TSK-GEL
G4000PWXL + G3000PWXL, eluent:
The weight average molecular weight (Mw) determined with 0.2 M saline, elution rate: 0.5 ml / min) was 22,000. The physical constants of the obtained compound are shown in Table 7.
【0142】[0142]
【表7】 [Table 7]
【0143】参考例46 ポリ−L−グルタミン酸(7
4) 参考例45の場合と同様にして、γ−ベンジル−N,O
−カルボニル−L−グルタメ−ト(72)を用いてN,
N−ジメチルホルムアミド中、重合開始剤としてトリエ
チルアミンを用いて重合させた。生成物を参考例45の
場合と同様にしてトリフルオロ酢酸、アニソールおよび
メタンスルホン酸で脱ベンジル化した後、精製して、標
記化合物(74)を得た。化合物(74)の重量平均分
子量(Mw)を、標準物質としてポリエチレングリコー
ルを用いたゲルパーミエイションクロマトグラフィー法
(カラム:TSK−GEL G4000PWXL+G3
000PWXL、溶出液:0.2M 食塩水、溶出速度:
0.5ml/分)で求めると、57,200であった。得
られた化合物の物理恒数を表7に示した。Reference Example 46 Poly-L-glutamic acid (7
4) In the same manner as in Reference Example 45, γ-benzyl-N, O
N-, using carbonyl-L-glutamate (72)
Polymerization was performed using triethylamine as a polymerization initiator in N-dimethylformamide. The product was debenzylated with trifluoroacetic acid, anisole and methanesulfonic acid in the same manner as in Reference Example 45, and then purified to obtain the title compound (74). The weight average molecular weight (Mw) of the compound (74) was determined by gel permeation chromatography using polyethylene glycol as a standard substance (column: TSK-GEL G4000PWXL + G3).
000PWXL, eluent: 0.2M saline, elution rate:
0.5 ml / min), it was 57,200. The physical constants of the obtained compound are shown in Table 7.
【0144】参考例47 ポリ−γ−〔8−(β−D−
マンノピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−L−グ
ルタミン酸ナトリウム塩(75) 参考例45で合成した化合物(73)を用いて、参考例
28の場合と同様にして1M 塩酸で処理して得た化合物
(73)の遊離酸129.0mgのN,N−ジメチルホル
ムアミド1.0ml溶液にN,N′−ジシクロヘキシルカ
ルボジイミド51.6mg(0.25ミリモル)及びN−
ヒドロキシコハク酸イミド35.5mg(0.31ミリモ
ル)をN,N−ジメチルホルムアミド0.5mlに溶解し
た液を加えて、4℃で2時間撹拌した。この溶液に2−
(4−ヒドロキシフェニル)エチルアミン6.8mg
(0.05ミリモル)、8−アミノオクチル β−D−
マンノピラノシド(15)p−トルエンスルホン酸塩9
6.0mg(0.20ミリモル)及びトリエチルアミン2
8μl をN,N−ジメチルホルムアミド0.5mlに溶解
した液を加えて4℃で2時間撹拌した。冷却浴を除き、
更に室温で2時間撹拌した。反応混合物に5%炭酸水素
ナトリウム水溶液5mlを加え、析出した不溶物を遠心分
離して除去した。得られた上澄液をミリポア濾紙を用い
て濾過した。濾液をゲル濾過カラムクロマトグラフィー
(セファデックスG−100、2.5cm×20cm)で精
製した。ポリ−L−グルタミン酸誘導体を含む分画を集
め、スペクトラ/ポア透析膜を用いて精製水に対して4
℃で2日間透析した。透析内液を取り出して、凍結乾燥
して、標記化合物(75)127.5mgを得た。化合物
(75)の糖含量はフェノール−硫酸法で比色定量し
た。2−(4−ヒドロキシフェニル)エチルアミノ基含
量は吸光度275nmを用いて定量した。得られた結果を
表8に示した。また、化合物の物理恒数を表9に示し
た。Reference Example 47 Poly-γ- [8- (β-D-
Mannopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (75) The compound (73) synthesized in Reference Example 45 was used, and treated with 1M hydrochloric acid in the same manner as in Reference Example 28. To a solution of 129.0 mg of the free acid of compound (73) in 1.0 ml of N, N-dimethylformamide, 51.6 mg (0.25 mmol) of N, N'-dicyclohexylcarbodiimide and N-
A solution prepared by dissolving 35.5 mg (0.31 mmol) of hydroxysuccinimide in 0.5 ml of N, N-dimethylformamide was added, and the mixture was stirred at 4 ° C for 2 hours. 2-in this solution
(4-hydroxyphenyl) ethylamine 6.8 mg
(0.05 mmol), 8-aminooctyl β-D-
Mannopyranoside (15) p-toluenesulfonate 9
6.0 mg (0.20 mmol) and triethylamine 2
A solution prepared by dissolving 8 μl in 0.5 ml of N, N-dimethylformamide was added, and the mixture was stirred at 4 ° C. for 2 hours. Except the cooling bath,
The mixture was further stirred at room temperature for 2 hours. To the reaction mixture, 5 ml of 5% aqueous sodium hydrogen carbonate solution was added, and the precipitated insoluble material was removed by centrifugation. The resulting supernatant was filtered using Millipore filter paper. The filtrate was purified by gel filtration column chromatography (Sephadex G-100, 2.5 cm × 20 cm). Fractions containing the poly-L-glutamic acid derivative were collected and purified using purified water using a Spectra / pore dialysis membrane.
It was dialyzed for 2 days at ° C. The dialyzed solution was taken out and freeze-dried to obtain 127.5 mg of the title compound (75). The sugar content of compound (75) was determined by colorimetry using the phenol-sulfuric acid method. The content of 2- (4-hydroxyphenyl) ethylamino group was quantified using an absorbance of 275 nm. The obtained results are shown in Table 8. The physical constants of the compounds are shown in Table 9.
【0145】[0145]
【表8】 [Table 8]
【0146】[0146]
【表9】 [Table 9]
【0147】参考例48 ポリ−γ−〔8−(β−D−
マンノピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−L−グ
ルタミン酸ナトリウム塩(76) 参考例47の場合と同様にして、化合物(74)の遊離
酸に化合物(15)のp−トルエンスルホン酸塩及び2
−(4−ヒドロキシフェニル)エチルアミンを用いて8
−(β−D−マンノピラノシルオキシ)オクチルアミノ
基及び2−(4−ヒドロキシフェニル)エチルアミノ基
の導入を行い、標記化合物(76)を得た。化合物(7
6)の糖含量及び2−(4−ヒドロキシフェニル)エチ
ルアミノ基含量を表8に示した。また、化合物の物理恒
数を表9に示した。Reference Example 48 Poly-γ- [8- (β-D-
Mannopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -L-glutamic acid sodium salt (76) In the same manner as in Reference Example 47, the free acid of compound (74) was added to p-toluenesulfonic acid salt of compound (15) and 2
8 with-(4-hydroxyphenyl) ethylamine
A-(β-D-mannopyranosyloxy) octylamino group and a 2- (4-hydroxyphenyl) ethylamino group were introduced to obtain the title compound (76). Compound (7
Table 8 shows the sugar content and 2- (4-hydroxyphenyl) ethylamino group content of 6). The physical constants of the compounds are shown in Table 9.
【0148】参考例49 γ−ベンジル−D−グルタメ
ート(78) 市販D−グルタミン酸(77)100g(680ミリモ
ル)の60%硫酸溶液75mlに、氷冷下でベンジルアル
コール75.0g(694ミリモル)を加えた。反応混
合物を70℃で1時間撹拌した後、生成した水を減圧下
で留去した。反応混合物を炭酸水素ナトリウム120g
を冷水400mlに溶解した液に撹拌しながら注いだ。更
に冷水200mlを加えてしばらく放置した。析出した結
晶を濾取し、冷水でよく洗浄した。生成物を熱水より2
回再結晶し、結晶を濾取した。結晶をエタノール100
ml及びエーテル100mlで洗浄した後、減圧下で乾燥し
て、標記化合物(78)52.1g(32%)を得た。Reference Example 49 γ-Benzyl-D-glutamate (78) To 75 ml of a 60% sulfuric acid solution of 100 g (680 mmol) of commercially available D-glutamic acid (77) was added 75.0 g (694 mmol) of benzyl alcohol under ice cooling. added. The reaction mixture was stirred at 70 ° C. for 1 hour, and then the produced water was distilled off under reduced pressure. 120 g of sodium hydrogen carbonate as the reaction mixture
Was poured into a liquid dissolved in 400 ml of cold water while stirring. Further, 200 ml of cold water was added and the mixture was left for a while. The precipitated crystals were collected by filtration and washed well with cold water. 2 products from hot water
The crystals were recrystallized twice and the crystals were collected by filtration. Crystallize with ethanol 100
After washing with 100 ml of ether and 100 ml of ether, it was dried under reduced pressure to obtain 52.1 g (32%) of the title compound (78).
【0149】78:m.p. 164-164.5 ℃ 〔α〕D 25 - 19.4°(c 1.29, AcOH) IR(KBr)cm-1 : 3000, 1724, 1582, 1517, 1173[0149] 78: mp 164-164.5 ℃ [α] D 25 - 19.4 ° (c 1.29 , AcOH) IR (KBr) cm -1: 3000, 1724, 1582, 1517, 1173
【0150】参考例50 γ−ベンジル−N,O−カル
ボニル−D−グルタメート(79) 化合物(78)24g(101ミリモル)の無水テトラ
ヒドロフラン150ml懸濁液に、窒素気流下、撹拌しな
がらビス(トリクロロメチルカーボネート)11g(3
7.1ミリモル)の無水テトラヒドロフラン40ml溶液
を5分間かけて滴下した。反応混合物を室温で15分間
撹拌した後、加熱を開始して内温40−50℃で4時間
撹拌した。室温まで冷却した後、減圧下で溶媒を留去し
た。得られた結晶性残渣にヘキサン150mlを加えて結
晶を濾取した。ヘキサン−酢酸エチル混液から再結晶し
て、標記化合物(79)17.7g(66%)を得た。Reference Example 50 γ-Benzyl-N, O-carbonyl-D-glutamate (79) A suspension of 24 g (101 mmol) of compound (78) in 150 ml of anhydrous tetrahydrofuran was stirred under a nitrogen stream while stirring for bis (trichloro). Methyl carbonate) 11 g (3
40 ml of anhydrous tetrahydrofuran (7.1 mmol) was added dropwise over 5 minutes. After stirring the reaction mixture at room temperature for 15 minutes, heating was started and the internal temperature was stirred at 40 to 50 ° C. for 4 hours. After cooling to room temperature, the solvent was distilled off under reduced pressure. To the obtained crystalline residue, 150 ml of hexane was added and the crystals were collected by filtration. Recrystallization from a hexane-ethyl acetate mixed solution gave 17.7 g (66%) of the title compound (79).
【0151】79:m.p. 84-85 ℃ 〔α〕D 25 + 16.7°(c 1.05, AcOEt) IR(KBr)cm-1 : 1867, 1716, 1704, 1258, 9281 H-NMR(CDCl3):δ 7.4(5H, m, aromatic H) 6.18(1H, s, NH) 5.14(2H, s, CH2ph) 4.36(1H, t, J=5.5Hz,α-CH) 2.60(2H, m, -CH2CO) 2.28(1H, m, Glu-CH2) 2.10(1H, m, Glu-CH2)79: mp 84-85 ° C. [α] D 25 + 16.7 ° (c 1.05, AcOEt) IR (KBr) cm −1 : 1867, 1716, 1704, 1258, 928 1 H-NMR (CDCl 3 ): δ 7.4 (5H, m, aromatic H) 6.18 (1H, s, NH) 5.14 (2H, s, CH 2 ph) 4.36 (1H, t, J = 5.5Hz, α-CH) 2.60 (2H, m,- CH 2 CO) 2.28 (1H, m, Glu-CH 2 ) 2.10 (1H, m, Glu-CH 2 )
【0152】参考例51 L−グルタミン酸とD−グル
タミン酸の不規則共重合体(80) γ−ベンジル−N,O−カルボニル−L−グルタメ−ト
(72)2.37g(90ミリモル)及びγ−ベンジル
−N,O−カルボニル−D−グルタメ−ト(79)26
0mg(10ミリモル)を、窒素気流下、撹拌しながら乾
燥N,N−ジメチルホルムアミド10mlに溶解した。こ
の溶液に、ヘキシルアミン13.2μlを乾燥N,N−
ジメチルホルムアミド100μl に溶解した溶液を加
え、室温で24時間撹拌した。反応混合物を撹拌しなが
らイソプロピルエーテル500mlに注いだ。析出した沈
殿物を濾取した後、エタノールで洗浄し、減圧下で乾燥
した。得られた沈殿物を、トリフルオロ酢酸17ml及び
アニソール3mlの混液に氷冷しながら溶解した。次いで
メタンスルホン酸17mlを加え、同温度で20分間撹拌
した。冷却浴を除き、更に室温で30分間撹拌した。反
応混合物を撹拌しながらイソプロピルエーテル300ml
に注ぎ、析出した沈殿物を濾取した。得られた沈殿物を
5%炭酸水素ナトリウム水溶液20mlに加え、室温で3
0分間撹拌した。得られた溶液をスペクトラ/ポア透析
膜を用いて、精製水に対して4℃で2日間透析した。透
析内液を取り出し、凍結乾燥して、標記化合物(80)
1.10gを得た。化合物(80)の平均分子量を、標
準物質としてポリエチレングリコールを用いたゲルパー
ミエイションクロマトグラフィーで求めると、重量平均
分子量(Mw)は13,000であった。得られた化合
物の物理恒数を表10に示した。Reference Example 51 Disordered Copolymer of L-Glutamic Acid and D-Glutamic Acid (80) 2.37 g (90 mmol) of γ-benzyl-N, O-carbonyl-L-glutamate (72) and γ- Benzyl-N, O-carbonyl-D-glutamate (79) 26
0 mg (10 mmol) was dissolved in 10 ml of dry N, N-dimethylformamide with stirring under a stream of nitrogen. Hexylamine (13.2 μl) was added to this solution with dry N, N-
A solution dissolved in 100 μl of dimethylformamide was added, and the mixture was stirred at room temperature for 24 hours. The reaction mixture was poured into 500 ml of isopropyl ether with stirring. The deposited precipitate was collected by filtration, washed with ethanol, and dried under reduced pressure. The obtained precipitate was dissolved in a mixed solution of 17 ml of trifluoroacetic acid and 3 ml of anisole while cooling with ice. Next, 17 ml of methanesulfonic acid was added, and the mixture was stirred at the same temperature for 20 minutes. The cooling bath was removed, and the mixture was further stirred at room temperature for 30 minutes. 300 ml of isopropyl ether while stirring the reaction mixture
And the deposited precipitate was collected by filtration. The precipitate obtained was added to 20 ml of a 5% aqueous sodium hydrogen carbonate solution and the mixture was stirred at room temperature for 3
Stir for 0 minutes. The obtained solution was dialyzed against purified water at 4 ° C. for 2 days using a Spectra / Pore dialysis membrane. The dialyzed solution was taken out and freeze-dried to give the title compound (80).
1.10 g were obtained. When the average molecular weight of the compound (80) was determined by gel permeation chromatography using polyethylene glycol as a standard substance, the weight average molecular weight (Mw) was 13,000. The physical constants of the obtained compound are shown in Table 10.
【0153】[0153]
【表10】 [Table 10]
【0154】参考例52 L−グルタミン酸とD−グル
タミン酸の不規則共重合体(81)及び(82) 参考例51の場合と同様にして、N,N−ジメチルホル
ムアミド中、γ−ベンジル−N,O−カルボニル−L−
グルタメ−ト(72)及びγ−ベンジル−N,O−カル
ボニル−D−グルタメ−ト(79)の重合反応の際のモ
ル比を1:1及び1:9にして重合反応させた後、脱ベ
ンジル化すると、それぞれ標記化合物(81)及び(8
2)を得た。得られた化合物の重量平均分子量を、参考
例51の場合と同様にして求めると、いずれの化合物も
13,000であった。得られた化合物の物理恒数を表
10に示した。Reference Example 52 L-Glutamic acid and D-glutamic acid irregular copolymers (81) and (82) In the same manner as in Reference Example 51, γ-benzyl-N, in N, N-dimethylformamide was used. O-carbonyl-L-
Glutamate (72) and γ-benzyl-N, O-carbonyl-D-glutamate (79) were subjected to a polymerization reaction at a molar ratio of 1: 1 and 1: 9, followed by depolymerization. After benzylation, the title compounds (81) and (8
2) was obtained. When the weight average molecular weight of the obtained compounds was determined in the same manner as in Reference Example 51, all the compounds were 13,000. The physical constants of the obtained compound are shown in Table 10.
【0155】参考例53 ポリ−γ−〔2−(4−ヒド
ロキシフェニル)エチルアミノ〕−D,L−グルタミン
酸ナトリウム塩(83) 化合物(80)38.7mg(0.003ミリモル)の
N,N−ジメチルホルムアミド0.5ml溶液、N,N′
−ジシクロヘキシルカルボジイミド1.85mg(0.0
0009ミリモル)、N−ヒドロキシコハク酸イミド
1.73mg(0.00015ミリモル)及び2−(4−
ヒドロキシフェニル)エチルアミン2.06mg(0.0
0015ミリモル)を、N,N−ジメチルホルムアミド
0.5mlに溶解した液を加えて室温で20時間撹拌し
た。反応混合物に5%炭酸水素ナトリウム水溶液5mlを
加えた。析出した不溶物を遠心分離して除いた後、上澄
液をミリポア濾紙を用いて濾過した。濾液をゲル濾過カ
ラムクロマトグラフィー(セファデックスG−100、
2.5cm×20cm)で精製した。ポリグルタミン酸誘導
体含有分画を集め、スペクトラ/ポア透析膜を用いて精
製水に対して4℃で2日間透析した。透析内液を取り出
して、凍結乾燥して、標記化合物(83)を得た。化合
物(83)の2−(4−ヒドロキシフェニル)エチルア
ミノ基含量は吸光度275nmを用いて定量した。得られ
た2−(4−ヒドロキシフェニル)エチルアミノ基含量
及び物理恒数を表11に示した。Reference Example 53 Poly-γ- [2- (4-hydroxyphenyl) ethylamino] -D, L-glutamic acid sodium salt (83) Compound (80) 38.7 mg (0.003 mmol) of N, N -Dimethylformamide 0.5 ml solution, N, N '
-Dicyclohexylcarbodiimide 1.85 mg (0.0
0009 mmol), 1.73 mg (0.00015 mmol) N-hydroxysuccinimide and 2- (4-
Hydroxyphenyl) ethylamine 2.06 mg (0.0
(0015 mmol) was dissolved in 0.5 ml of N, N-dimethylformamide, and the mixture was stirred at room temperature for 20 hours. To the reaction mixture was added 5 ml of 5% aqueous sodium hydrogen carbonate solution. The precipitated insoluble matter was removed by centrifugation, and the supernatant was filtered using Millipore filter paper. The filtrate was subjected to gel filtration column chromatography (Sephadex G-100,
(2.5 cm x 20 cm). Fractions containing the polyglutamic acid derivative were collected and dialyzed against purified water at 4 ° C. for 2 days using a Spectra / Pore dialysis membrane. The dialyzed solution was taken out and freeze-dried to obtain the title compound (83). The 2- (4-hydroxyphenyl) ethylamino group content of the compound (83) was quantified by using the absorbance at 275 nm. Table 11 shows the obtained 2- (4-hydroxyphenyl) ethylamino group content and physical constants.
【0156】[0156]
【表11】 [Table 11]
【0157】参考例54 ポリ−γ−〔2−(4−ヒド
ロキシフェニル)エチルアミノ〕−D,L−グルタミン
酸 ナトリウム塩(84)及び(85) 参考例53に記載した方法と同様にして、化合物(8
1)及び(82)に、2−(4−ヒドロキシフェニル)
エチルアミノ基の導入を行い、それぞれ標記化合物(8
4)及び(85)を得た。得られた化合物の2−(4−
ヒドロキシフェニル)エチルアミノ基含量及び物理恒数
を表11に示した。Reference Example 54 Poly-γ- [2- (4-hydroxyphenyl) ethylamino] -D, L-glutamic acid sodium salt (84) and (85) A compound was prepared in the same manner as in Reference Example 53. (8
2- (4-hydroxyphenyl) in 1) and (82)
An ethylamino group was introduced, and the title compound (8
4) and (85) were obtained. 2- (4- of the obtained compound
Table 11 shows the content of hydroxyphenyl) ethylamino group and the physical constants.
【0158】参考例55 γ−ベンジル−N−(9−フ
ルオレニルメトキシカルボニル)−L−グルタメート
(87) 文献記載の方法(E.R. BLOUT AND R.H. KARTSON, J. A
m. Chem. Soc., 78, 941(1956))で合成したγ−ベンジ
ル−L−グルタメ−ト(86)6.0g(25.28ミ
リモル)及び炭酸ナトリウム2.68g(25.28ミ
リモル)を、水120ml及びアセトニトリル60mlの混
液に溶解した後、氷冷した。ついでN−(9−フルオレ
ニルメトキシカルボニルオキシ)コハク酸イミド8.5
3g(25.28ミリモル)をアセトニトリル36mlに
溶解した液を撹拌しながら滴下した。冷却浴を除いた
後、室温で更に2時間撹拌した。反応液を少量まで濃縮
した後、大量の水を加え析出した不溶物を濾去した。濾
液を希塩酸で酸性にした後、析出した生成物を酢酸エチ
ルで抽出した。抽出液を水洗した後、硫酸マグネシウム
で乾燥し、減圧下で溶媒を留去して残渣12.3gを得
た。残渣に酢酸エチル−ヘキサン混液を加えて洗浄し、
生成物を集め、標記化合物(87)9.4g(81%)
を得た。Reference Example 55 γ-benzyl-N- (9-fluorenylmethoxycarbonyl) -L-glutamate (87) The method described in the literature (ER BLOUT AND RH KARTSON, J. A.
m. Chem. Soc., 78, 941 (1956)), 6.0 g (25.28 mmol) of γ-benzyl-L-glutamate (86) and 2.68 g (25.28 mmol) of sodium carbonate. Was dissolved in a mixed solution of 120 ml of water and 60 ml of acetonitrile and then ice-cooled. Then N- (9-fluorenylmethoxycarbonyloxy) succinimide 8.5
A solution of 3 g (25.28 mmol) dissolved in 36 ml of acetonitrile was added dropwise with stirring. After removing the cooling bath, the mixture was further stirred at room temperature for 2 hours. The reaction solution was concentrated to a small amount, a large amount of water was added, and the precipitated insoluble material was filtered off. The filtrate was acidified with dilute hydrochloric acid, and the precipitated product was extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 12.3 g of a residue. Ethyl acetate-hexane mixture was added to the residue for washing,
The product was collected and the title compound (87) 9.4 g (81%)
I got
【0159】87:無定形粉末 〔α〕D 24 + 9.3 °(c 0.92, CHCl3) IR(KBr)cm-1 : 1728, 1688, 15121 H-NMR(CDCl3-CD3OD):δ 7.8-7.2(13H, m, aromatic H) 5.06(2H, s, CH2ph) 4.37(1H, dd, J=7.5Hz, Fmoc-CH2) 4.34(1H, dd, J=7.5Hz, 10Hz, Fmoc-CH2) 4.26(1H, t, J=10.5Hz, Fmoc-CH2) 4.01(1H, m, Glu-CH) 2.44(2H, m, -CH2COO-) 2.19(1H, m, Glu-CH2) 1.95(1H, m, Glu−CH2)87: Amorphous powder [α] D 24 + 9.3 ° (c 0.92, CHCl 3 ) IR (KBr) cm −1 : 1728, 1688, 1512 1 H-NMR (CDCl 3 −CD 3 OD): δ 7.8-7.2 (13H, m, aromatic H) 5.06 (2H, s, CH 2 ph) 4.37 (1H, dd, J = 7.5Hz, Fmoc-CH 2 ) 4.34 (1H, dd, J = 7.5Hz, 10Hz, Fmoc-CH 2 ) 4.26 (1H, t, J = 10.5Hz, Fmoc-CH 2 ) 4.01 (1H, m, Glu-CH) 2.44 (2H, m, -CH 2 COO-) 2.19 (1H, m, Glu -CH 2) 1.95 (1H, m , Glu-CH 2)
【0160】参考例56 γ−ベンジル−α−tert
−ブチル−N−(9−フルオレニルメトキシカルボニ
ル)−L−グルタメート(88) 化合物(87)18g(39.17ミリモル)を塩化メ
チレン375mlに溶解した後、窒素気流下で−18℃に
冷却した。この溶液に濃硫酸1.95ml(36.58ミ
リモル)を加えた後、撹拌しながらイソブテンガス約6
0mlを吹き込んだ。反応容器を密栓した後、室温に16
時間放置した。反応混合物にトリエチルアミン5.1ml
を加えて中和した後、減圧下で溶媒を留去した。得られ
た残渣を水層と酢酸エチル層とに分配した。有機層を分
離して水、炭酸水素ナトリウム水溶液及び水で順次洗浄
した。硫酸マグネシウムで乾燥した後、減圧下で溶媒を
留去した。得られたシロップ状残渣をシリカゲルカラム
クロマトグラフィー(ヘキサン−酢酸エチル=4:1)
で精製して、標記化合物(88)18.1g(89%)
を得た。Reference Example 56 γ-benzyl-α-tert
-Butyl-N- (9-fluorenylmethoxycarbonyl) -L-glutamate (88) 18 g (39.17 mmol) of compound (87) was dissolved in 375 ml of methylene chloride and then cooled to -18 ° C under a nitrogen stream. did. After adding 1.95 ml (36.58 mmol) of concentrated sulfuric acid to this solution, about 6 parts of isobutene gas was added with stirring.
0 ml was blown. After sealing the reaction vessel tightly, bring it to room temperature 16
Left for hours. 5.1 ml of triethylamine was added to the reaction mixture.
Was added to neutralize, and the solvent was distilled off under reduced pressure. The obtained residue was partitioned into an aqueous layer and an ethyl acetate layer. The organic layer was separated and washed successively with water, aqueous sodium hydrogen carbonate solution and water. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure. The obtained syrupy residue was subjected to silica gel column chromatography (hexane-ethyl acetate = 4: 1).
After purification with 18.1 g (89%) of the title compound (88).
I got
【0161】88:シロップ状 〔α〕D 24 + 50.7°(c 1.34, CHCl3) IR(film)cm-1 : 1732, 1516, 14501 H-NMR(CDCl3):δ 7.8-7.2(13H, m, aromatic H) 5.11(2H, s, CH2ph) 4.37(2H, dd, J=7Hz, Fmoc-CH2) 4.32(1H, m, Glu-CH2) 4.20(1H, t, J=7Hz, Fmoc-CH) 2.42(2H, m, -CH2COO-) 2.22(1H, m, Glu-CH2) 1.97(1H, m, Glu-CH2) 1.45(9H, s, C(CH3)3)88: Syrup [α] D 24 + 50.7 ° (c 1.34, CHCl 3 ) IR (film) cm −1 : 1732, 1516, 1450 1 H-NMR (CDCl 3 ): δ 7.8-7.2 (13H , m, aromatic H) 5.11 (2H, s, CH 2 ph) 4.37 (2H, dd, J = 7Hz, Fmoc-CH 2 ) 4.32 (1H, m, Glu-CH 2 ) 4.20 (1H, t, J = 7Hz, Fmoc-CH) 2.42 (2H, m, -CH 2 COO-) 2.22 (1H, m, Glu-CH 2 ) 1.97 (1H, m, Glu-CH 2 ) 1.45 (9H, s, C (CH 3 ) 3 )
【0162】実施例1 α−tert−ブチル−N−(9−
フルオレニルメトキシカルボニル)−L−グルタメート
(89) 化合物(88)15g(29.09ミリモル)のメタノ
ール156ml及びテトラヒドロフラン156ml混液に、
10%パラジウム−炭素、5.63gを加え、窒素気流
下、10℃に冷却した。次いでギ酸アンモニウム5.6
3g(89.28ミリモル)を加え、同温度で2時間激
しく撹拌した。触媒を濾去した後、濾液を減圧下で濃縮
乾固した。得られた残渣をシリカゲルカラムクロマトグ
ラフィー(クロロホルム−メタノール=10:1)で精
製して、標記化合物(89)8.9g(75%)を得
た。Example 1 α-tert-butyl-N- (9-
Fluorenylmethoxycarbonyl) -L-glutamate (89) To a mixture of 15 g (29.09 mmol) of compound (88) in 156 ml of methanol and 156 ml of tetrahydrofuran,
10% Palladium-carbon (5.63 g) was added, and the mixture was cooled to 10 ° C under a nitrogen stream. Then ammonium formate 5.6
3 g (89.28 mmol) was added, and the mixture was vigorously stirred at the same temperature for 2 hours. After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol = 10: 1) to obtain 8.9 g (75%) of the title compound (89).
【0163】89:m.p. 94.5-95.5 ℃ 〔α〕D 24 + 0.4 °(c 1.34, CHCl3) IR(film)cm-1 : 1728, 1688, 15121 H-NMR(CDCl3):δ 7.8-7.2(13H, m, aromatic H) 4.38(2H, dd, J=6Hz, Fmoc-CH2) 4.35(2H, dd, J=6Hz, Fmoc-CH2) 4.28(1H, m, Glu-CH) 4.18(1H, t, J=7Hz, Fmoc-CH) 2.45(1H, br.signal, OH) 2.40(2H, m, -CH2COO-) 2.17(1H, m, Glu-CH2) 1.91(1H, m, Glu-CH2) 1.45(9H, s, C(CH3)3)89: mp 94.5-95.5 ° C. [α] D 24 + 0.4 ° (c 1.34, CHCl 3 ) IR (film) cm −1 : 1728, 1688, 1512 1 H-NMR (CDCl 3 ): δ 7.8- 7.2 (13H, m, aromatic H) 4.38 (2H, dd, J = 6Hz, Fmoc-CH 2 ) 4.35 (2H, dd, J = 6Hz, Fmoc-CH 2 ) 4.28 (1H, m, Glu-CH) 4.18 (1H, t, J = 7Hz, Fmoc-CH) 2.45 (1H, br.signal, OH) 2.40 (2H, m, -CH 2 COO-) 2.17 (1H, m, Glu-CH 2 ) 1.91 (1H, m, Glu-CH 2 ) 1.45 (9H, s, C (CH 3 ) 3 )
【0164】参考例57 8−〔α−tert−ブチル−N
−(9−フルオレニルメトキシカルボニル)−L−グル
タミド〕オクチル α−D−マンノピラノシド(90) α−tert−ブチル−N−(9−フルオレニルメトキシカ
ルボニル)−L−グルタメート(89)1.42g
(3.344ミリモル)及びN−ヒドロキシコハク酸イ
ミド385mg(3.344ミリモル)のN,N−ジメチ
ルホルムアミド8ml溶液に、N,N′−ジシクロロヘキ
シルカルボジイミド690mg(3.344ミリモル)を
加え、室温で2時間撹拌した。析出した不溶物を濾去し
た後、濾液を8−アミノオクチル α−D−マンノピラ
ノシド(9)895mg(3.04ミリモル)のN,N−
ジメチルホルムアミド5ml溶液に加え、室温で16時間
撹拌した。析出した不溶物を濾去した後、濾液を減圧下
で濃縮乾固した。得られた残渣をシリカゲルカラムクロ
マトグラフィー(クロロホルム−メタノール=10:
1)で精製して、標記化合物(90)1.56g(73
%)を得た。Reference Example 57 8- [α-tert-butyl-N
-(9-Fluorenylmethoxycarbonyl) -L-glutamide] octyl α-D-mannopyranoside (90) α-tert-butyl-N- (9-fluorenylmethoxycarbonyl) -L-glutamate (89) 1. 42 g
To a solution of 385 mg (3.344 mmol) of N-hydroxysuccinimide (3.344 mmol) and 8 ml of N, N-dimethylformamide was added 690 mg (3.344 mmol) of N, N'-dicyclolohexylcarbodiimide, Stir at room temperature for 2 hours. The precipitated insoluble material was removed by filtration, and the filtrate was treated with 8-aminooctyl α-D-mannopyranoside (9) (895 mg, 3.04 mmol) of N, N-.
It was added to a 5 ml solution of dimethylformamide and stirred at room temperature for 16 hours. The precipitated insoluble material was filtered off, and the filtrate was concentrated to dryness under reduced pressure. The obtained residue was subjected to silica gel column chromatography (chloroform-methanol = 10:
Purified in 1), 1.56 g (73) of the title compound (90).
%) Was obtained.
【0165】90:無定形粉末 〔α〕D 28 + 21.0°(c 0.79, CHCl3) IR(CHCl3)cm-1 : 1716, 16601 H-NMR(CD3OD):δ 7.9-7.3(8H, m, aromatic H) 4.69(1H, d, J1,2=1.5Hz, H-1) 4.39(1H, dd, J=7Hz, Fmoc-CH2) 4.29(1H, dd, J=7Hz, Fmoc-CH2) 4.21(1H, t, J=7Hz, Fmoc-CH) 4.03(1H, dd, J=4.5Hz, Glu-CH) 3.80(1H, dd, J5,6a=2.5Hz, J6a,6b=12.5Hz, H-6a) 3.76(1H, dd, J1,2=1.5Hz, J2,3=3.5Hz, H-2) 3.59(1H, t, J3,4=9.5Hz, H-4) 3.50(1H, ddd, H-5) 2.30(2H, m, -CH2COO-) 2.10(1H, m, Glu-CH2) 1.90(1H, m, Glu-CH2) 1.45(9H, s, C(CH3)3)90: Amorphous powder [α] D 28 + 21.0 ° (c 0.79, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1716, 1660 1 H-NMR (CD 3 OD): δ 7.9-7.3 ( 8H, m, aromatic H) 4.69 (1H, d, J 1 , 2 = 1.5Hz, H-1) 4.39 (1H, dd, J = 7Hz, Fmoc-CH 2 ) 4.29 (1H, dd, J = 7Hz, Fmoc-CH 2 ) 4.21 (1H, t, J = 7Hz, Fmoc-CH) 4.03 (1H, dd, J = 4.5Hz, Glu-CH) 3.80 (1H, dd, J 5 , 6a = 2.5Hz, J 6a , 6b = 12.5Hz, H-6a) 3.76 (1H, dd, J 1 , 2 = 1.5Hz, J 2 , 3 = 3.5Hz, H-2) 3.59 (1H, t, J 3 , 4 = 9.5Hz, H-4) 3.50 (1H, ddd, H-5) 2.30 (2H, m, -CH 2 COO-) 2.10 (1H, m, Glu-CH 2 ) 1.90 (1H, m, Glu-CH 2 ) 1.45 ( 9H, s, C (CH 3 ) 3 )
【0166】参考例58 8−〔α−tert−ブチル−N
−(9−フルオレニルメトキシカルボニル)−L−グル
タミド〕オクチル 2,3,4,6−テトラ−O−アセ
チル−α−D−マンノピラノシド(91) 化合物(90)1.77g(2.52ミリモル)のピリ
ジン15ml溶液に、無水酢酸5mlを加え、室温に16時
間放置した。反応混合物を大量の水に注いだ後、析出し
た生成物を酢酸エチルで抽出した。有機層を希塩酸、炭
酸水素ナトリウム溶液及び水で順次洗浄した。硫酸マグ
ネシウムで乾燥した後、減圧下で溶媒を留去して、標記
化合物(91)2.06g(94%)を得た。Reference Example 58 8- [α-tert-butyl-N
-(9-Fluorenylmethoxycarbonyl) -L-glutamide] octyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (91) Compound (90) 1.77 g (2.52 mmol) 5 ml of acetic anhydride was added to a solution of 15) in pyridine and the mixture was allowed to stand at room temperature for 16 hours. After pouring the reaction mixture into a large amount of water, the precipitated product was extracted with ethyl acetate. The organic layer was washed successively with dilute hydrochloric acid, sodium hydrogen carbonate solution and water. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure to obtain 2.06 g (94%) of the title compound (91).
【0167】91:無定形粉末 〔α〕D 22.5 + 19.2°(c 0.5, CHCl3) IR(CHCl3)cm-1 : 1744, 1664, 1514, 1450, 13711 H-NMR(CDCl3):δ 7.8-7.2(8H, m, aromatic H) 5.98(1H, s, NH) 5.62(1H, d, J=7.5Hz, NH) 5.34(1H, dd, J2,3=3.5Hz, J3,4=10Hz, H-3) 5.27(1H, t, J3,4=10Hz, H-4) 5.22(1H, dd, J1,2=1.5Hz, J2,3=3.5Hz, H-2) 4.78(1H, d, J1,2=1.5Hz, H-1) 4.39(2H, m, Fmoc-CH2) 4.26(1H, dd, J5,6a=5.5Hz, J6a,6b=12.5Hz, H-6a) 4.21(2H, t, J=7Hz, Fmoc-CH Glu-CH) 4.10(1H, dd, J5,6b=2.5Hz, H-6b) 3.97(1H, ddd, H-5) 3.65(1H, m, -CH2O) 3.42(1H, m, -CH2O) 3.23(2H, m, -CH2N) 2.20(2H, m, -CH2COO-) 2.15(3H, s, OAc) 2.09(3H, s, OAc) 2.04(3H, s, OAc) 1.98(3H, s, OAc) 1.47(9H, s, C(CH3)3) 1.7-1.2(12H, m, -(CH2)6-)91: Amorphous powder [α] D 22.5 + 19.2 ° (c 0.5, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1744, 1664, 1514, 1450, 1371 1 H-NMR (CDCl 3 ): δ 7.8-7.2 (8H, m, aromatic H) 5.98 (1H, s, NH) 5.62 (1H, d, J = 7.5Hz, NH) 5.34 (1H, dd, J 2 , 3 = 3.5Hz, J 3 , 4 = 10Hz, H-3) 5.27 (1H, t, J 3 , 4 = 10Hz, H-4) 5.22 (1H, dd, J 1 , 2 = 1.5Hz, J 2 , 3 = 3.5Hz, H-2 ) 4.78 (1H, d, J 1 , 2 = 1.5Hz, H-1) 4.39 (2H, m, Fmoc-CH 2 ) 4.26 (1H, dd, J 5 , 6a = 5.5Hz, J 6a , 6b = 12.5 Hz, H-6a) 4.21 (2H, t, J = 7Hz, Fmoc-CH Glu-CH) 4.10 (1H, dd, J 5 , 6b = 2.5Hz, H-6b) 3.97 (1H, ddd, H-5 ) 3.65 (1H, m, -CH 2 O) 3.42 (1H, m, -CH 2 O) 3.23 (2H, m, -CH 2 N) 2.20 (2H, m, -CH 2 COO-) 2.15 (3H, s, OAc) 2.09 (3H, s, OAc) 2.04 (3H, s, OAc) 1.98 (3H, s, OAc) 1.47 (9H, s, C (CH 3 ) 3 ) 1.7-1.2 (12H, m,- (CH 2 ) 6- )
【0168】参考例59 8−〔N−(9−フルオレニ
ルメトキシカルボニル)−L−グルタミド〕オクチル
2,3,4,6−テトラ−O−アセチル−α−D−マン
ノピラノシド(92) 化合物(91)2.0g(2.29ミリモル)を85%
ギ酸−メタノール溶液57mlに溶解し、室温に16時間
放置した。反応混合物をトルエンで希釈した後、減圧下
で濃縮乾固した。得られた残渣をシリカゲルカラムクロ
マトグラフィー(クロロホルム−メタノール=7:1)
で精製して、標記化合物(92)1.90g(定量的)
を得た。Reference Example 59 8- [N- (9-fluorenylmethoxycarbonyl) -L-glutamide] octyl
85% of 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (92) Compound (91) 2.0 g (2.29 mmol)
It was dissolved in 57 ml of formic acid-methanol solution and left at room temperature for 16 hours. The reaction mixture was diluted with toluene and then concentrated to dryness under reduced pressure. The obtained residue is subjected to silica gel column chromatography (chloroform-methanol = 7: 1).
After purification with 1.90 g of the title compound (92) (quantitative)
I got
【0169】92:無定形粉末 〔α〕D 26.5 + 26.2°(c 0.5, CHCl3) IR(CHCl3)cm-1 : 3400, 1745, 1371, 1084, 10511 H-NMR(CDCl3):δ 7.8-7.2(8H, m, aromatic H) 6.18(1H, s, NH) 6.03(1H, d, J=7.5Hz, NH) 5.32(1H, dd, J2,3=3.5Hz, J3,4=10Hz, H-3) 5.26(1H, t, J3,4=10Hz, H-4) 5.21(1H, dd, J1,2=1.5Hz, J2,3=3.5Hz, H-2) 4.33(3H, m, Fmoc-CH2, Glu-CH) 4.25(1H, dd, J5,6a=5.5Hz, J6a,6b=12.5Hz, H-6a) 4.20(1H, t, J=7Hz, Fmoc-CH) 4.10(1H, dd, J5,6b=2.5Hz, H-6b) 3.88(1H, ddd, H-5) 3.66(1H, m, -CH2O) 3.42(1H, m, -CH2O) 3.27(2H, m, -CH2N) 2.56(1H, m, Glu-CH2) 2.45(1H, m, Glu-CH2) 2.14(3H, s, OAc) 2.09(3H, s, OAc) 2.03(3H, s, OAc) 1.98(3H, s, OAc) 1.85(1H, br.s, OH) 1.6-1.2(12H, m, -(CH2)6-)92: Amorphous powder [α] D 26.5 + 26.2 ° (c 0.5, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3400, 1745, 1371, 1084, 1051 1 H-NMR (CDCl 3 ): δ 7.8-7.2 (8H, m, aromatic H) 6.18 (1H, s, NH) 6.03 (1H, d, J = 7.5Hz, NH) 5.32 (1H, dd, J 2 , 3 = 3.5Hz, J 3 , 4 = 10Hz, H-3) 5.26 (1H, t, J 3 , 4 = 10Hz, H-4) 5.21 (1H, dd, J 1 , 2 = 1.5Hz, J 2 , 3 = 3.5Hz, H-2 ) 4.33 (3H, m, Fmoc-CH 2 , Glu-CH) 4.25 (1H, dd, J 5 , 6a = 5.5Hz, J 6a , 6b = 12.5Hz, H-6a) 4.20 (1H, t, J = 7Hz, Fmoc-CH) 4.10 (1H, dd, J 5 , 6b = 2.5Hz, H-6b) 3.88 (1H, ddd, H-5) 3.66 (1H, m, -CH 2 O) 3.42 (1H, m , -CH 2 O) 3.27 (2H, m, -CH 2 N) 2.56 (1H, m, Glu-CH 2 ) 2.45 (1H, m, Glu-CH 2 ) 2.14 (3H, s, OAc) 2.09 (3H , s, OAc) 2.03 (3H, s, OAc) 1.98 (3H, s, OAc) 1.85 (1H, br.s, OH) 1.6-1.2 (12H, m,-(CH 2 ) 6- )
【0170】参考例60 8−〔γ−L−グルタミド〕
オクチル 2,3,4,6−テトラ−O−アセチル−α
−D−マンノピラノシド(93) 化合物(92)1.9g(2.341ミリモル)をモル
ホリン20mlに溶解した後、室温に40分間放置した。
反応混合物をトルエンで希釈した後、減圧下で濃縮乾固
した。残渣にトルエンを加えて濃縮乾固することを繰り
返して、残存するモルホリンを完全に除去した。得られ
た残渣をシリカゲルカラムクロマトグラフィー(クロロ
ホルム−メタノール=5:1)で精製して、標記化合物
(93)590mg(43%)を得た。Reference Example 60 8- [γ-L-glutamide]
Octyl 2,3,4,6-tetra-O-acetyl-α
-D-mannopyranoside (93) 1.9 g (2.341 mmol) of the compound (92) was dissolved in 20 ml of morpholine, and the mixture was allowed to stand at room temperature for 40 minutes.
The reaction mixture was diluted with toluene and then concentrated to dryness under reduced pressure. Toluene was added to the residue and concentrated to dryness was repeated to completely remove the remaining morpholine. The obtained residue was purified by silica gel column chromatography (chloroform-methanol = 5: 1) to obtain 590 mg (43%) of the title compound (93).
【0171】93:無定形粉末 IR(KBr)cm-1 : 3000, 1750, 1640, 1595, 1530, 1323,1
226, 1136, 1089, 104793: Amorphous powder IR (KBr) cm -1 : 3000, 1750, 1640, 1595, 1530, 1323,1
226, 1136, 1089, 1047
【0172】参考例61 8−〔γ−(N,O−ジカル
ボニル)−L−グルタミド〕オクチル2,3,4,6−
テトラ−O−アセチル−α−D−マンノピラノシド(9
4) 化合物(93)490mg(0.828ミリモル)の無水
テトラヒドロフラン20ml溶液に、ビス(トリクロロメ
チルカーボネート)86mg(0.29ミリモル)を加
え、窒素気流下、60℃で3時間加熱撹拌した。室温ま
で冷却した後、減圧下で溶媒を留去した。残渣にトルエ
ンを加えて濃縮乾固することを繰り返して、生成した塩
化水素を完全に除き、標記化合物(94)500mg(9
8%)を得た。Reference Example 61 8- [γ- (N, O-dicarbonyl) -L-glutamide] octyl 2,3,4,6-
Tetra-O-acetyl-α-D-mannopyranoside (9
4) To a solution of 490 mg (0.828 mmol) of compound (93) in 20 ml of anhydrous tetrahydrofuran was added 86 mg (0.29 mmol) of bis (trichloromethyl carbonate), and the mixture was heated and stirred at 60 ° C. for 3 hours under a nitrogen stream. After cooling to room temperature, the solvent was distilled off under reduced pressure. Toluene was added to the residue, and the mixture was concentrated to dryness. The generated hydrogen chloride was completely removed, and 500 mg of the title compound (94) (9
8%).
【0173】94:無定形粉末 IR(KBr)cm-1 : 1857, 1787, 1747, 1659, 1369, 10881 H-NMR(CDCl3) : δ 4.76(1H, s, H-1) 2.12(3H, s, OAc) 2.06(3H, s, OAc) 2.01(3H, s, OAc) 0.96(3H, s, OAc)94: Amorphous powder IR (KBr) cm −1 : 1857, 1787, 1747, 1659, 1369, 1088 1 H-NMR (CDCl 3 ): δ 4.76 (1H, s, H-1) 2.12 (3H , s, OAc) 2.06 (3H, s, OAc) 2.01 (3H, s, OAc) 0.96 (3H, s, OAc)
【0174】参考例62 ポリ−γ−〔8−(2,3,
4,6−テトラ−O−アセチル−α−D−マンノピラノ
シルオキシ)オクチルアミノ〕−γ−ベンジル−L−グ
ルタメート(95) 化合物(94)500mg(0.828ミリモル)及び文
献記載の方法(J. Am.Chem. Soc., 78, 941(1956))で
合成したγ−ベンジル−(N,O−カルボニル)−L−
グルタメート(72)220mg(0.828ミリモル)
の無水N,N−ジメチルホルムアミド10mlに、n−ヘ
キシルアミン296mg(2.92ミリモル)を無水N,
N−ジメチルホルムアミド10mlに溶解した液0.02
8ml(0.0082ミリモル)を加えて、室温で24時
間撹拌した。反応混合物をエタノール150mlに注ぎ、
析出した沈殿物を遠心分離して集めた。沈殿物をエタノ
ールでよく洗浄した後、減圧下、50℃で4時間加熱乾
燥して、標記化合物(95)140mgを得た。Reference Example 62 Poly-γ- [8- (2,3,
4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy) octylamino] -γ-benzyl-L-glutamate (95) Compound (94) 500 mg (0.828 mmol) and described in the literature. Γ-benzyl- (N, O-carbonyl) -L- synthesized by the method (J. Am. Chem. Soc., 78, 941 (1956)).
220 mg (0.828 mmol) of glutamate (72)
N-hexylamine (296 mg, 2.92 mmol) was added to anhydrous N, N-dimethylformamide (10 ml).
Liquid 0.02 dissolved in 10 ml of N-dimethylformamide
8 ml (0.0082 mmol) was added and the mixture was stirred at room temperature for 24 hours. Pour the reaction mixture into 150 ml of ethanol,
The deposited precipitate was collected by centrifugation. The precipitate was thoroughly washed with ethanol and then dried by heating under reduced pressure at 50 ° C. for 4 hours to obtain 140 mg of the title compound (95).
【0175】参考例63 ポリ−γ−〔8−(α−D−
マンノピラノシルオキシ)オクチルアミノ〕−L−グル
タミン酸ナトリウム塩(96) 参考例62で得た化合物(95)140mgを無水テトラ
ヒドロフラン30mlに溶解した後、1M ナトリウムメト
キシド−メタノール溶液1mlを加えて室温で3時間撹拌
した。反応混合物を減圧下で濃縮乾固した後、得られた
残渣に氷冷下、アニソール0.6mlを含むトリフルオロ
酢酸4mlを加えて溶解した。この溶液にメタンスルホン
酸4mlを加え、同温度で1時間撹拌した。反応混合物を
撹拌しながらイソプロピルエーテル200mlに注いだ
後、析出した沈殿物を遠心分離して集めた。沈殿物を飽
和炭酸水素ナトリウム水溶液10mlに溶解した後、スペ
クトラ/ポア3(分子量カットオフ=約3,500)透
析膜を用いて、精製水に対して48時間透析した。透析
内液を取り出し、凍結乾燥して、標記化合物(96)6
0mgを得た。化合物(96)の平均分子量分布をゲルパ
ーミエイションクロマトグラフィー(カラム:TSK−
GEL G4000PWXL+G3000PWXL、溶
出液:0.2M 食塩水、溶出速度:0.5ml/分)によ
り、標準物質としてポリエチレングリコールを用いて測
定すると数平均分子量(Mn)=10,368、重量平
均分子量(Mw)=11,320、分子量分布(Mw/
Mn)=1.09であることが判明した。また、化合物
(96)のマンノース含量をフェノール−硫酸法で比色
定量するとその含量は1重量%であることが判明した。Reference Example 63 Poly-γ- [8- (α-D-
Mannopyranosyloxy) octylamino] -L-glutamic acid sodium salt (96) 140 mg of the compound (95) obtained in Reference Example 62 was dissolved in 30 ml of anhydrous tetrahydrofuran, and 1 ml of 1M sodium methoxide-methanol solution was added. Stir at room temperature for 3 hours. The reaction mixture was concentrated to dryness under reduced pressure, and 4 ml of trifluoroacetic acid containing 0.6 ml of anisole was added to and dissolved in the resulting residue under ice cooling. 4 ml of methanesulfonic acid was added to this solution, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was poured into 200 ml of isopropyl ether while stirring, and the deposited precipitate was collected by centrifugation. The precipitate was dissolved in 10 ml of a saturated aqueous sodium hydrogen carbonate solution, and then dialyzed against purified water for 48 hours using a Spectra / Pore 3 (molecular weight cutoff = about 3,500) dialysis membrane. The dialyzed solution was taken out and freeze-dried to give the title compound (96) 6
0 mg was obtained. The average molecular weight distribution of compound (96) was determined by gel permeation chromatography (column: TSK-
GEL G4000PWXL + G3000PWXL, eluent: 0.2M saline, elution rate: 0.5 ml / min), using polyethylene glycol as a standard substance, number average molecular weight (Mn) = 10,368, weight average molecular weight (Mw) = 11,320, molecular weight distribution (Mw /
It was found that Mn) = 1.09. Further, the mannose content of the compound (96) was colorimetrically determined by the phenol-sulfuric acid method and found to be 1% by weight.
【0176】96:無定形粉末 〔α〕D 24 - 61.1°(c 0.35, 0.01MPBS) IR(KBr)cm-1 : 3300, 1720, 1655, 1549, 1410, 1258[0176] 96: amorphous powder [α] D 24 - 61.1 ° (c 0.35 , 0.01MPBS) IR (KBr) cm -1: 3300, 1720, 1655, 1549, 1410, 1258
【0177】参考例64 ポリ−γ−〔8−(α−D−
キシロピラノシルオキシ)オクチルアミノ〕−γ−〔2
−(4−ヒドロキシフェニル)エチルアミノ〕−ドキソ
ルビシン−L−グルタミン酸ナトリウム塩(97) 参考例41で得た化合物(68)13.0mgを水5mlに
溶解し、ドキソルビシン塩酸塩5.0mgの水溶液3mlを
加えて、1N 塩酸でpHを7.0に調製した。得られた溶
液に塩酸1−エチル−3−(3−ジメチルアミノプロピ
ル)カルボジイミド10mgを加えて、室温で15時間撹
拌した。反応混合物をスペクトラポア/ポア3(分子量
カットオフ=約3,500)透析膜を用いて、0.01
M リン酸緩衝液(pH7.0)及び水に対してそれぞれ4
℃で24時間透析した。反応内液を取り出し、凍結乾燥
した。得られたドキソルビシン量を吸光度490nmを用
いて定量すると、1モルのドキソルビシンが導入されて
いることが判明した。Reference Example 64 Poly-γ- [8- (α-D-
Xylopyranosyloxy) octylamino] -γ- [2
-(4-Hydroxyphenyl) ethylamino] -doxorubicin-L-glutamic acid sodium salt (97) 13.0 mg of the compound (68) obtained in Reference Example 41 was dissolved in 5 ml of water, and a solution of 5.0 mg of doxorubicin hydrochloride in 3 ml of water. Was added to adjust the pH to 7.0 with 1N hydrochloric acid. 10 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride was added to the resulting solution, and the mixture was stirred at room temperature for 15 hours. The reaction mixture was treated with Spectrapore / Pore 3 (molecular weight cutoff = about 3,500) dialysis membrane to obtain 0.01
4 each for M phosphate buffer (pH 7.0) and water
It dialyzed at 24 degreeC for 24 hours. The reaction solution was taken out and freeze-dried. When the amount of doxorubicin obtained was quantified using an absorbance of 490 nm, it was found that 1 mol of doxorubicin had been introduced.
【0178】実験例 1.試料 参考例35で得たポリグルタミン酸(分子量13,30
0)にガラクトース36個を修飾したものを検体試料と
した。対照試料としては無修飾のポリグルタミン酸(分
子量13,300)を用いた。Experimental Example 1. Sample Polyglutamic acid obtained in Reference Example 35 (molecular weight 13, 30
The sample sample was prepared by modifying 0) with 36 galactoses. Unmodified polyglutamic acid (molecular weight 13,300) was used as a control sample.
【0179】2.方法 動物実験に先立ち検体の 125I標識化を行った。 125I
標識化はクロラミンT法により、常法通り行った。反応
液をセファデックスG−25カラムでゲル濾過し、高分
子フラクションを得た。このフラクションにウシ血清ア
ルブミン1%及び非ラベル体を加え1mg/ml の投与液を
調整し、以下の動物実験に用いた。ラット(SD系雄
性、7週令)の大腿静脈内に 125I標識した検体試料あ
るいは対照試料を1mg/kg で投与し、投与後1、2及び
3分後に頚動脈より採血し、5分後には腹部大動脈より
全採血し致死せしめ、主要な11の臓器を摘出した。血
液は遠心分離後の血漿を、摘出臓器はそのまま秤量後、
ガンマカウンターにより放射活性を測定し、血漿中濃度
及び各臓器中濃度を算出した。また、同様に検体試料あ
るいは対照試料を投与した後、1時間及び4時間後の主
要臓器中の濃度も上記と同様に測定した。各動物実験
は、1群3匹で行った。2. Methods Samples were labeled with 125 I prior to animal experiments. 125 I
The labeling was performed by the chloramine T method in the usual way. The reaction solution was subjected to gel filtration with a Sephadex G-25 column to obtain a polymer fraction. To this fraction, 1% bovine serum albumin and an unlabeled product were added to prepare a 1 mg / ml administration solution, which was used in the following animal experiments. A 125 I-labeled sample or control sample was administered at 1 mg / kg into the femoral vein of a rat (SD male, 7 weeks old), and blood was collected from the carotid artery 1, 2 and 3 minutes after the administration, and 5 minutes later. The whole blood was collected from the abdominal aorta and killed, and 11 major organs were extracted. Blood is plasma after centrifugation, and the extracted organs are weighed as they are,
Radioactivity was measured with a gamma counter to calculate plasma concentration and concentration in each organ. Similarly, the concentrations in the main organs 1 hour and 4 hours after the administration of the specimen sample or the control sample were also measured in the same manner as above. Each animal experiment was performed with 3 animals per group.
【0180】3.結果と考察 投与後5分までの血中濃度の結果を図1に示した。検体
は対照と比較して速やかに血中から消失することがわか
った。また投与5分後に臓器分布(図2)では対照が腎
臓に集積していたのに比較して、検体では腎臓の集積が
減り肝臓への集積が確認された。更に、その他の各臓器
中濃度においても、検体では対照より少なくなっている
ことより、ガラクトース修飾によりポリグルタミン酸は
肝臓への指向性が増大したことが明らかとなった。3. Results and Discussion Results of blood concentration up to 5 minutes after administration are shown in FIG. It was found that the specimen disappeared from the blood more quickly than the control. Further, 5 minutes after the administration, in the organ distribution (FIG. 2), the accumulation of the kidney was decreased and the accumulation in the liver was confirmed in the sample, compared with the accumulation of the control in the kidney. Furthermore, even in the concentrations in other organs, the amount of the sample was lower than that of the control, which revealed that the galactose modification increased the tropism of polyglutamic acid to the liver.
【0181】投与5分、1時間、4時間後の肝臓及び腎
臓中の検体及び対照の濃度の時間に対する推移を示した
のが図3及び図4である。腎臓では検体のAUC(曲線
下面積)は対照と比較して小さいが、肝臓では逆に検体
のAUCは非常に大きく、検体は肝臓に蓄積する傾向が
認められた。FIGS. 3 and 4 show changes with time of the concentrations of the specimen and the control in the liver and kidney 5 minutes, 1 hour and 4 hours after administration. In the kidney, the AUC (area under the curve) of the sample was smaller than that of the control, whereas in the liver, the AUC of the sample was conversely very large, and the sample tended to accumulate in the liver.
【0182】従来から肝臓には特異的なガラクトースを
認識するレクチンの存在が知られており、ガラクトース
修飾ポリグルタミン酸は、このレクチンに認識されて肝
臓に集積すると考えられた。したがって、本発明物質は
肝臓への薬物送達系(DDS)の担体として非常に有用
であることが示唆される。また本発明中のそのほかの糖
修飾ポリグルタミン酸においても、ある臓器あるいは癌
細胞などに特異的な糖を認識するレクチンが存在するな
らば、臓器指向性のあるDDS担体として有用である。The presence of a lectin that specifically recognizes galactose has been known in the liver, and it was considered that galactose-modified polyglutamic acid was recognized by this lectin and accumulated in the liver. Therefore, it is suggested that the substance of the present invention is very useful as a carrier for a drug delivery system (DDS) to the liver. The other sugar-modified polyglutamic acid in the present invention is also useful as an organ-directed DDS carrier if a lectin that recognizes a sugar specific to a certain organ or cancer cell is present.
【図1】静脈投与後の血中推移を示すグラフ。FIG. 1 is a graph showing changes in blood after intravenous administration.
【図2】投与5分後の各臓器内濃度を示すグラフ。FIG. 2 is a graph showing the concentration in each organ 5 minutes after administration.
【図3】腎臓内の濃度推移を示すグラフ。FIG. 3 is a graph showing changes in concentration in the kidney.
【図4】肝臓内の濃度推移を示すグラフ。FIG. 4 is a graph showing changes in concentration in the liver.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 野草 秀夫 千葉県柏市明原2丁目9−10 パイロット ハウス柏103 (72)発明者 洲崎 浩 東京都調布市染地3丁目1−166 多摩川 住宅 ホ−8−106 (72)発明者 権正 晃徳 千葉県柏市千代田3丁目8−7 ヴィヌス 柏203 ─────────────────────────────────────────────────── ─── Continuation of front page (72) Hideo Nogusa 2-9-10 Akihara, Kashiwa-shi, Chiba Pilot House Kashiwa 103 (72) Inventor Hiroshi Susaki 3-1-166 Senji, Chofu-shi, Tokyo Tamagawa Housing Ho-8 −106 (72) Inventor Akinori Gonsho 3-8-7 Chiyoda, Kashiwa City, Chiba Vinus Kashiwa 203
Claims (2)
導体。 【化1】 (式中、R3 は9−フルオレニルメトキシカルボニル基
を表し、R4 はカルボキシル基の保護基を表す)1. A glutamic acid derivative represented by the following formula (III): Embedded image (In the formula, R 3 represents a 9-fluorenylmethoxycarbonyl group, and R 4 represents a protecting group for a carboxyl group.)
ミン酸に、9−フルオレニルメトキシカルボン酸の反応
性誘導体を反応させ、更にα−カルボキシル基を保護
し、次にγ−カルボキシル基の保護基を脱離することを
特徴とする式(III) 【化2】 (式中、R3 及びR4 は前記と同じ)で示されるグルタ
ミン酸誘導体の製法。2. A glutamic acid having a protected γ-carboxyl group is reacted with a reactive derivative of 9-fluorenylmethoxycarboxylic acid to further protect the α-carboxyl group, and then a protective group for the γ-carboxyl group. Formula (III) characterized by desorbing (In the formula, R 3 and R 4 are the same as the above), and a method for producing a glutamic acid derivative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8182579A JP2698570B2 (en) | 1991-05-13 | 1996-07-12 | Production method of glutamic acid derivative |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13522191 | 1991-05-13 | ||
| JP3-135221 | 1991-05-13 | ||
| JP8182579A JP2698570B2 (en) | 1991-05-13 | 1996-07-12 | Production method of glutamic acid derivative |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4144984A Division JP2589431B2 (en) | 1991-05-13 | 1992-05-12 | Sugar-modified polyglutamic acid derivative and production method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08337566A true JPH08337566A (en) | 1996-12-24 |
| JP2698570B2 JP2698570B2 (en) | 1998-01-19 |
Family
ID=26469118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8182579A Expired - Lifetime JP2698570B2 (en) | 1991-05-13 | 1996-07-12 | Production method of glutamic acid derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2698570B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008285624A (en) * | 2007-05-21 | 2008-11-27 | Biomedical Technology Hybrid Ltd | Method for producing nanoparticles comprising hydrophobized poly (γ-glutamic acid) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02500749A (en) * | 1987-06-05 | 1990-03-15 | サイトジェン、コーポレーション | Anthracycline antibiotic amine derivatives and their antibody conjugates |
-
1996
- 1996-07-12 JP JP8182579A patent/JP2698570B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02500749A (en) * | 1987-06-05 | 1990-03-15 | サイトジェン、コーポレーション | Anthracycline antibiotic amine derivatives and their antibody conjugates |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008285624A (en) * | 2007-05-21 | 2008-11-27 | Biomedical Technology Hybrid Ltd | Method for producing nanoparticles comprising hydrophobized poly (γ-glutamic acid) |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2698570B2 (en) | 1998-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3169222B2 (en) | Novel linker for bioactive agents | |
| WO2000025825A1 (en) | Dds compounds and method for assaying the same | |
| JPS61243026A (en) | Polymerizable drug and manufacture | |
| JP2002515081A (en) | Multivalent polymer for treatment of rotavirus infection | |
| KR950007923B1 (en) | Sialic acid derivatives with active carbonyl groups | |
| JP2589431B2 (en) | Sugar-modified polyglutamic acid derivative and production method thereof | |
| EP1086118A1 (en) | Vitamin b 12? derivatives and methods for their preparation | |
| Sashiwa et al. | Chemical modification of chitosan 8: preparation of chitosan–dendrimer hybrids via short spacer | |
| Findeis | Stepwise synthesis of a GalNAc‐containing cluster glycoside ligand of the asialoglycoprotein receptor | |
| JP2698570B2 (en) | Production method of glutamic acid derivative | |
| KR100249067B1 (en) | Anthracycline-conjugates and the method of process therefor | |
| JPH08337591A (en) | Glycosyl oxyalkylamine and its production | |
| JPH0159275B2 (en) | ||
| JP2589435B2 (en) | Sugar-modified polylysine derivative | |
| JPH0140823B2 (en) | ||
| Chernyak et al. | Synthesis of lysine-containing fragments of the Proteus mirabilis O27 O-specific polysaccharide and neoglyco-conjugates therefrom | |
| JP2791001B2 (en) | Glycosyl-protein derivatives | |
| JPH085914B2 (en) | Glycosyl-protein derivative | |
| CN114773412A (en) | Non-basal-protection single-arm carbohydrate-containing compound and preparation method thereof | |
| JP2774429B2 (en) | Branched-chain derivatives having a sugar skeleton | |
| JP2906228B2 (en) | Glucopyranose derivative salt | |
| JP2003073391A (en) | Method of producing galacto type trehalose or derivative thereof and ligand for vero toxin originating from trehalose obtained using the same | |
| JP2795162B2 (en) | Dihydrochalcone derivative and method for producing the same | |
| JP2001261706A (en) | Sialic acid branched cyclodextrin derivatives and their intermediates | |
| JP4071415B2 (en) | Sialic acid branched cyclodextrin derivatives |